

CITATION REPORT

List of articles citing

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

DOI: 10.1056/nejmoa1611925

New England Journal of Medicine, 2017, 377, 644-657.

Source: <https://exaly.com/paper-pdf/66515000/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2224	Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. 2016 , 118, 1830-43		46
2223	Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes. 2017 , 70, 704-712		106
2222	Response to Comment on Lovshin et al. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1 α in Patients With Type 2 Diabetes. <i>Diabetes Care</i> 2017;40:1073-1081. 2017 , 40, e159-e160		
2221	Therapy: SGLT inhibition in T1DM - definite benefit with manageable risk. 2017 , 13, 698-699		4
2220	SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review. 2017 , 8, 1245-1251		34
2219	Cardiovascular safety of canagliflozin. 2017 , 247, 7		1
2218	Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes. 2017 , 60, 422-434		55
2217	Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus. 2017 , 14, 445-453		5
2216	Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy. 2018 , 1067, 197-217		35
2215	Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes. 2017 , 10, 1303-1316		4
2214	Orale Triple-Therapie Binnvolle Strategie oder nur Verzögerungstaktik?. 2017 , 13, 416-420		
2213	Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions. 2017 , 17, 112		18
2212	Is the Way to Someone's Heart Through Their Stomach? The Cardiorenal Paradox of Incretin-Based Hypoglycemic Drugs in Heart Failure. 2017 , 10,		10
2211	Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK. 2017 , 8, 1175-1185		3
2210	Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors. 2017 , 52 Suppl 1, S4-S7		
2209	Research roundup. 2017 , 2, 292-293		
2208	Inkretinbasierte Diabetesmedikamente. 2017 , 13, 498-504		

2207	Insulin and Its Cardiovascular Effects: What Is the Current Evidence?. 2017 , 17, 120		19
2206	Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. 2017 , 136, 1643-1658		256
2205	When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?. 2017 , 102, 924-933		119
2204	Weight Management in Patients with Type 1 Diabetes and Obesity. 2017 , 17, 92		48
2203	Canagliflozin: A Review in Type 2 Diabetes. 2017 , 77, 1577-1592		21
2202	Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis. 2017 , 40, 1479-1485		99
2201	Choosing the Best Therapy for Your Patients in Today's Diabetes World. 2017 , 41, 465-466		
2200	The effect of SGLT2 inhibitors on cardiovascular events and renal function. 2017 , 10, 1251-1261		9
2199	A New Chapter for Diabetic Kidney Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 885-887	59.2	16
2198	Pharmacological management of type 2 diabetes: what's new in 2017?. 2017 , 10, 1383-1394		16
2197	Practical Ways to Achieve Targets in Diabetes Care 2017. 2017 , 9, 978-982		
2196	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. 2017 , 5, 864-876		174
2195	SGLT2 inhibitors in type 1 diabetes: knocked down, but up again?. 2017 , 5, 841-843		8
2194	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017 , 377, 1228-1239	59.2	1017
2193	Diabetes Research and Care Through the Ages. 2017 , 40, 1302-1313		7
2192	Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus. 2017 , 31, 459-470		2
2191	Can we go beyond surrogates?. 2017 , 9, 976-977		2
2190	SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System. 2017 , 5, 680-681		97

2189 Diabetesassozierte Nierener krankung. **2017**, 13, 365-380

2188 Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. **2017**, 33, e2924 91

2187 Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association. **2017**, 16, 93-95 12

2186 Leaving the Gluocentric View: Can SGLT2 Inhibitors Halt CVD in Patients With Type 2 Diabetes?. **2017**, 70, 713-714

2185 Metformin: new insights into an archetypal cardiometabolic drug. **2017**, 6, 92-94

2184 Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure. **2017**, 2, 347-354 87

2183 Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. **2017**, 5, 709-717 208

2182 Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS. **2017**, 13, 517-518 9

2181 Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes. **2017**, 6, 175-186 12

2180 SGLT2 inhibitors in the real world: too good to be true?. **2017**, 5, 673-675 9

2179 Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes. **2017**, 18, 1433-1438 40

2178 Why Should be the Strategy of Type 2 Diabetes Treatment Radically Changed. **2017**, 24, 263-272

2177 Will Canagliflozin Lend Credence to the Potential Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Renal Endpoints in Diabetic Nephropathy. **2017**, 46, 459-461 2

2176 Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial. **2017**, 39, 2438-2447 6

2175 Chronic kidney disease. **2017**, 3, 17088 261

2174 Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *New England Journal of Medicine*, **2017**, 377, 2099 59.2 123

2173 Does the evidence support population-wide screening for type 2 diabetes? No. **2017**, 60, 2153-2156 6

2172 Liraglutide and Renal Outcomes in Type 2 Diabetes. *New England Journal of Medicine*, **2017**, 377, 2197-2208 25

2171	Response to Comment on Kaul. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. <i>Diabetes Care</i> 2017;40:821-831. 2017 , 40, e175-e176	2
2170	Review article: effects of type 2 diabetes therapies on bone metabolism. 2017 , 9, 75	18
2169	Glycaemic studies: Food for thought and fuel for debate. 2017 , 14, 379-380	
2168	Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development. 2017 , 31, 399-421	2
2167	Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus. 2017 , 39, 2230-2242.e2	13
2166	The CANVAS trial programme raises more questions than answers. 2017 , 34, 232-233	1
2165	Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database. 2017 , 27, 1108-1113	47
2164	Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting. 2017 , 17, 64	1
2163	Cardiovascular disease prevention strategies for type 2 diabetes mellitus. 2017 , 18, 1243-1260	30
2162	Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. 2017 , 5, 610-621	217
2161	SGLT2 inhibition: a new era in renoprotective medicine?. 2017 , 5, 569-571	6
2160	Diabetes: Lower risk of cardiovascular death with canagliflozin. 2017 , 14, 442	
2159	Canagliflozin: increased risk of amputation. 2017 , 1657, 10-10	
2158	American Diabetes Association 77th Scientific Sessions. 2017 , 9, 894-897	
2157	The impact of glucose-lowering medications on cardiovascular disease. 2018 , 7, 13-17	
2156	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CRENDENCE) Study Rationale, Design, and Baseline Characteristics. 2017 , 46, 462-472	149
2155	Personalizing Type 2 Diabetes Management: Use of a Patient-Centered Approach to Individualizing A1C Goals and Pharmacological Regimens. 2017 , 35, 321-328	0
2154	American Association of Diabetes Educators 2017. 2017 , 9, 1054-1057	1

2153	Accès à l'innovation thérapeutique : la médecine et nouveaux médicaments en diabéologie. 2017 , 11, IIS28-IIS37	1
2152	Achterbahnfahrt mit Schreck und Jubel. 2017 , 11, 3-4	
2151	Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus. 2017 , 32, 974-983	16
2150	Empagliflozin reduces albuminuria-a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial. 2017 , 5, 478	1
2149	Comprehensive algorithm released on management of type 2 diabetes. 2017 , 23, 24-25	
2148	Heart failure: an underestimated therapeutic target in diabetes. 2018 , 7, 10-12	2
2147	Integrating cardioprotective glucose-lowering medications into clinical practice. 2018 , 7, 24-27	
2146	Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A. 2017 , 8, 1604	21
2145	Macrovascular Complications in Patients with Diabetes and Prediabetes. 2017 , 2017, 7839101	99
2144	New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data. 2017 , 2017, 1253425	8
2143	The Difference between SGLT2 and DPP-4 Inhibitors on Glucose Fluctuation in Patients with Type 2 Diabetes. 2017 , 04,	
2142	Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus. 2017 , 41, 357-366	17
2141	Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D). 2017 , 13, 1569-1576	3
2140	Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis. 2017 , 16, 93	21
2139	Updates on cardiovascular outcome trials in diabetes. 2017 , 16, 128	36
2138	Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?. 2017 , 16, 129	28
2137	Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial. 2017 , 16, 130	36
2136	Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG). 2017 , 16, 137	9

2135	Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). 2017, 9, 53	15
2134	A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin. 2017, 9, 54	29
2133	Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center. 2017, 9, 96	11
2132	Kardiovaskuläre Risikoreduktion durch Antidiabetika über Glukosesenkung hinaus. 2017, 11, 32-36	1
2131	Antidiabetika: Nun ein Viertes mit Herzschutz. 2017, 14, 34-34	
2130	SGLT2 inhibitors and cardiovascular outcomes. 2017, 55, 111-112	
2129	Diabetes mellitus Typ 2. 2017,	
2128	Kardiovaskuläre Outcome-Studien in der Diabetologie – ein Überblick. 2017, 10, 119-121	
2127	Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists-what will REWIND add?. 2017, 5, 476	4
2126	Recent advances in understanding/managing type 2 diabetes mellitus. 2017, 6,	2
2125	New anti-diabetic agents. 2017, 60, 992	
2124	Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. 2017, 11, 2905-2919	36
2123	Monotherapy in Patients with Type 2 Diabetes Mellitus. 2017, 41, 349-356	12
2122	Antihyperglycemic Medications and Cardiovascular Risk Reduction. 2017, 13, 86-90	5
2121	PROCOLOS CLÍNICOS DA RESIDENCIA DE CLINICA MÉDICA. 2017, 4, 3	
2120	Treatment target of diabetes for prevention of coronary artery disease. 2017, 23, 170-173	
2119	Recent Updates on Diabetic Nephropathy. 2017, 18, 214	2
2118	The Antidiabetic Armamentarium: Reducing the Residual Cardiovascular Risk with HbA-Lowering Medications : Editorial to: "GLP-1 Receptor Agonists and Cardiovascular Disease: A Meta-Analysis of Recent Cardiac Outcome Trials" by Jia X, Alam M, Ye Y et al. 2018, 32, 1-3	

2117	Nocturnal hypertension in diabetes: Potential target of sodium/glucose cotransporter 2 (SGLT2) inhibition. 2018 , 20, 424-428		12
2116	Place des inhibiteurs des SGLT2 dans le traitement du patient diabétique de type 2. 2018 , 12, 22-30		8
2115	Treatment of type 2 diabetes mellitus in elderly patients. 2018 , 218, 74-88		3
2114	Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes. 2018 , 32, 135-145		49
2113	Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review. 2018 , 21, 881-890		93
2112	Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2018 , 378, 967-968	59.2	12
2111	Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. 2018 , 6, 370-381		137
2110	Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida. 2018 , 34, 1099-1115		3
2109	The safety of gliptins : updated data in 2018. 2018 , 17, 387-405		70
2108	Basic Concepts in Insulin Resistance and Diabetes Treatment. 2018 , 19-35		3
2107	2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. 2018 , 81, 189-222		14
2106	SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis. 2018 , 12, 265-283		48
2105	What are the cardiovascular effects of the newer classes of drugs for type 2 diabetes?. 2018 , 31, 12-14		
2104	Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study. 2018 , 20, 1770-1775 ¹³		
2103	Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)". 2018 , 137, 989-991		6
2102	The cost of cardiovascular-disease-related death in patients with type 2 diabetes mellitus. 2018 , 34, 1081-1087 ⁴		
2101	The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions. 2018 , 23, 303-323		27
2100	Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study. 2018 , 20, 1781-1786		25

2099	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. 2018 , 20, 853-872	264
2098	Targeting Other Modifiable Risk Factors for the Prevention of Heart Failure: Diabetes, Smoking, Obesity, and Inactivity. 2018 , 12, 1	
2097	Abnormal Myocardial Dietary Fatty Acid Metabolism and Diabetic Cardiomyopathy. 2018 , 34, 605-614	32
2096	Letter by Koh Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)". 2018 , 137, 984-985	2
2095	The year 2017 in cardiology: aorta and peripheral circulation. 2018 , 39, 730-738	5
2094	The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin. 2018 , 132, 489-507	55
2093	Update of pathophysiology and management of diabetic kidney disease. 2018 , 117, 662-675	158
2092	Is the CANVAS of canaglifozin wide?. 2018 , 38, 353-354	
2091	Do sulphonylureas still have a place in clinical practice?. 2018 , 6, 821-832	61
2090	Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A Meta-analysis of Randomized Controlled Trials. 2018 , 44, 410-414	35
2089	Sodium-glucose cotransporter-2 inhibitors induced eu-glycemic diabetic ketoacidosis: The first report in a type 2 diabetic (T2D) Taiwanese and literature review of possible pathophysiology and contributing factors. 2018 , 117, 849-854	4
2088	Antidiabetic drugs for stroke prevention in patients with type-2 diabetes. The neurologist's point of view. 2018 , 150, 275-281	1
2087	Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions. 2018 , 137, 1060-1073	20
2086	Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. 2018 , 130, 381-393	17
2085	Why only macro and not micro in type 2 diabetes? Time to change the goals of clinical trials in diabetes. 2018 , 34, e3012	3
2084	Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?. 2018 , 32, 213-222	32
2083	Metabolic Karma-The Atherogenic Legacy of Diabetes: The 2017 Edwin Bierman Award Lecture. 2018 , 67, 785-790	15
2082	SGLT2 Inhibitors: Cardiovascular Benefits Beyond Glycemic Control. 2018 , 6, 34-39	1

2081	Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus. 2018 , 11, 2-14	4
2080	Renal Effects of Incretin-Based Diabetes Therapies: Pre-clinical Predictions and Clinical Trial Outcomes. 2018 , 18, 28	8
2079	Treatment of Diabetes in People With Heart Failure. 2018 , 42 Suppl 1, S196-S200	17
2078	Pharmacologic Glycemic Management of Type 2 Diabetes in Adults. 2018 , 42 Suppl 1, S88-S103	108
2077	ONE-YEAR TIME ANALYSIS IN AN ACADEMIC DIABETES CLINIC: QUANTIFYING OUR BURDEN. 2018 , 24, 489-491	5
2076	Diabetes in Older People. 2018 , 42 Suppl 1, S283-S295	45
2075	Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. 2018 , 319, 1580-1591	216
2074	The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus. 2018 , 78, 717-726	43
2073	The 2018 update of the American College of Physicians glycaemic management recommendations: An invitation to continued inertia?. 2018 , 20, 1809-1811	3
2072	Renal Interstitial Exhaustion and SGLT2 Blockers. 2018 , 126, 1791-1792	1
2071	Sodium-Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus: A Review of Large-Scale Cardiovascular Outcome Studies and Possible Mechanisms of Benefit. 2018 , 26, 312-320	4
2070	Are the effects of drugs to prevent and to treat heart failure always concordant? The statin paradox and its implications for understanding the actions of antidiabetic medications. 2018 , 20, 1100-1105	13
2069	Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study. 2018 , 20, 1852-1858	30
2068	Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. 2018 , 20, 1988-1993	111
2067	In Response. 2018 , 126, 1792-1793	
2066	Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk. 2018 , 9, 919-926	23
2065	Glucose-lowering treatment in cardiovascular and peripheral artery disease. 2018 , 39, 86-98	4
2064	Drug repurposing in kidney disease. 2018 , 94, 40-48	28

2063	Does lower limb amputation concern all SGLT2 inhibitors?. 2018 , 14, 326-328	35
2062	Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction. 2018 , 41, 1285-1291	23
2061	Baseline characteristics and enrichment results from the SONAR trial. 2018 , 20, 1829-1835	22
2060	Potential Benefits of Sodium-Glucose Cotransporter-2 Inhibitors in the Perioperative Period. 2018 , 127, 306-307	1
2059	Contrasting effects on the risk of macrovascular and microvascular events of antihyperglycemic drugs that enhance sodium excretion and lower blood pressure. 2018 , 35, 707-713	3
2058	Leptin-Aldosterone-Nephrilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity. 2018 , 137, 1614-1631	105
2057	Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics. 2018 , 20, 2014-2018	13
2056	Cardiovascular Protection in People With Diabetes. 2018 , 42 Suppl 1, S162-S169	30
2055	Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment. 2018 , 36, 1427-1440	48
2054	Chronic Kidney Disease in Diabetes. 2018 , 42 Suppl 1, S201-S209	36
2053	CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. 2018 , 14, 361-377	203
2052	MECHANISMS IN ENDOCRINOLOGY: Diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review. 2018 , 178, R127-R139	33
2051	Type 2 Diabetes and the Reduction of Cardiovascular Risk: Sorting Out the Actors and the Roles. 2018 , 34, 532-535	1
2050	Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials. 2018 , 20, 1755-1761	49
2049	Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System. 2018 , 6, e000475	15
2048	Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. 2018 , 85, 32-37	116
2047	Pathophysiological Links Between Diabetes and Blood Pressure. 2018 , 34, 585-594	24
2046	The Genetic Link Between Diabetes and Atherosclerosis. 2018 , 34, 565-574	7

2045	Cardiorenal interactions. 2018 , 60, e144-e147	1
2044	Treatment of type 2 diabetes mellitus in elderly patients. 2018 , 218, 74-88	22
2043	Type 2 Diabetes and Thiazide Diuretics. 2018 , 18, 6	15
2042	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME ² trial. 2018 , 39, 363-370	171
2041	Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study. 2018 , 9, 583-612	173
2040	[Treatment of type 2 diabetes mellitus in elderly patients]. 2018 , 53, 89-99	8
2039	European Association for the Study of Diabetes 2017. 2018 , 10, 90-93	0
2038	SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?. 2018 , 20, 1531-1534	62
2037	Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease. 2018 , 33, 2005-2011	46
2036	Diabetes medications and cardiovascular disease: at long last progress. 2018 , 25, 87-93	9
2035	Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis. 2018 , 25, 495-502	66
2034	Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice. 2018 , 391, 395-406	3
2033	Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin. 2018 , 20, 1367-1368	2
2032	MECHANISMS IN ENDOCRINOLOGY: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?. 2018 , 178, R113-R125	51
2031	Incremental burden of type 2 diabetes in patients experiencing cardiovascular hospitalizations. 2018 , 34, 1005-1012	
2030	A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment. 2018 , 17, 293-302	22
2029	Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study. 2018 , 9, 285-295	21
2028	Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study. 2018 , 9, 253-268	56

2027	Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin. 2018 , 20, 1321-1326	31
2026	[Chronic Kidney Disease - Update 2018]. 2018 , 143, 169-173	3
2025	Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. 2018 , 20, 1369-1376	49
2024	Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies. 2018 , 61, 1503-1516	40
2023	Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment. 2018 , 9, 521-543	34
2022	Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis. 2018 , 44, 112-120	24
2021	Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus. 2018 , 47, 81-96	30
2020	Personalizing Glucose-Lowering Therapy in Patients with Type 2 Diabetes and Cardiovascular Disease. 2018 , 47, 137-152	6
2019	The Evolving Epidemiology of Atherosclerotic Cardiovascular Disease in People with Diabetes. 2018 , 47, 1-32	12
2018	Diabetes and ischaemic stroke: a deadly association. 2018 , 39, 2387-2389	3
2017	Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States. 2018 , 9, 565-581	10
2016	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. 2018 , 200, 83-89	89
2015	A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. 2018 , 71, 471-476	88
2014	Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases. 2018 , 222, e13050	10
2013	Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio. 2018 , 52, 632-638	6
2012	The pharmacological management of metabolic syndrome. 2018 , 11, 397-410	56
2011	Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials. 2018 , 20, 1235-1245	19
2010	Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential. 2018 , 9, 33-50	26

2009	Selection of the Best of 2017 in Vascular Risk and Cardiac Rehabilitation. 2018 , 71, 227-228	
2008	Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet. 2018 , 9, 1025-1032	55
2007	Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis. 2018 , 7,	66
2006	Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes. 2018 , 130, 154-158	5
2005	International Diabetes Federation 2017. 2018 , 10, 353-356	78
2004	Ranting in 2018: Are We Making Progress?. 2018 , 20, 91-93	
2003	Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect. 2018 , 41, 219-223	11
2002	Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. 2018 , 20, 1361-1366	52
2001	Effect of glucose-lowering therapies on heart failure. 2018 , 15, 282-291	34
2000	Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. 2018 , 20, 1111-1120	101
1999	Powerful diuretics: A common denominator in landmark hypertension and type 2 diabetes mellitus trials. 2018 , 20, 136-142	1
1998	The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus. 2018 , 23, 445-459	4
1997	Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers for the Treatment of Hypertension in Adults With Type 2 Diabetes: Why We Favour Angiotensin Receptor Blockers. 2018 , 42, 118-123	4
1996	Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction. 2018 , 6, 1-7	51
1995	Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs. 2018 , 254, 291-296	23
1994	Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial. 2018 , 41, 604-612	35
1993	Heart Failure: Epidemiology, Pathophysiology, and Management of Heart Failure in Diabetes Mellitus. 2018 , 47, 117-135	16
1992	Short Leukocyte Telomere Length Predicts Albuminuria Progression in Individuals With Type 2 Diabetes. 2018 , 3, 592-601	17

1991	Antidiabetic drugs for stroke prevention in patients with type-2 diabetes. The neurologist's point of view. 2018 , 150, 275-281	4
1990	Management of diabetes in older adults. 2018 , 28, 206-218	30
1989	Selection of the Best of 2017 in Clinical Cardiology. Therapeutic Novelities. 2018 , 71, 60	
1988	Selección de lo mejor del año 2017 en riesgo vascular y rehabilitación cardíaca. 2018 , 71, 227-228	
1987	American Heart Association 2017. 2018 , 10, 271-275	1
1986	Prognostic significance of day-by-day variability of home blood pressure on progression to macroalbuminuria in patients with diabetes. 2018 , 36, 1068-1075	14
1985	Treatment of Hypertension to Prevent and Treat Heart Failure in Diabetic Patients Should Include Sodium Glucose Co-Transporter 2 Inhibitors. 2018 , 6, 85	1
1984	Novel therapies for diabetic kidney disease. 2018 , 8, 18-25	23
1983	Keeping the right track in the treatment of patients with type 2 diabetes. 2018 , 20, 52-54	2
1982	Cardiovascular outcomes with canagliflozin - is it on the CANVAS?. 2018 , 19, 163-166	4
1981	Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?. 2018 , 41, 6-10	78
1980	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Editors' Expert Forum. 2018 , 41, 14-31	263
1979	DECLARE-TIMI 58: Participants' baseline characteristics. 2018 , 20, 1102-1110	80
1978	Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized clinical trials. 2018 , 20, 1213-1222	25
1977	Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects. 2018 , 23, 419-437	53
1976	Glucosuria and all-cause mortality among general screening participants. 2018 , 22, 850-859	5
1975	Running Out of Success in HF Therapy ?. 2018 , 24, 63-64	
1974	GLP-1 receptor agonists and cardiovascular protection: A class effect or not?. 2018 , 44, 193-196	15

1973	Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease. 2018 , 14, 78-80	5
1972	Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?. 2018 , 131, 461-463	4
1971	Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page. 2018 , 137, 130-133	7
1970	Have we really demonstrated the cardiovascular safety of anti-hyperglycaemic drugs? Rethinking the concepts of macrovascular and microvascular disease in type 2 diabetes. 2018 , 20, 1089-1095	4
1969	Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study. 2018 , 20, 1515-1519	28
1968	Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS). 2018 , 20, 1176-1185	19
1967	When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. 2018 , 34, e2981	12
1966	Heart failure risk and major cardiovascular events in diabetes: an overview of within-group differences in non-insulin antidiabetic treatment. 2018 , 23, 469-479	4
1965	From the editor: A run of success in treating atherosclerotic vascular disease. 2018 , 12, 1-2	
1964	Cardiovascular outcomes in diabetic kidney disease: insights from recent clinical trials. 2018 , 8, 8-17	6
1963	Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. 2018 , 39, 2274-2281	12
1962	Cardioprotective anti-hyperglycaemic medications: a review of clinical trials. 2018 , 39, 2368-2375	26
1961	Changes in patient characteristics, glucose lowering treatment, glycemic control and complications in type 2 diabetes in general practices (Disease Analyzer, Germany: 2008-2016). 2018 , 130, 244-250	6
1960	Unsweetening the Heart: Possible Pleiotropic Effects of SGLT2 Inhibitors on Cardio and Cerebrovascular Alterations in Resistant Hypertensive Subjects. 2018 , 31, 274-280	3
1959	Canagliflozin and cardiovascular and renal events in type 2 diabetes. 2018 , 130, 149-153	21
1958	The year in cardiology 2017: heart failure. 2018 , 39, 832-839	4
1957	Selección de lo mejor del año 2017 en cardiología clínica. Novedades terapéuticas. 2018 , 71, 60	2
1956	Management of T2DM in 2017: Clinically relevant results from cardiovascular outcome trials. 2018 , 14, 67-68	1

1955	Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus. 2018 , 16, 123-131	
1954	Managing diabetic kidney disease. 2018 , 125, 55-66	7
1953	The year in cardiology 2017: prevention. 2018 , 39, 345-353	3
1952	Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents. 2018 , 78, 203-214	5
1951	Rationale, design, and baseline characteristics of the CARdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. 2018 , 17, 39	57
1950	Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy. 2018 , 17, 52	33
1949	Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease. 2018 , 17, 54	17
1948	Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study). 2018 , 10, 11	14
1947	Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial. 2018 , 10, 30	15
1946	The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data. 2018 , 17, 83-95	2
1945	Are the favorable cardiovascular outcomes of empagliflozin treatment explained by its effects on multiple cardiometabolic risk factors? A simulation of the results of the EMPA-REG OUTCOME trial. 2018 , 141, 181-189	11
1944	Summary of the 2018 ISN Frontiers Meeting: Kidney Disease and Cardiovascular Disease. 2018 , 3, 804-816	78
1943	Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease. 2018 , 32, 720-725	30
1942	Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. 2018 , 94, 26-39	160
1941	Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. 2018 , 360, k119	93
1940	Microvascular complications in diabetes patients with heart failure and reduced ejection fraction-insights from the Beta-blocker Evaluation of Survival Trial. 2018 , 20, 1549-1556	11
1939	Nocturnal Hypertension: New Technology and Evidence. 2018 , 71, 997-1009	104
1938	Glucagon-like peptide 1 in health and disease. 2018 , 14, 390-403	187

1937	Blood glucose reduction by diabetic drugs with minimal hypoglycaemia risk for cardiovascular outcomes: Evidence from meta-regression analysis of randomized controlled trials. 2018 , 20, 2131-2139	9
1936	Effects of sodium-glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes. 2018 , 1, e00015	7
1935	SGLT2 inhibition and heart failure-current concepts. 2018 , 23, 409-418	21
1934	Precision medicine in the management of type 2 diabetes. 2018 , 6, 891-900	60
1933	A practical approach and algorithm for intensifying beyond basal insulin in type 2 diabetes. 2018 , 20, 2064-2074	
1932	Effects and Safety of Sodium Glucose Cotransporter 2 Inhibitors in Diabetes Patients With Drug-Refractory Advanced Heart Failure. 2018 , 82, 1959-1962	8
1931	[Type 2 Diabetes and Vascular Endothelial Dysfunction]. 2018 , 40, 65-75	9
1930	Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice. 2018 , 830, 68-75	19
1929	The effects of diabetes therapy on bone: A clinical perspective. 2018 , 32, 713-719	14
1928	Unexplained reciprocal regulation of diabetes and lipoproteins. 2018 , 29, 186-193	11
1927	New antihyperglycaemic agents and cardiovascular disease: let's be optimistic. 2018 , 33, 444-454	3
1926	Canagliflozin inhibits interleukin-1 β -stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. 2018 , 8, 5276	111
1925	Management of Diabetes and/or Hyperglycemia in Hospitalized Patients with Renal Insufficiency. 2018 , 598-615	1
1924	Management of Diabetes and/or Hyperglycemia in Acute Coronary Syndrome, Acute Stroke, and Acute Heart Failure. 2018 , 632-647	
1923	Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials. 2018 , 27, 1301-1309	2
1922	Pharmacogenetics of oral antidiabetic therapy. 2018 , 19, 577-587	9
1921	Expanded algorithm for managing patients with acute decompensated heart failure. 2018 , 23, 597-607	4
1920	HbA1C, finding the right target in 2018. 2018 , 12, 607-608	1

1919	Sodium Glucose Cotransporter 2 Inhibitors and Amputation Risk: Achilles' Heel or Opportunity for Discovery?. 2018 , 137, 1460-1462	8
1918	Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. 2018 , 71, 2628-2639	263
1917	Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2. 2018 , 6, 633-639	80
1916	New pharmacological approaches for cardiovascular risk. 2018 , 151, 145-147	
1915	Prognostic significance of home pulse pressure for progression of diabetic nephropathy: KAMOGAWA-HBP study. 2018 , 41, 363-371	4
1914	Diabetes and Hypertension: Clinical Update. 2018 , 31, 515-521	9
1913	SGLT-2-Inhibitoren als Standardmedikation für Risikopatienten. 2018 , 14, 96-98	
1912	Preventing the development and progression of diabetic kidney disease: Where do we stand?. 2018 , 12, 585-590	4
1911	Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study. 2018 , 20, 1983-1987	55
1910	Treatment with Oral Drugs. 2018 , 1-44	
1909	New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors. 2018 , 18, 27	36
1908	Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review. 2018 , 140, 118-128	50
1907	Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist. 2018 , 137, 1218-1220	14
1906	Dyspnoe bei Diabetes und Herzinsuffizienz. 2018 , 14, 36-43	1
1905	Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions. 2018 , 9, 851-861	11
1904	Nephroprotektion durch SGLT-2-Hemmung. 2018 , 14, 93-95	
1903	Renal Hyperfiltration in Adolescents with Type 2 Diabetes: Physiology, Sex Differences, and Implications for Diabetic Kidney Disease. 2018 , 18, 22	21
1902	Poststatin era in atherosclerosis management: lessons from epidemiologic and genetic studies. 2018 , 29, 246-258	5

1901	Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells. 2018 , 152, 45-59	73
1900	New Glucose-Lowering Agents for Diabetic Kidney Disease. 2018 , 25, 149-157	10
1899	The MARLINA-T2D trial: putting the results into clinical perspective. 2018 , 13, 173-176	1
1898	Impact of Body Weight Loss From Maximum Weight on Fragility Bone Fractures in Japanese Patients With Type 2 Diabetes: The Fukuoka Diabetes Registry. 2018 , 41, 1061-1067	12
1897	Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. 2018 , 272, 33-40	24
1896	European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS). 2018 , 20, 895-896	13
1895	JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. 2018 , 33, 1950-1959	118
1894	Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program. 2018 , 138, 458-468	262
1893	Comprehensive risk management of diabetic kidney disease in patients with type 2 diabetes mellitus. 2018 , 9, 100-107	4
1892	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. 2018 , 71, 1379-1390	43
1891	Diabetic Kidney Disease. 2018 , 13, 335-338	16
1890	SGLT2 inhibitors: are they safe?. 2018 , 130, 72-82	36
1889	Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors. 2018 , 20, 740-744	25
1888	Novel Biomarkers for Predicting Cardiovascular Disease in Patients With Diabetes. 2018 , 34, 624-631	8
1887	SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection. 2018 , 6, 435-437	30
1886	Cardiovascular Screening and Primary Prevention in Older Adults. 2018 , 34, 81-93	1
1885	Safety of diabetes drugs in patients with heart failure. 2018 , 218, 98-107	
1884	Sodium-glucose co-transporter-2 inhibitors and cardiovascular outcome studies in people with type 2 diabetes: From efficacy to effectiveness. 2018 , 20, 763-765	

1883	Degree of ketonaemia and its association with insulin resistance after dapagliflozin treatment in type 2 diabetes. 2018 , 44, 73-76	25
1882	Prevalence of micro- and macrovascular diabetes complications at time of type 2 diabetes diagnosis and associated clinical characteristics: A cross-sectional baseline study of 6958 patients in the Danish DD2 cohort. 2018 , 32, 34-40	53
1881	Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. 2018 , 20, 479-487	216
1880	Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes. 2018 , 34, 313-318	5
1879	Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk. 2018 , 32, 210-215	18
1878	The kidney and cardiovascular outcome trials. 2018 , 10, 88-89	27
1877	Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. 2018 , 20, 620-628	89
1876	Can SGLT2 Inhibitors Cause Acute Renal Failure? Plausible Role for Altered Glomerular Hemodynamics and Medullary Hypoxia. 2018 , 41, 239-252	40
1875	Antidiabetic drugs and stroke risk. Current evidence. 2018 , 48, 1-5	20
1874	Safety of diabetes drugs in patients with heart failure. 2018 , 218, 98-107	
1873	Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure. 2018 , 23, 481-497	2
1872	Empagliflozin across the stages of diabetic heart disease. 2018 , 39, 371-373	6
1871	Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach. 2018 , 20, 497-507	22
1870	SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms. 2018 , 12, 59-63	37
1869	Type 2 diabetes and cardiovascular prevention: the dogmas disputed. 2018 , 60, 224-228	8
1868	Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study. 2018 , 20, 582-589	86
1867	Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. 2018 , 137, 119-129	252
1866	Are SGLT2 Inhibitors Ready for Prime Time for CKD?. 2018 , 13, 318-320	26

1865	The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis. 2018 , 26, 70-80	70
1864	Canagliflozin reduces plasma uremic toxins and alters the intestinal microbiota composition in a chronic kidney disease mouse model. 2018 , 315, F824-F833	37
1863	Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study. 2018 , 9, 49-66	77
1862	Impacts of sodium-glucose co-transporter type 2 inhibitors on central blood pressure. 2018 , 15, 154-157	2
1861	Initiation of dapagliflozin and treatment-emergent fractures. 2018 , 20, 1070-1074	26
1860	Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the perioperative setting. 2018 , 65, 143-147	11
1859	10. Microvascular Complications and Foot Care:. 2018 , 41, S105-S118	205
1858	Comparison between sodium-glucose cotransporter 2 inhibitors and pioglitazone as additions to insulin therapy in type 2 diabetes patients: A systematic review with an indirect comparison meta-analysis. 2018 , 9, 882-892	5
1857	Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes. 2018 , 20, 800-811	5
1856	Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes. 2018 , 47, 97-116	2
1855	Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na/H exchanger, lowering of cytosolic Na and vasodilation. 2018 , 61, 722-726	241
1854	SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus. 2018 , 136, 23-31	13
1853	Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study. 2018 , 19, 189-201	27
1852	9. Cardiovascular Disease and Risk Management:. 2018 , 41, S86-S104	370
1851	Diabetes mellitus as a poor mobilizer condition. 2018 , 32, 184-191	12
1850	Diabetes area patent participation analysis - part II: years 2011-2016. 2018 , 28, 111-122	5
1849	Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study. 2018 , 314, F412-F422	46
1848	Novel avenues for drug discovery in diabetic kidney disease. 2018 , 13, 65-74	7

1847	Diabetes Canada 2017. 2018 , 10, 188-191	
1846	Exogenous Insulin Infusion Can Decrease Atherosclerosis in Diabetic Rodents by Improving Lipids, Inflammation, and Endothelial Function. 2018 , 38, 92-101	29
1845	Canagliflozin: Cui Bono?. 2018 , 137, 335-337	3
1844	Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial. 2018 , 41, e4-e5	116
1843	Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World). 2018 , 137, 1450-1459	148
1842	Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). 2018 , 137, 323-334	284
1841	Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus. 2018 , 9, 27-36	5
1840	Renal outcomes with dipeptidyl peptidase-4 inhibitors. 2018 , 44, 101-111	18
1839	Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. 2018 , 20, 344-351	124
1838	Pharmaceutical Interventions for Diabetes Prevention in Patients at Risk. 2018 , 18, 13-24	2
1837	Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New. 2018 , 42, 325-334	10
1836	Cardiac effects of SGLT2 inhibitors: the sodium hypothesis. 2018 , 114, 12-18	77
1835	Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study. 2018 , 3,	59
1834	L'Internista ospedaliero nella gestione del paziente diabetico complesso. 2018 , 6, 1	0
1833	The good, the bad, and the ugly: sodium-glucose cotransporter-2 inhibitors (gliflozins) and perioperative diabetes. 2018 , 46, 155-158	6
1832	Diabetestherapie geriatrischer Patienten: Was sagen die Leitlinien?. 2018 , 13, 40-47	
1831	Tackling Cardiovascular Risk in Type 2 Diabetes: Does Baseline Glucose Control Matter?. 2018 , 4-5, 6-7	
1830	Moderne Antidiabetika in der Diabetologie. 2018 , 7, 292-300	

1829	Echocardiographic feature of diabetic cardiomyopathy: where are we now?. 2018 , 8, 47-56	18
1828	Is there a distinct phenotype of diabetic patients who benefit from tofogliflozin?. 2018 , 3, e58-e59	
1827	Should All Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease Receive an SGLT2 Inhibitor?. 2018 , 71,	
1826	S2k-Leitlinie Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter. 2018 , 13, 423-489	9
1825	Clinical Decision Support for Peripheral Artery Disease: Answering the Call. 2018 , 7, e011184	0
1824	Evaluating the Diabetes-Cardiology interface: a glimpse into the diabetes management of cardiology inpatients in western Sydney's 'diabetes hotspot' and the establishment of a novel model of care. 2018 , 10, 90	3
1823	Cardioprotective glucose-lowering medications: evidence and uncertainties in a new therapeutic era. 2018 , 7, 2-3	4
1822	Prevalence of Complexities Hypertension Associated with Type 2 Diabetes: A Cross Sectional Study. 2018 , 15,	
1821	Moderne Antidiabetika in der Kardiologie. 2018 , 7, 286-291	1
1820	Therapie des Typ-2-Diabetes. 2018 , 13, S144-S165	7
1819	Cardiomyopathie du diabète : nouvelles données physiopathologiques. 2018 , 12, 657-662	
1818	SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists. 2018 , 10, 615-625	9
1817	Possibility of a New Therapeutic Strategy for Left Ventricular Dysfunction in Type 2 Diabetes. 2018 , 10, 799-805	10
1816	A systematic review comparing the evidence for kidney function outcomes between oral antidiabetic drugs for type 2 diabetes. 2018 , 3, 74	3
1815	How to tackle congestion in acute heart failure. 2018 , 33, 462-473	9
1814	Update on renal disease in diabetic patients in primary care. 2018 , 2018, 32-36	
1813	New Tubulocentric Insights for Diabetic Nephropathy: From Pathophysiology to Treatment. 2018 ,	1
1812	Canagliflozin in the Diabetic-Obese and Poorly Controlled. 2018 , 08,	

1811 Cardiovascular outcome trials in diabetes: what have we learnt?. **2018**, 9, 7-12

1810 Full Issue PDF. **2018**, 3, I-CLVIII

1809 Treatment approach to type 2 diabetes: Past, present and future. **2018**, 9, 209-219

32

1808 Inhibiteurs des SGLT2 : l'effet classe se confirme. **2018**, 12, 637-639

1807 Cardiovascular outcome trials in type 2 diabetes: A nurse practitioner perspective. **2018**, 30, S43-S52

0

1806 7. Fallstricke in der pharmakologischen Therapie des Diabetes. **2018**, 128-140

1805 The Evolving Role of the Cardiologist in the Management of Type 2 Diabetes. **2018**, 18, 144

4

1804 Glucagon-like peptide-1 receptor agonists and cardiovascular protection in type 2 diabetes: a pathophysiology-based review of clinical implications. **2018**, 33, 665-675

5

1803 Spanish Diabetes Society (SED) recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes: 2018 Update. **2018**, 65, 611-624

1802 Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure. **2018**, 14, 1273-1285

4

1801 Diabetestherapie mit oralen Antidiabetika bei chronischer Niereninsuffizienz. **2018**, 13, 425-434

1800 The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. **2018**, 14, 1287-1302

41

1799 Calorie Restriction Mimetics: Upstream-Type Compounds for Modulating Glucose Metabolism. **2018**, 10,

38

1798 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. **2018**, 72, 3200-3223

180

1797 Type-2 diabetes mellitus and cardiovascular disease. **2018**, 14, 491-509

87

1796 Fasigliam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial. **2018**, 41, 2603-2609

16

1795 SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?. **2018**, 41, 2444-2447

13

1794 Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial. **2018**, 72, 2297-2305

24

1793	Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. 2018 , 363, k4365	159
1792	Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes. 2018 , 2018, 3106056	40
1791	[Diabetology: The most important innovations of the past 10 years]. 2018 , 160, 38-42	
1790	Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control. 2018 , 9, 1514	80
1789	Implications of the CANVAS Study in Reducing Cardiovascular Outcomes. 2018 , 18, 142	0
1788	Emerging paradigms of treating diabetic nephropathy. 2018 , 6, 912-913	3
1787	Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review. 2018 , 93, 1629-1647	20
1786	Cardiologist and Diabetologist crosstalk in the era of cardiovascular outcome trials of novel glucose-lowering drugs. 2018 , 21, 80-86	2
1785	[Use of dipeptidyl peptidase-4 inhibitors in patients with diabetes]. 2018 , 44 Suppl 1, 10-17	
1784	[Use of dipeptidyl peptidase-4 inhibitors in diabetic patients in special situations]. 2018 , 44 Suppl 1, 18-25	
1783	The Vulnerable Phase of Heart Failure. 2018 , 25, e456-e464	8
1782	Farmacos que mejoran el pronóstico cardiovascular en diabetes y los cardiólogos aún no usamos. 2018 , 71, 999-1000	3
1781	Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease-1: Study Protocol for a Multicenter Clinical Trial. 2018 , 5, 2054358118813088	6
1780	Consensus document of the Spanish Society of Arteriosclerosis (SEA) for the prevention and treatment of cardiovascular disease in type 2 diabetes mellitus. 2018 , 30 Suppl 1, 1-19	2
1779	Spanish Diabetes Society (SED) recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes: 2018 Update. 2018 , 65, 611-624	19
1778	Cardiovascular Benefits of GLP-1 Receptor Agonism: Is Inflammation a Key?. 2018 , 3, 858-860	5
1777	Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis. 2018 , 2018, 1232583	48
1776	Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials. 2018 , 6, E594-E602	17

1775	Secretary Capacity of Pancreatic Beta-Cells Is Enhanced 6 Months After Renal Denervation in Hypertensive Patients. 2018 , 72, 3372-3374	4
1774	Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis. 2018 , 11, 835-843	52
1773	The Intersection of Diabetes and Cardiovascular Disease-A Focus on New Therapies. 2018 , 5, 160	4
1772	Innovative Strategies in Heart Failure: Present and Future. 2018 , 49, 558-567	2
1771	Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin. 2018 , 62, 424-430	8
1770	Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes. 2018 , 1, e186125	45
1769	Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. 2018 , 72, 3370-3372	61
1768	Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial. 2018 , 72, 3274-3284	31
1767	The Heart and Vascular Team: Time for Endocrinologists to Join the Club?. 2018 , 72, 3285-3286	
1766	Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes. 2018 , 14, 419-428	6
1765	Hepatic ketogenic insufficiency reprograms hepatic glycogen metabolism and the lipidome. 2018 , 3,	26
1764	The past decade in type 2 diabetes and future challenges. 2018 , 17, 451-459	7
1763	Factors associated with choice of intensification treatment for type 2 diabetes after metformin monotherapy: a cohort study in UK primary care. 2018 , 10, 1639-1648	5
1762	Clinical and Investigative Endocrinology and Diabetes. 2018 , 24 Suppl 2, 1-22	0
1761	Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus. 2018 , 17, 153	50
1760	Reviewing the role of healthy volunteer studies in drug development. 2018 , 16, 336	18
1759	By What Standard Should We Manage Diabetes?. 2018 , 36, 12-13	1
1758	Pleiotropic effects of SGLT2 inhibitors beyond the effect on glycemic control. 2018 , 9, 212-214	9

1757	The future of febuxostat after the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial: who CARES?. 2018 , 19, 1853-1856	6
1756	GOALS FOR MEDICAL TREATMENT IN OBESITY AND PREDIABETES: IMPROVING OUTCOMES FOR BOTH. 2018 , 24, 1093-1098	0
1755	[Update on Diabetic Nephropathy 2018]. 2018 , 143, 1460-1465	
1754	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. 2018 , 39, 4243-4254	113
1753	Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: The SHIFT-J study. 2018 , 20, 1527-1535	28
1752	Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. 2018 , 19, 1630-1641	78
1751	Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition. 2018 , 38, 2207-2216	49
1750	Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications. 2018 , 20, 112	4
1749	Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?. 2018 , 20, 113	16
1748	Metabolic Acidosis and Cardiovascular Disease Risk in CKD. 2018 , 13, 1451-1452	5
1747	Executive Summary of the 2018 Joint Consensus Document on Cardiovascular Disease Prevention in Italy. 2018 , 25, 327-341	12
1746	2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. 2018 , 36, 1058-2011	1262
1745	Targeted HFpEF therapy based on matchmaking of human and animal models. 2018 , 315, H1670-H1683	8
1744	Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes. 2018 , 14, 1637-1640	7
1743	Cardiovascular Safety of Antihyperglycemic Agents: "Do Good or Do No Harm". 2018 , 78, 1567-1592	1
1742	Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications. 2018 , 96, 1184-1187	11
1741	Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk. 2018 , 72, 1763-1773	34
1740	The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review. 2018 , 72, 1856-1869	43

1739	Dangers of Hypoglycemia in Cardiac Patients With Diabetes: Time to Switch to Safer, Newer Drugs. 2018 , 72, 1787-1789	3
1738	Renal tubular solute transport and oxygen consumption: insights from computational models. 2018 , 27, 384-389	3
1737	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. 2018 , 392, 1519-1529	771
1736	Full Issue PDF. 2018 , 11, e917-e1097	
1735	Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease. 2018 , 44, 457-464	133
1734	Anti-Inflammatory Therapy and Coronary Artery Calcification Over Time. 2018 , 11, 1552-1553	
1733	A Quantitative Systems Pharmacology Kidney Model of Diabetes Associated Renal Hyperfiltration and the Effects of SGLT Inhibitors. 2018 , 7, 788-797	9
1732	Endpunktstudien in der Diabetestherapie. 2018 , 14, 376-383	
1731	Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. 2018 , 138, 2908-2918	48
1730	SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. 2018 , 3,	57
1729	Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 2018 , 61, 2461-2498	656
1728	Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 2018 , 41, 2669-2701	1307
1727	The Role of Deprescribing in Older Adults with Chronic Kidney Disease. 2018 , 35, 973-984	21
1726	Effects of SGLT2 Inhibitors on Circulating Stem and Progenitor Cells in Patients With Type 2 Diabetes. 2018 , 103, 3773-3782	20
1725	The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials. 2018 , 38, 1089-1108	8
1724	The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients. 2018 , 72, e13274	5
1723	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. 2018 , 190, E1192-E1206	16
1722	Chronic kidney disease epidemic: How do we deal with it?. 2018 , 23 Suppl 4, 116-120	42

1721	New clinical trial designs for establishing drug efficacy and safety in a precision medicine era. 2018 , 20 Suppl 3, 14-18	15
1720	Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. 2018 , 17, 132	93
1719	Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. 2018 , 35, 1763-1774	193
1718	The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. 2018 , 11, 749-761	120
1717	Lower extremity arterial disease in patients with diabetes: a contemporary narrative review. 2018 , 17, 138	58
1716	Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis. 2018 , 27, 839-879	6
1715	SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. 2018 , 14, 1113-1121	17
1714	Canagliflozin and Cardiovascular disease- results of the CANVAS trial. 2018 , 8, 267-268	2
1713	Dapagliflozin Attenuates Na/H Exchanger-1 in Cardiofibroblasts via AMPK Activation. 2018 , 32, 553-558	37
1712	Left ventricular noncompaction with intractable heart failure responsive to empagliflozin. 2018 , 18, 192-196	1
1711	SGLT2 inhibitors: practical considerations and recommendations for cardiologists. 2018 , 33, 676-682	9
1710	Liraglutide and Glycaemic Outcomes in the LEADER Trial. 2018 , 9, 2383-2392	13
1709	Does a gluten-free diet determine the efficacy of sotagliflozin in patients with concomitant type 1 diabetes mellitus and celiac disease?. 2018 , 13, 249-250	1
1708	Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study. 2018 , 1, e00036	18
1707	Medical and lifestyle management of peripheral arterial disease. 2018 , 68, 1595-1606	23
1706	Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease - Implications for Clinical Practice. 2018 , 14, 40-49	9
1705	Effects of intensive interventions compared to standard care in people with type 2 diabetes and microalbuminuria on risk factors control and cardiovascular outcomes: A systematic review and meta-analysis of randomised controlled trials. 2018 , 146, 76-84	9
1704	Evidence-Based Management of Diabetes in Older Adults. 2018 , 35, 1065-1078	11

1703	Diabetes and Atherosclerosis: Old Players in a New Field, Osteoporosis. 2018 , 16, 524-527	9
1702	Two Glucose-Lowering Mechanisms of Canagliflozin Depending on Body Weight Changes in Drug-Naïve Subjects with Type 2 Diabetes. 2018 , 18, 309-315	3
1701	Treatment with Oral Drugs. 2018 , 527-569	
1700	Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients. 2018 , 9, 1575	76
1699	COSMIC project: consensus on the objectives of the metabolic syndrome in clinic. 2018 , 11, 683-697	7
1698	Impacts of Diabetes and an SGLT2 Inhibitor on the Glomerular Number and Volume in db/db Mice, as Estimated by Synchrotron Radiation Micro-CT at SPring-8. 2018 , 36, 329-346	11
1697	Revisiting the Diabetes-Heart Failure Connection. 2018 , 18, 134	8
1696	Cardiology Consult Manual. 2018 ,	
1695	Association of Albuminuria With Intraglomerular Hydrostatic Pressure and Insulin Resistance in Subjects With Impaired Fasting Glucose and/or Impaired Glucose Tolerance. 2018 , 41, 2414-2420	13
1694	Betreuungsmanagement geriatrischer Patienten mit Diabetes mellitus. 2018 , 14, 351-362	3
1693	Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort. 2018 , 137, 270-279	6
1692	Diabetes Treatment in the Elderly: Incorporating Geriatrics, Technology, and Functional Medicine. 2018 , 18, 95	12
1691	Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis. 2018 , 6, 823-830	28
1690	World Health Organization Guidelines on Medicines for Diabetes Treatment Intensification: Commentary From the American College of Physicians High Value Care Committee. 2018 , 169, 398-400	5
1689	Living with Type 2 Diabetes: Patient Commentary in Response to the Paper 'SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice'. 2018 , 9, 1729-1732	1
1688	Sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes in North India: A 12-month prospective study in real-world setting. 2018 , 72, e13237	6
1687	Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist". 2018 , 138, 660-661	
1686	Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data. 2018 , 11, 187-197	14

1685	Primary and Secondary Prevention of Cardiovascular Disease. 2018 , 63-76	
1684	SGLT1 inhibition: Pros and cons. 2018 , 838, 153-156	19
1683	Ertugliflozin as a monotherapy for the treatment of type 2 diabetes. 2018 , 19, 1841-1847	6
1682	Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis. 2018 , 19, 58	10
1681	Spotlight on Antidiabetic Agents with Cardiovascular or Renoprotective Benefits. 2018 , 22, 18-034	1
1680	Age-Related Changes in Glucose Metabolism, Hyperglycemia, and Cardiovascular Risk. 2018 , 123, 886-904	90
1679	Drugs That Improve Cardiovascular Prognosis in Diabetes and Are Not Yet Used by Cardiologists. 2018 , 71, 999-1000	1
1678	2018 Standards of Care Update: Pharmacologic Approaches to Glycemic Management in People With Type 2 Diabetes. 2018 , 31, 254-260	3
1677	Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. 2018 , 2018, 6150861	31
1676	Design and baseline characteristics of the eValuation of ERTugliflozin efficacy and Safety CardioVascular outcomes trial (VERTIS-CV). 2018 , 206, 11-23	139
1675	Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians. 2018 , 42, 3-18	19
1674	Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function. 2018 , 15, 494-503	21
1673	Treatment of Diabetes in Patients with Heart Failure. 2018 , 20, 97	
1672	Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes. 2018 , 18, 92	18
1671	SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes. 2018 , 44, 493-499	24
1670	Refueling the Failing Heart: A Case for Sodium-Glucose Cotransporter 2 Inhibition in Cardiac Energy Homeostasis. 2018 , 3, 588-590	5
1669	Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease. 2018 , 17, 117	4
1668	Antihyperglycemic Medications and Impact on Cardiovascular Outcomes: A Review of Current Evidence. 2018 , 38, 739-757	3

1667	SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL. 2018 , 71, 2497-2506	68
1666	Prevention of Heart Failure With SGLT-2 Inhibition: Insights From CVD-REAL. 2018 , 71, 2507-2510	7
1665	Sitagliptin on carotid intima-media thickness in type 2 diabetes patients receiving primary or secondary prevention of cardiovascular disease: A subgroup analysis of the PROLOGUE study. 2018 , 271, 331-335	7
1664	Glucose lowering strategies and cardiovascular disease in type 2 diabetes - teachings from the TOSCA.IT study. 2018 , 28, 722-726	1
1663	[Diabetes Mellitus Type 2: Recent Publications and New Drugs]. 2018 , 143, 772-776	0
1662	The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors. 2018 , 57, 2105-2114	14
1661	Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. 2018 , 20, 2255-2263	39
1660	Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study. 2018 , 84, 2029-2039	19
1659	A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks. 2018 , 41, 1121-1124	34
1658	Why Weight? An Analytic Review of Obesity Management, Diabetes Prevention, and Cardiovascular Risk Reduction. 2018 , 20, 39	15
1657	Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?. 2018 , 19, 773-777	4
1656	Diabetes Mellitus-induced Bone Fragility. 2018 , 57, 2773-2785	24
1655	Improved Glycemic Control With Minimal Change in Medication Regimen Complexity in a Pharmacist-Endocrinologist Diabetes Intense Medical Management (DIMM) "Tune Up" Clinic. 2018 , 52, 1091-1097	2
1654	Highlights from the British Society for Heart Failure 20th Annual Autumn Meeting: three decades of heart failure. 2018 , 14, 203-206	
1653	Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations. 2018 , 35, 939-965	7
1652	Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. 2018 , 7,	7
1651	Multiplex proteomics for prediction of major cardiovascular events in type 2 diabetes. 2018 , 61, 1748-1757	28
1650	Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes-A Proposed MARE Definition. 2018 , 3, 1030-1038	15

1649	Canagliflozin for the treatment of type 2 diabetes: a comparison between Japanese and non-Japanese patients. 2018 , 19, 895-908	13
1648	The role of SGLT2 inhibitors in managing type 2 diabetes. 2018 , 31, 35-40	8
1647	SGLT inhibition: a possible adjunctive treatment for type 1 diabetes. 2018 , 25, 246-250	9
1646	Metformin use in the first year after kidney transplant, correlates, and associated outcomes in diabetic transplant recipients: A retrospective analysis of integrated registry and pharmacy claims data. 2018 , 32, e13302	13
1645	Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. 2018 , 71, 2360-2372	186
1644	Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study. 2018 , 44, 373-375	2
1643	Typ-2-Diabetes [Update 2018]. 2018 , 14, 294-308	1
1642	Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). 2018 , 203, 25-29	15
1641	SGLT2 inhibition and glucagon secretion in humans. 2018 , 44, 383-385	19
1640	Change in Albuminuria and Risk of Renal and Cardiovascular Outcomes: Natural Variation Should Be Taken into Account. 2018 , 3, 939-949	8
1639	Herzinsuffizienz bei Diabetes. 2018 , 14, 384-392	
1638	Do we need biomarkers for diabetics progressing to heart failure?. 2018 , 59, 98-99	2
1637	Are We Ready to Bell The Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes. 2018 , 138, 4-6	11
1636	Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus: A Need to Rethink. 2018 , 138, 7-9	21
1635	Effects of sodium glucose co-transporter 2 inhibitors on the kidney. 2018 , 15, 375-386	24
1634	Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. 2018 , 138, 1537-1550	149
1633	2020 vision - An overview of prospects for diabetes management and prevention in the next decade. 2018 , 143, 101-112	22
1632	Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists. 2018 , 143, 88-100	28

1631	Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. 2018 , 20, 2598-2607	34
1630	Advances in Clinical Cardiology 2017: A Summary of Key Clinical Trials. 2018 , 35, 899-927	1
1629	Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons. 2018 , 9, 1491-1500	7
1628	Historical Milestones in the Management of Stable Coronary Artery Disease over the Last Half Century. 2018 , 131, 1285-1292	3
1627	Oral diabetes medication monotherapy and short-term mortality in individuals with type 2 diabetes and coronary artery disease. 2018 , 6, e000516	4
1626	SGLT2 inhibition and kidney protection. 2018 , 132, 1329-1339	75
1625	Histones and heart failure in diabetes. 2018 , 75, 3193-3213	14
1624	Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts. 2018 , 6, e13741	66
1623	HbA and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study. 2018 , 41, 1981-1990	95
1622	Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). 2018 , 20, 2585-2597	115
1621	Evolution of Glucose-Lowering Drugs for Type 2 Diabetes. 2018 , 431-454	2
1620	The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents. 2018 , 143, 1-14	28
1619	Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. 2018 , 61, 1923-1934	160
1618	Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study. 2018 , 20, 2792-2799	41
1617	Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes. 2018 , 19, 1087-1095	9
1616	Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics. 2018 , 203, 30-38	29
1615	Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review. 2018 , 2018, 1025893	13
1614	Cardiovascular and Renal Outcomes of Newer Anti-Diabetic Medications in High-Risk Patients. 2018 , 20, 65	6

1613	Renal outcomes in CVOTs: keep calm and carry on. 2018 , 6, 674-676	4
1612	Blood Glucose Management of Type 2 Diabetes in the Older People. 2018 , 12, 170-174	5
1611	The optimal blood pressure target in diabetes mellitus: a quest coming to an end?. 2018 , 32, 641-650	9
1610	Association of Blood Pressure Measurements With Peripheral Artery Disease Events. 2018 , 138, 1805-1814	38
1609	Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes. 2018 , 52, 1224-1232	3
1608	Hypoglycemia Among Patients with Type 2 Diabetes: Epidemiology, Risk Factors, and Prevention Strategies. 2018 , 18, 53	62
1607	Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. 2018 , 6, 619-632	72
1606	Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms. 2018 , 33, 197-210	2
1605	The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity. 2018 , 9, 421	53
1604	Choice of Treatment Regimen as Add-On to Insulin in Japanese Patients with Type 2 Diabetes Mellitus: Physicians' Perspective in a Real-World Setting, Insight from a Web Survey. 2018 , 9, 1869-1881	
1603	Cardiovascular Disease in Diabetes. 2018 , 219-237	
1602	Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review. 2018 , 72, 1845-1855	121
1601	Insulin and Other Hypoglycemic Drugs. 2018 , 40, 537-546	2
1600	Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease. 2018 , 315, F1406-F1415	16
1599	Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. 2018 , 15, 937-943	11
1598	Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component?. 2018 , 20, 2515-2522	62
1597	Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study. 2018 , 17, 86	1
1596	Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial. 2018 , 41, 2136-2146	51

1595	Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction. 2018 , 17, 99	21
1594	Roles of Perivascular Adipose Tissue in the Pathogenesis of Atherosclerosis. 2018 , 9, 3	38
1593	Recent Advances in Primary and Secondary Prevention of Atherosclerotic Stroke. 2018 , 20, 145-166	22
1592	Cardiovascular effects of sodium glucose cotransporter 2 inhibitors. 2018 , 11, 133-148	15
1591	Beware of early drug intolerance in secondary prevention of cardiovascular disease. 2018 , 4, 202-204	
1590	Myocardial considerations in type 2 diabetes: 2018. 2018 , 10, 784-788	0
1589	SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice. 2018 , 9, 1757-1773	39
1588	Meta-analysis of the association between sodium-glucose co-transporter-2 inhibitors and risk of skin cancer among patients with type 2 diabetes. 2018 , 20, 2919-2924	5
1587	Review: In type 2 diabetes, SGLT-2 inhibitors or GLP-1 agonists reduce mortality vs control or DPP-4 inhibitors. 2018 , 169, JC2	2
1586	Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data. 2018 , 315, F1295-F1306	28
1585	SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism. 2018 , 314, F969-F984	52
1584	Review: In adults with type 1 diabetes, SGLT-2 inhibitors reduce HbA1c but increase diabetic ketoacidosis. 2018 , 169, JC3	3
1583	CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management. 2018 , 34, 1350-1361	2
1582	The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. 2018 , 41, 2229-2235	40
1581	National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. 2018 , 27, 1123-1208	141
1580	The safety of empagliflozin plus metformin for the treatment of type 2 diabetes. 2018 , 17, 837-848	3
1579	Is IGF-1 a useful inhibitor of Na ⁺ /H ⁺ -exchanger activity?. 2018 , 224, e13164	0
1578	Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury. 2018 , 17, 108	72

1577	Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets. 2018, 5, 1	59
1576	Actionable Metabolic Pathways in Heart Failure and Cancer-Lessons From Cancer Cell Metabolism. 2018, 5, 71	14
1575	Mechanisms of Aerobic Exercise Impairment in Diabetes: A Narrative Review. 2018, 9, 181	19
1574	Use of Readily Accessible Inflammatory Markers to Predict Diabetic Kidney Disease. 2018, 9, 225	20
1573	Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach. 2018, 18, 64	19
1572	Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study. 2018, 17, 91	31
1571	Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors. 2018, 17, 101	77
1570	The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies. 2018, 17, 815-824	10
1569	A Low-Protein Diet for Diabetic Kidney Disease: Its Effect and Molecular Mechanism, an Approach from Animal Studies. 2018, 10,	21
1568	Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD). 2018, 10,	19
1567	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. 2018, 24, 91-120	321
1566	Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice. 2018, 94, 912-925	70
1565	Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. 2018, 17, 73	83
1564	Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. 2018, 16, 116	28
1563	Making sense of newer treatment options for type 2 diabetes. 2018, 48, 762-769	
1562	Non-insulin pharmacological therapies for treating type 1 diabetes. 2018, 19, 947-960	8
1561	SGLT2 Inhibitors and Cardiovascular Outcomes: Current Perspectives and Future Potentials. 2018, 18, 63	9
1560	Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?. 2018, 20, 2711-2723	16

1559	ISPAD Clinical Practice Consensus Guidelines 2018: Type 2 diabetes mellitus in youth. 2018 , 19 Suppl 27, 28-46	109
1558	Cardiometabolic and Related Updates. 2018 , 52, 4-6	1
1557	Glycemic variability in the development of cardiovascular complications in diabetes. 2018 , 34, e3047	70
1556	Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials. 2018 , 17, 85	15
1555	SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. 2018 , 41, 1543-1556	99
1554	A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. 2018 , 94, 524-535	74
1553	Corrigendum to: The EHJ Editorial Board Meeting. 2018 , 39, 2389	
1552	Branched-Chain Amino Acids: The Metabolic Link Between Type 2 Diabetes Mellitus and Cardiovascular Disease?. 2018 , 11, e002182	
1551	Insulin therapy for type 2 diabetes - are we there yet? The d-Nav ² story. 2018 , 4, 8	4
1550	Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases. 2018 , 104, 257-268	8
1549	Diabetic foot syndrome in patients with diabetes. A multicenter German/Austrian DPV analysis on 33 870 patients. 2018 , 34, e3020	11
1548	The Berlin Declaration: A call to improve early actions related to type 2 diabetes. Why is primary care important?. 2018 , 12, 383-392	6
1547	Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines. 2018 , 17, 9	27
1546	How to interpret the role of SDF-1 β in diabetic complications during therapy with DPP-4 inhibitors. 2018 , 17, 22	5
1545	Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. 2018 , 17, 30	15
1544	Diabetes, cardiovascular disease and the microcirculation. 2018 , 17, 57	162
1543	Nachsorge nach Nierentransplantation. 2018 , 13, 167-172	
1542	The European Medicines Agency's approval of new medicines for type 2 diabetes. 2018 , 20, 2059-2063	12

1541 In Response. **2018**, 127, 307-308

1540	The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus. 2018 , 57, 2147-2156	41
1539	Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. 2018 , 122, 1439-1459	148
1538	Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study. 2018 , 4, 11	13
1537	The Alchemist's Nightmare: Might Mesenchymal Stem Cells That Are Recruited to Repair the Injured Heart Be Transformed Into Fibroblasts Rather Than Cardiomyocytes?. 2018 , 137, 2068-2073	15
1536	Critical Appraisal of the 2018 ACC Scientific Sessions Late-Breaking Trials From a Statistician's Perspective. 2018 , 71, 2957-2969	16
1535	Cardiovascular Disease and Diabetic Kidney Disease. 2018 , 38, 217-232	36
1534	Real-World Data Analytics Fit for Regulatory Decision-Making. 2018 , 44, 197-217	10
1533	Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis. 2018 , 9, 1945-1958	13
1532	An Update of Pathogenesis and Treatment in Patients with Chronic Kidney Disease (CKD) and Cardio-Renal Syndrome. 2018 , 64, 227-234	1
1531	Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Amputation: Results and Challenges From the Real World. 2018 , 178, 1199-1200	2
1530	Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes. 2018 , 178, 1190-1198	81
1529	Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure. 2018 , 17, 74	5
1528	SGLT inhibitor adjunct therapy in type 1 diabetes. 2018 , 61, 2126-2133	56
1527	Nonsevere Hypoglycemia Episode Clinical and Economic Outcomes: A Comparison between Sulfonylurea and Sodium-Glucose Cotransporter 2 Inhibitor as Add-On to Metformin from a Canadian Perspective. 2018 , 2018, 3718958	1
1526	The treatment of type 2 diabetes in heart failure. 2018 , 35, 123-126	2
1525	2018 ESC/ESH Guidelines for the management of arterial hypertension. 2018 , 39, 3021-3104	3698
1524	Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors. 2018 , 3, 575-587	162

1523	Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data. 2018 , 17, 118	18
1522	Rationale and Design of the STOP-OB Study for Evaluating the Effects of Tofogliflozin and Glimepiride on Fat Deposition in Type 2 Diabetes Patients Treated with Metformin/DPP-4 Inhibitor Dual Therapy. 2018 , 9, 2117-2125	2
1521	The bark giving diabetes therapy some bite: the SGLT inhibitors. 2018 , 61, 2075-2078	2
1520	Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). 2018 , 32, 1035-1039	2
1519	Effect of Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot Study. 2018 , 20, 681-688	12
1518	Cardiorenal Syndrome Revisited. 2018 , 138, 929-944	112
1517	SGLT2 inhibitors and amputation risk: Real-world data from a diabetes foot wound clinic. 2018 , 13, 46-47	9
1516	New pharmacological approaches for cardiovascular risk. 2018 , 151, 145-147	
1515	An interesting cross-talk between the glucagon-like peptide-1 receptor axis and angiotensin receptor pathway for modulation of renal sodium handling in obesity. 2018 , 41, 784-786	1
1514	Adjunctive therapy for glucose control in patients with type 1 diabetes. 2018 , 11, 159-173	12
1513	GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE REVIEW OF HOW TO WEIGH THE OPTIONS, SELECT THE RIGHT PATIENTS, AND MAXIMIZE BENEFITS. 2018 ,	
1512	Practical Ways to Achieve Targets in Diabetes Care. 2018 , 10, 911-915	2
1511	The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes. 2018 , 41, 1259-1267	9
1510	Development of SGLT1 and SGLT2 inhibitors. 2018 , 61, 2079-2086	109
1509	The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. 2018 , 61, 2098-2107	125
1508	Focusing on Sodium Glucose Cotransporter-2 and the Sympathetic Nervous System: Potential Impact in Diabetic Retinopathy. 2018 , 2018, 9254126	10
1507	Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. 2018 , 61, 2118-2125	79
1506	SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. 2018 , 61, 2108-2117	381

1505	SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases. 2018 , 61, 2134-2139	32
1504	[At the heart of diabetic cardiomyopathy: Bcl2 knockout mice to investigate glucotoxicity]. 2018 , 34, 563-570	1
1503	Diabetes and the Cardiovascular System. 2018 , 1-29	
1502	Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials. 2018 , 65, 693-705	11
1501	Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. 2018 , 61, 1724-1733	47
1500	The effect of Ramadan fasting and continuing sodium-glucose co-transporter-2 (SGLT2) inhibitor use on ketonemia, blood pressure and renal function in Muslim patients with type 2 diabetes. 2018 , 142, 85-91	20
1499	Only Trials Tell the Truth About Treatment Effects. 2018 , 71, 2640-2642	3
1498	Leptin, cardiovascular diseases and type 2 diabetes mellitus. 2018 , 39, 1176-1188	112
1497	Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic β cells in db/db mice: The earlier and longer, the better. 2018 , 20, 2442-2457	20
1496	Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION). 2018 , 65, 859-867	17
1495	Full Issue PDF. 2018 , 3, I-CLXXIV	
1494	Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. 2018 , 6, 605-617	245
1493	SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review. 2018 , 72, 267-277	60
1492	Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. 2018 , 41, 1783-1791	63
1491	Dulaglutide and renal protection in type 2 diabetes. 2018 , 6, 588-590	11
1490	Unmasking and aggravation of polycythemia vera by canagliflozin. 2018 , 35, 1613-1616	4
1489	Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride. 2018 , 41, 1809-1816	35
1488	Are Sodium-Glucose Cotransporter 2 Inhibitors Really Useful and Safe for Advanced Heart Failure?. 2018 , 82, 1752-1753	1

1487	Chronic Kidney Disease-Induced Insulin Resistance: Current State of the Field. 2018 , 18, 44	9
1486	Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA. 2018 , 18, 45	21
1485	SGLT2 inhibitors and the kidney: Effects and mechanisms. 2018 , 12, 1117-1123	26
1484	Increase in glycated haemoglobin concentrations after unwarranted prescription changes. 2018 , 20, 2510-2511	1
1483	Metabolic Complications, Nutritional Deficiencies, and Medication Management Following Metabolic Surgery. 2018 , 5-33	1
1482	Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. 2018 , 20, 2532-2540	81
1481	Ever-Increasing Insulin-Requiring Patients Globally. 2018 , 20, S21-S24	28
1480	Diabetes management before, during, and after bariatric and metabolic surgery. 2018 , 32, 870-875	11
1479	Metabolomic and microarray analyses of adipose tissue of dapagliflozin-treated mice, and effects of 3-hydroxybutyrate on induction of adiponectin in adipocytes. 2018 , 8, 8805	17
1478	Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. 2018 , 6, 691-704	304
1477	Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial. 2018 , 15, 469-472	19
1476	Metabolic remodelling in heart failure. 2018 , 15, 457-470	195
1475	Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science. 2018 , 52, 1238-1249	2
1474	Canagliflozin Improves the Recovery of Blood Flow in an Experimental Model of Severe Limb Ischemia. 2018 , 3, 327-329	16
1473	Diabetes-related cardiomyopathy: The sweet story of glucose overload from epidemiology to cellular pathways. 2019 , 45, 238-247	27
1472	Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys. 2019 , 24, 256-262	53
1471	Physician experiences with sodium-glucose cotransporter (SGLT2) inhibitors, a new class of medications in type 2 diabetes, and adverse effects. 2018 , 20, e50	3
1470	Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes. 2019 , 21, 28-36	38

1469	Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial). 2019 , 49, 64-71	58
1468	Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: A nested case-control study. 2019 , 21, 52-60	21
1467	Cardiometabolic effects of antidiabetic drugs in non-alcoholic fatty liver disease. 2019 , 39, 122-127	1
1466	Diabetic kidney disease. 2019 , 209-215	
1465	Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study. 2019 , 21, 252-260	25
1464	Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison. 2019 , 21, 261-266	6
1463	Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. 2019 , 21, 210-217	50
1462	Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials. 2019 , 21, 3-14	29
1461	Myocardial metabolism in heart failure: Purinergic signalling and other metabolic concepts. 2019 , 194, 132-144	24
1460	Real-world opportunity of empagliflozin to improve blood pressure control in African American patients with type 2 diabetes: A National Cardiovascular Data Registry "research-to-practice" project from the diabetes collaborative registry. 2019 , 21, 393-396	0
1459	Management of type 2 diabetes in renal disease: The twilight of the gods. 2019 , 34, 231-233	
1458	Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin. 2019 , 21, 227-233	7
1457	Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials. 2019 , 10, 418-428	13
1456	SGLT-2 Inhibitors and Peripheral Artery Disease: A Statistical Hoax or Reality?. 2019 , 44, 207-222	10
1455	Kardiovaskuläre Ergebnisse unter Dapagliflozin bei Typ-2-Diabetes. 2019 , 15, 262-264	
1454	Therapie geriatrischer Patienten mit Diabetes Nicht alles geht, aber vieles. 2019 , 13, 35-41	
1453	The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes. 2019 , 62, 364-369	9
1452	An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical trials. 2019 , 28, 811-820	4

1451	Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study. 2019 , 21, 2651-2659	8
1450	Cardiac Biomarkers and Risk of Atrial Fibrillation in Chronic Kidney Disease: The CRIC Study. 2019 , 8, e012200	13
1449	Class effects of SGLT2 inhibitors on cardiorenal outcomes. 2019 , 18, 99	71
1448	The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes. 2019 , 42, 1921-1929	21
1447	The sodium-glucose cotransporter 2 inhibitor luseogliflozin can suppress muscle atrophy in Db/Db mice by suppressing the expression of. 2019 , 65, 23-28	10
1446	Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials. 2019 , 30, 578-589	29
1445	The Effect of Type 2 Diabetes on Bone Biomechanics. 2019 , 17, 291-300	6
1444	Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy. 2019 , 317, F767-F780	61
1443	Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments. 2019 , 14, 23-32	30
1442	Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial. 2019 , 11, 62	7
1441	The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. 2019 , 6, 927-935	40
1440	Prevalence and Disease Burden of Chronic Kidney Disease. 2019 , 1165, 3-15	136
1439	Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. 2019 , 62, 1854-1867	29
1438	Prognostic nomogram and score to predict renal survival of patients with biopsy-proven diabetic nephropathy. 2019 , 155, 107809	8
1437	Clinical Predictors of the Need for Further Treatment Escalation in Patients with Type 2 Diabetes on Basal Insulin Therapy - A Retrospective Observational Study. 2019 , 127, 663-671	4
1436	Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. 2019 , 21, 2667-2673	42
1435	What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?. 2019 , 10, 1719-1731	3
1434	National ambulatory care non-insulin antidiabetic medication prescribing trends in the United States from 2009 to 2015. 2019 , 14, e0221174	9

1433	Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice. 2019 , 36, 2895-2909	11
1432	Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial. 2019 , 18, 106	16
1431	Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs. 2019 , 5, 27-30	4
1430	Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study. 2019 , 21, 702-712	47
1429	Severe hypoglycemia and the risk of cardiovascular disease and mortality in type 2 diabetes: a nationwide population-based cohort study. 2019 , 18, 103	22
1428	Emerging urine-based proteomic biomarkers as valuable tools in the management of chronic kidney disease. 2019 , 19, 853-856	7
1427	Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus. 2019 , 44, 984-992	27
1426	Eine diabetische Nephropathie bestimmt die Diabetestherapie mit. 2019 , 13, 31-36	
1425	Implementing simple algorithms to improve glucose and lipid management in people with diabetes and acute coronary syndrome. 2019 , 36, 1643-1651	11
1424	Glycaemic variability: The under-recognized therapeutic target in type 1 diabetes care. 2019 , 21, 2599-2608	21
1423	Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease. 2019 , 75, 1481-1490	5
1422	[Outcome studies on SGLT-2 inhibitors]. 2019 , 60, 903-911	1
1421	SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. 2019 , 16,	76
1420	The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes. 2019 , 34, 106-116	8
1419	Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. 2019 , 18, 107	44
1418	A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes. 2019 , 21, 2496-2504	6
1417	The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States. 2019 , 2, e00076	14
1416	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. 2019 , 21, 1270-1278	73

1415	Concurrent Use of Teneagliptin and Canagliflozin Improves Glycemic Control with Beneficial Effects on Plasma Glucagon and Glucagon-Like Peptide-1: A Single-Arm Study. 2019 , 10, 1835-1846	6
1414	Hispanic representation in diabetes cardiovascular outcomes trials. 2019 , 7, e000656	5
1413	Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients. 2019 , 33, 435-442	14
1412	Hipertensi3 arterial en la enfermedad renal cr3nica. 2019 , 12, 4772-4778	1
1411	2018 ESC/ESH Guidelines for the management of arterial hypertension. 2019 , 72, 160.e1-160.e78	8
1410	Diabetes and the Cardiovascular System. 2019 , 1-29	
1409	Approaches to Risk Assessment Among Older Patients With Diabetes. 2019 , 19, 59	8
1408	The future of new drugs for diabetes management. 2019 , 155, 107785	18
1407	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. 2019 , 140, 739-750	140
1406	Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?. 2019 , 10, 1625-1643	
1405	Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?. 2019 , 98, iii-ix	17
1404	Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme. 2019 , 21, 2474-2485	19
1403	Evaluation of Risk Factors for Major Amputation in Patients With Diabetes and Peripheral Artery Disease Receiving Antiplatelet Therapy - Post Hoc Analysis of a Prospective Observational Multicenter Cohort Study (SEASON). 2019 , 83, 1929-1936	3
1402	Why Do Patients With Well-Controlled Vascular Risk Factors Develop Progressive Chronic Kidney Disease?. 2019 , 35, 1170-1180	3
1401	A Potential Mechanism of Cardio-Renal Protection with Sodium-Glucose Cotransporter 2 Inhibitors: Amelioration of Renal Congestion. 2019 , 44, 449-456	11
1400	Heart Failure: Complications of Type 2 Diabetes. 2019 , 20, 1	
1399	The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. 2019 , 21, 1402-1411	103
1398	Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus. 2019 , 155, 107791	5

1397	Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance. 2019 , 20,	19
1396	Prevalence of pre-existing dysglycaemia among inpatients with acute coronary syndrome and associations with outcomes. 2019 , 154, 130-137	3
1395	Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 Inhibitor. 2019 , 21, 385-392	2
1394	Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis. 2019 , 21, 2274-2283	17
1393	Sodium glucose co-transporter 2 inhibitors mediated ketogenesis in patients with metabolic syndrome: clear benefit or anticipated fear?. 2019 , 4, e13-e15	1
1392	Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus. 2019 , 19, 54	4
1391	Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death. 2019 , 9, 9887	21
1390	SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice. 2019 , 10, 1595-1622	24
1389	Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. 2019 , 180, 398-416	7
1388	Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin. 2019 , 104, 3647-3660	12
1387	Prevention of Major Adverse Cardiovascular and Renal Outcomes with Sodium-Glucose Cotransporter 2 Inhibitors. 2019 , 20, 87	
1386	Clinical aspects of heart failure in individuals with diabetes. 2019 , 62, 1529-1538	9
1385	Impact of FDA-Required Cardiovascular Outcome Trials on Type 2 Diabetes Clinical Study Initiation From 2008 to 2017. 2019 , 2168479019860122	2
1384	Class effect for SGLT-2 inhibitors: a tale of 9 drugs. 2019 , 18, 94	16
1383	Substantial and Sustained Improvements in Blood Pressure, Weight and Lipid Profiles from a Carbohydrate Restricted Diet: An Observational Study of Insulin Resistant Patients in Primary Care. 2019 , 16,	30
1382	Cardiac Insulin Resistance in Heart Failure: The Role of Mitochondrial Dynamics. 2019 , 20,	19
1381	Pharmacotherapy of Children and Adolescents with Type 1 Diabetes Mellitus. 2020 , 261, 105-118	2
1380	Use of Insulin in the Inpatient Setting: Need for Continued Use. 2019 , 19, 64	3

1379	Diabetes und Niere [nach vielen Jahren der Stagnation endlich Neuigkeiten?]. 2019 , 15, 416-425	
1378	Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease. 2019 , 21, 100	3
1377	Trends of mortality in diabetic patients in Taiwan: A nationwide survey in 2005-2014. 2019 , 118 Suppl 2, S83-S89	14
1376	Cardiologist as a cardiometabolic specialist. 2019 , 21, 1432-1435	1
1375	Debate on Insulin vs Non-insulin Use in the Hospital Setting-Is It Time to Revise the Guidelines for the Management of Inpatient Diabetes?. 2019 , 19, 65	30
1374	Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice. 2019 , 11, 57	25
1373	SGLT2 inhibitors and the changing landscape for treatment of diabetes. 2019 , 15, 861-867	3
1372	Natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes. 2019 , 33, 2518-2530	16
1371	Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice. 2019 , 18, 83	21
1370	Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease. 2019 , 9, 723-730	22
1369	Response: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (2019;43:158-73). 2019 , 43, 379-380	1
1368	Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk. 2019 , 21, 38	
1367	Pharmacological treatment for Type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK. 2019 , 36, 1063-1071	7
1366	MicroRNA as novel biomarkers and therapeutic targets in diabetic kidney disease: An update. 2019 , 1, 375-388	14
1365	DPP-4 Inhibition and the Path to Clinical Proof. 2019 , 10, 376	36
1364	Bilateral gangrene of fingers in a patient on empagliflozin: First case report. 2019 , 10, 133-136	3
1363	Trends in antidiabetic medical treatment from 2005 to 2014 in Taiwan. 2019 , 118 Suppl 2, S74-S82	4
1362	Nephro Update Europe 2018. 2019 , 5, 173-181	1

1361	SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions. 2019 , 12, 1001-1012	15
1360	Prevention of macrovascular complications in patients with type 2 diabetes mellitus: Review of cardiovascular safety and efficacy of newer diabetes medications. 2019 , 10, 324-332	9
1359	Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations. 2019 , 21, 2354-2367	16
1358	Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes. 2019 , 21, 2422-2428	23
1357	Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity. 2019 , 18, 85	19
1356	Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study. 2019 , 8, e012244	8
1355	Management of Diabetes Mellitus in Normal Renal Function, Renal Dysfunction and Renal Transplant Recipients, Focusing on Glucagon-Like Peptide-1 Agonist: A Review Based upon Current Evidence. 2019 , 20,	4
1354	The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection. 2019 , 11, 1285-1303	13
1353	Renal Disease in Diabetes. 2019 , 791-807	
1352	A Case of Severe Acute Kidney Injury Exacerbated by Canagliflozin in a Patient with Type 2 Diabetes. 2019 , 2019, 8639629	2
1351	Therapie geriatrischer Patienten mit Diabetes. 2019 , 16, 51-57	
1350	Diabetestherapie geriatrischer Patienten: Was sagen die Leitlinien?. 2019 , 19, 36-43	0
1349	2017 Guidelines for the management of heart failure by pharmacists. 2019 , 152, 301-316	0
1348	Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials. 2019 , 155, 107808	3
1347	Studies With Molecules Within the Same Class, but With Different Designs Yield Different Results. EMPA-REG, CANVAS and DECLARE. 2019 , 72, 1095-1096	
1346	Hypoxia-inducible factor-1 β s the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy. 2019 , 9, 14754	50
1345	Heart failure in patients with type 2 diabetes mellitus: assessment with echocardiography and effects of antihyperglycemic treatments. 2019 , 17, 177-186	9
1344	Empagliflozin in type 1 diabetes. 2019 , 12, 1555-1561	4

1343	Sodium-Glucose Cotransporter 2 Inhibitors: Mechanisms of Action and Various Effects. 2019 , 20, 74	0
1342	Appraisal of Non-Cardiovascular Safety for Sodium-Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials. 2019 , 10, 1066	12
1341	Diabetic kidney diseases revisited: A new perspective for a new era. 2019 , 30, 250-263	54
1340	Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis. 2019 , 16, e1002942	30
1339	Is Heart Failure with Preserved Ejection Fraction a Kidney Disorder?. 2019 , 21, 86	6
1338	Empagliflozin and Protecting Microvascular Support of Heart Mechanics: SGLT2 Inhibition or More?. 2019 , 4, 592-595	1
1337	Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes. 2019 , 12, 1783-1794	4
1336	Chronic Kidney Disease Diagnosis and Management: A Review. 2019 , 322, 1294-1304	252
1335	SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects. 2019 , 8, e013389	78
1334	Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis. 2019 , 10, 2321-2330	5
1333	Impaired glucose tolerance and albuminuria in patients with chronic heart failure: a subanalysis of the SUPPORT trial. 2019 , 6, 1252-1261	4
1332	Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases. 2019 , 28, 1620-1628	17
1331	Sodium-glucose co-transporter 2 inhibitors and the risk of fractures: A propensity score-matched cohort study. 2019 , 28, 1629-1639	7
1330	Investigation of a Dipeptidyl Peptidase-4 Inhibitor/Thiazolidinedione Combination Drug for Patients With Type 2 Diabetes and Poor Glycemic Control: Difficulty With Patient Enrollment. 2019 , 11, 89-97	1
1329	Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. 2019 , 50, 345-356	80
1328	Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study. 2019 , 14, e0224549	6
1327	Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!. 2019 , 101, 154001	37
1326	Personalized Management of Type 2 Diabetes. 2019 , 19, 115	3

1325	The major molecular mechanisms mediating the renoprotective effects of SGLT2 inhibitors: An update. 2019 , 120, 109526	6
1324	Impact of CVOTs in primary and secondary prevention of kidney disease. 2019 , 157, 107907	1
1323	Risk of coronary artery disease according to glucose abnormality status and prior coronary artery disease in Japanese men. 2019 , 101, 153991	8
1322	Insuffisance cardiaque : ce que vous devez en savoir. 2019 , 13, S3-S9	
1321	Transposabilit� dans la pratique clinique des derni�res grandes Etudes en diab�tologie. 2019 , 13, S40-S50	
1320	When should fixed ratio basal insulin/glucagon-like peptide-1 receptor agonists combination products be considered?. 2019 , 33, 107473	5
1319	Therapie des Typ-2-Diabetes. 2019 , 14, S167-S187	19
1318	Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. 2019 , 10, 1347	36
1317	Occurrence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial. 2019 , 4, 1214-1220	20
1316	Inibitori di SGLT-2 e chetoacidosi euglicemica: conoscere per prevenire. 2019 , 20, 336-340	1
1315	Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus. 2019 , 1, 405-413	7
1314	Heart Failure and Diabetes Mellitus: Defining the Problem and Exploring the Interrelationship. 2019 , 132, S3-S12	
1313	Renal Effects of Sodium-Glucose Co-Transporter Inhibitors. 2019 , 132, S30-S38.e4	5
1312	Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. 2019 , 132, S49-S57.e5	7
1311	Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors. 2019 , 132, S21-S29	1
1310	Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection: JACC Review Topic of the Week. 2019 , 74, 2511-2524	32
1309	A Novel TNF-� Converting Enzyme (TACE) Selective Inhibitor JTP-96193 Prevents Insulin Resistance in KK-A Type 2 Diabetic Mice and Diabetic Peripheral Neuropathy in Type 1 Diabetic Mice. 2019 , 42, 1906-1912	6
1308	Rationale and Design of the CANONICAL Study - Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Canagliflozin for Heart Failure With Preserved Ejection Fraction With Type 2 Diabetes Mellitus. 2019 , 1, 347-351	2

1307	Diabetes Mellitus Is Associated With Increased Risk of Ischemic Stroke in Patients With and Without Coronary Artery Disease. 2019 , 50, 3347-3354	13
1306	Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide. 2019 , 12, 2125-2136	26
1305	[New ESC guidelines 2019 "Diabetes, prediabetes and cardiovascular diseases" : Paradigm shift in reduction of cardiovascular risk in patients with diabetes mellitus]. 2019 , 44, 684-687	5
1304	Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors. 2019 , 124 Suppl 1, S20-S27	20
1303	Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure. 2019 , 15, 519-530	0
1302	Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering. 2019 , 191, E1128-E1135	13
1301	Mineral and Electrolyte Disorders With SGLT2i Therapy. 2019 , 3, e10242	18
1300	Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model. 2019 , 22, 1402-1409	6
1299	Metformin Use Is Associated With a Lower Risk of Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus: a Retrospective Cohort Analysis. 2019 , 8, e011640	27
1298	Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials. 2019 , 10, 2201-2217	5
1297	Les inhibiteurs de SGLT2 : simple innovation, ou réel progrès?. 2019 , 13, S1-S2	
1296	Études cardiovasculaires chez le patient diabétique de type 2 à risque : conclusions et impact des essais publiés en 2017-2018. 2019 , 13, S10-S24	6
1295	Bénéfices cardiovasculaires et risques des inhibiteurs de SGLT2 : mécanismes de la protection. 2019 , 13, S25-S30	0
1294	Mise au point sur le profil de tolérance de la classe des inhibiteurs de SGLT2. 2019 , 13, S31-S39	2
1293	Treatment of heart failure with sodium glucose co-transporter-2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions. 2019 , 36, 1550-1561	2
1292	Individually Silica-Embedded Gold Nanorod Superlattice for High Thermal and Solvent Stability and Recyclable SERS Application. 2019 , 6, 1900986	5
1291	SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks. 2019 , 7, 949-958	38
1290	How Does CREDENCE Inform Best Use of SGLT2 Inhibitors in CKD?. 2019 , 14, 1667-1669	8

1289	Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. 2019 , 45, 409-418	54
1288	Is pharmacotherapy enough for urgent weight loss in severely obese patients?. 2019 , 20, 367-371	
1287	Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus. 2019 , 139, 152-154	12
1286	Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCCEL trial. 2019 , 18, 138	25
1285	Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. 2019 , 10, 1733-1752	26
1284	Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes. 2019 , 62, 349-357	33
1283	The Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit. 2019 , 10, 1771-1792	27
1282	The efficacy and safety of luseogliflozin and sitagliptin depending on the sequence of administration in patients with type 2 diabetes mellitus: a randomized controlled pilot study. 2019 , 20, 2185-2194	2
1281	Potential Impact on Lipoprotein Subfractions in Type 2 Diabetes. 2019 , 12, 1179551419866811	9
1280	Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study). 2019 , 18, 110	15
1279	Cardiovascular outcome trials of the newer anti-diabetic medications. 2019 , 62, 342-348	16
1278	The effect of circuit resistance training, empagliflozin or "vegeterranean diet" on physical and metabolic function in older subjects with type 2 diabetes: a study protocol for a randomized control trial (CEV-65 trial). 2019 , 19, 228	6
1277	Mild to moderate chronic kidney disease and cardiovascular events in patients with type 2 diabetes mellitus. 2019 , 15, 365-373	6
1276	Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes. 2019 , 36, 2567-2586	7
1275	Steeds meer aandacht voor renale effecten SGLT2-remmers. 2019 , 17, 12-16	
1274	Challenges and Opportunities Associated with Incorporating New Evidence of Drug-Mediated Cardioprotection in the Economic Modeling of Type 2 Diabetes: A Literature Review. 2019 , 10, 1753-1769	3
1273	Liraglutide in a real-world setting: Joint modeling of metabolic response, prediction of efficacy, and cardiovascular risk. 2019 , 66, 376-384	1
1272	Atrial Fibrillation and Diabetes Mellitus: JACC Review Topic of the Week. 2019 , 74, 1107-1115	91

1271	Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care. 2019 , 13, 485-494	3
1270	Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. 2019 , 140, 1693-1702	205
1269	Early Rapid Decline in Kidney Function as a Beneficial Sign After Starting Antihypertensive Medication. 2019 , 8, e013145	1
1268	Diabetes mellitus und Herz. 2019 , 15, 580-583	
1267	Peripheral Artery Disease and African Americans: Review of the Literature. 2019 , 13, 1	2
1266	Gliflozin schützt Nieren und Herz bei Patienten mit diabetischem Nierenschaden. 2019 , 13, 12-13	
1265	Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus. 2019 , 28, 321-327	13
1264	GLP-101: A Diabetes Educator's Guide to Glucagon-Like-Peptide-1 Receptor Agonists. 2019 , 7, 32-41	
1263	Glycosuria amount in response to hyperglycaemia and risk for diabetic kidney disease and related events in Type 1 diabetic patients. 2019 , 34, 1731-1738	7
1262	The right place for Sulphonylureas today. 2019 , 157, 107836	14
1261	SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. 2019 , 7, 845-854	335
1260	Glucose-lowering drugs and heart failure: implications of recent cardiovascular outcome trials in type 2 diabetes. 2019 , 157, 107835	6
1259	The Efficacy and Mechanism of Chinese Herbal Medicine on Diabetic Kidney Disease. 2019 , 2019, 2697672	17
1258	Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. 2019 , 366, l4772	47
1257	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. 2019 , 140, 1569-1577	57
1256	Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. 2019 , 18, 112	73
1255	Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs. 2019 , 18, 115	5
1254	Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes: A Network Meta-analysis. 2019 ,	

1253	Canagliflozin and Renal Outcomes in Diabetic Nephropathy. <i>New England Journal of Medicine</i> , 2019 , 381, 1087-1088	59.2	4
1252	Association of Antihyperglycemic Therapy with Risk of Atrial Fibrillation and Stroke in Diabetic Patients. 2019 , 55,		5
1251	SGLT-2 inhibitors for people with type 2 diabetes - Authors' reply. 2019 , 394, 560-561		4
1250	Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure. 2019 , 124, 1790-1796		20
1249	New antihyperglycemic medications with cardiovascular protection for patients with diabetes: What do surgeons need to know?. 2019 , 158, 1113-1117		2
1248	Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension. 2020 , 33, 207-213		10
1247	A comprehensive approach to type 2 diabetes mellitus [A recommendation document]. 2019 , 66, 443-458		1
1246	Heart-Failure Therapy - New Drugs but Old Habits?. <i>New England Journal of Medicine</i> , 2019 , 381, 2063-2064	59.2	4
1245	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2019 , 381, 1995-2008	59.2	2021
1244	Management of type 2 diabetes: now and the future. 2019 , 19, 403-405		2
1243	Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors. 2019 , 21, 130		22
1242	Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. 2019 , 140, 1463-1476		163
1241	A Call for More Complete Reporting of Cardiovascular Death. 2019 , 140, 887-888		0
1240	Progression of diabetic kidney disease in T2DN rats. 2019 , 317, F1450-F1461		16
1239	Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases. 2019 , 11, 80		21
1238	Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes. 2019 , 131, 555-565		4
1237	Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. 2019 , 40, 1447-1467		85
1236	Chronic Kidney Disease as a Risk Factor for Heart Failure With Preserved Ejection Fraction: A Focus on Microcirculatory Factors and Therapeutic Targets. 2019 , 10, 1108		19

1235	Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy. 2019 , 39, 1213-1221	1
1234	Renal glucosuria is associated with lower body weight and lower rates of elevated systolic blood pressure: results of a nationwide cross-sectional study of 2.5 million adolescents. 2019 , 18, 124	10
1233	Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing. 2019 , 12, 620-628	8
1232	Review of multimodal treatment for type 2 diabetes: combining metabolic surgery and pharmacotherapy. 2019 , 10, 2042018819875407	14
1231	Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK. 2019 , 10, 2131-2137	13
1230	Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes. 2019 , 42, 2290-2297	10
1229	Association of Inpatient Glucose Measurements With Amputations in Patients Hospitalized With Acute Diabetic Foot. 2019 , 104, 5445-5452	12
1228	Effects of empagliflozin on nondiabetic salt-sensitive hypertension in uninephrectomized rats. 2019 , 42, 1905-1915	14
1227	Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis. 2019 , 9, e030596	7
1226	Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes. 2019 , 11, 133-143	6
1225	Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCCEL Trial. 2019 , 140, 1613-1622	26
1224	Trends in incidence and case fatality of acute myocardial infarction, angina and coronary revascularisation in people with and without type 2 diabetes in Scotland between 2006 and 2015. 2019 , 62, 418-425	15
1223	Two cases of advanced stage rapidly progressive diabetic nephropathy effectively treated with combination therapy including RAS blocker, GLP-1 receptor agonist and SGLT-2 inhibitor. 2019 , 8, 128-133	1
1222	Canagliflozin, a sodium-glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats. 2019 , 10, 933-946	20
1221	Do Endocannabinoids Regulate Glucose Reabsorption in the Kidney?. 2019 , 143, 24-27	8
1220	F-Sodium Fluoride Imaging of Coronary Atherosclerosis in Ambulatory Patients With Diabetes Mellitus. 2019 , 39, 276-284	21
1219	Mineralocorticoid Antagonism and Diabetic Kidney Disease. 2019 , 19, 4	15
1218	FDA guidance on antihyperglycemic therapies for type 2 diabetes: One decade later. 2019 , 21, 1073-1078	27

1217	Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis. 2019 , 10, 473-491	13
1216	Management of diabetes mellitus in patients undergoing liver transplantation. 2019 , 141, 556-573	14
1215	Protracted glycosuria after discontinuation of sodium-glucose cotransporter 2 inhibitors: Implications for weekly dosing and extended risk of euglycemic diabetes ketoacidosis. 2019 , 11, 410-411	5
1214	In response to Yaribeygi et al. "Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways". 2019 , 234, 9906-9907	
1213	New approach to diabetes care: From blood glucose to cardiovascular disease. 2019 , 38, 53-63	3
1212	Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers. 2019 , 21, 1223-1236	24
1211	Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. 2019 , 21, 1237-1250	114
1210	Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. 2019 , 139, e56-e528	3937
1209	Cardiovascular Disease in Type 2 Diabetes: A Review of Sex-Related Differences in Predisposition and Prevention. 2019 , 94, 287-308	24
1208	Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease. 2019 , 68, 248-257	52
1207	Heart Failure With Preserved Ejection Fraction: Is Ischemia Due to Coronary Microvascular Dysfunction a Mechanistic Factor?. 2019 , 132, 692-697	19
1206	New Agents for the Treatment of Type 2 Diabetes. 2019 , 35, 315-328	11
1205	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. 2019 , 21, 1199-1208	51
1204	Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk. 2018 , 9, 1517	25
1203	Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?. 2019 , 33, 87-95	35
1202	New approach to diabetes care: from blood glucose to cardiovascular disease. 2019 , 38, 53-63	5
1201	Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial. 2019 , 19, 343-348	7
1200	Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians. 2019 , 10, 393-428	10

1199	Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. 2019 , 79, 219-230	82
1198	Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. 2019 , 16, 133-143	63
1197	SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart. 2019 , 4, 15-26	50
1196	Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs. 2019 , 13, 204-211	13
1195	Obesity-related heart failure with preserved ejection fraction: new treatment strategies. 2019 , 47, 67-72	5
1194	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. 2019 , 21, 1169-1186	325
1193	Structural and Functional Imaging of Muscle, Heart, Endocrine Pancreas and Kidneys in Cardiometabolic Drug Development. 2019 , 161-189	
1192	Associations of Arterial Stiffness Indices With Measures of Insulin Resistance and Renal Sodium Reabsorption. 2019 , 32, 810-812	3
1191	Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session. 2019 , 21, 31	8
1190	Global vascular guidelines on the management of chronic limb-threatening ischemia. 2019 , 69, 3S-125S.e40	294
1189	Pharmacoepidemiology: Using randomised control trials and observational studies in clinical decision-making. 2019 , 85, 1907-1924	6
1188	Learning Physiology From Inherited Kidney Disorders. 2019 , 99, 1575-1653	28
1187	The Effect of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in Patients Prescribed Regular U-500 Insulin. 2019 , 53, 1111-1116	1
1186	SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class. 2019 , 19, 64	7
1185	Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care. 2019 , 104, 3296-3302	8
1184	The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes. 2019 , 8,	13
1183	SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects. 2019 , 55,	21
1182	Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure. 2019 , 21, 70	41

1181	Performance of a clinical/proteomic panel to predict obstructive peripheral artery disease in patients with and without diabetes mellitus. 2019 , 6, e000955	7
1180	Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy. 2019 , 2019, 3901741	8
1179	Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data. 2019 , 53, 1227-1237	10
1178	Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease. 2019 , 21, 32	9
1177	Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?. 2019 , 12, 693-695	1
1176	CRENDENCE and DELIGHT deliver on renal benefits. 2019 , 15, 459-460	2
1175	GLucose COntrol Safety & Efficacy in type 2 Diabetes, a systematic review and NETWORK meta-analysis. 2019 , 14, e0217701	6
1174	Dapagliflozin: A Review in Type 2 Diabetes. 2019 , 79, 1135-1146	37
1173	Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. 2019 , 140, e294-e324	168
1172	Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes. 2019 , 42, 1716-1723	5
1171	Rationale, Design for the ASSET Study: A Prospective Randomized Study Comparing Empagliflozin's Effect to Sitagliptin on Cardiac Fat Accumulation/Function in Patients with Type 2 Diabetes. 2019 , 10, 1509-1521	2
1170	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. 2019 , 7, 606-617	304
1169	The expanding realm of SGLT2 inhibitors. 2019 , 7, 585-587	2
1168	Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. 2019 , 58, S1-S109.e33	329
1167	An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors. 2019 , 18, 691-701	14
1166	Ten things you should know about type 2 diabetes [Part 1]. 2019 , 2019, 23-25	1
1165	Role of Noninsulin Therapies in the Treatment of Type 1 Diabetes. 2019 , 32, 164-170	
1164	Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies. 2019 , 30, 1923-1940	22

1163	Cardiorenal syndrome in heart failure with preserved ejection fraction-an under-recognized clinical entity. 2019 , 24, 421-437	15
1162	Assessment of Heart Failure in Diabetes Cardiovascular Outcomes Trials: Is What We Are Currently Capturing Adequate?. 2019 , 19, 39	3
1161	Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment. 2019 , 131, 367-375	2
1160	Frequency and Prognosis of Treated Hypertensive Patients According to Prior and New Blood Pressure Goals. 2019 , 74, 130-136	9
1159	Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease. 2019 , 2, e00072	1
1158	The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. 2019 , 18, 64	19
1157	Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?. 2019 , 12, 313-321	22
1156	Residual vascular risk in diabetes - Will the SPPARM alpha concept hold the key?. 2019 , 13, 2723-2725	2
1155	Lifetime benefits of early detection and treatment of diabetic kidney disease. 2019 , 14, e0217487	10
1154	Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials. 2019 , 153, 138-144	27
1153	Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. 2019 , 73, 2791-2802	152
1152	Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes. 2019 , 14, 862-872	13
1151	Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. 2019 , 25, 584-619	30
1150	A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults. 2019 , 21, 2248-2256	6
1149	Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta-Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials. 2019 , 8, e012356	37
1148	Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors. 2019 , 8,	37
1147	Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2019 , 381, 841-851	59.2 567
1146	Canagliflozin for Japanese patients with chronic heart failure and type II diabetes. 2019 , 18, 76	30

1145	Ten things you should know about type 2 diabetes [part 2]. 2019 , 2019, 22-24		
1144	GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective. 2019 , 10, 1205-1217		4
1143	Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan. 2019 , 25, 646-651		
1142	Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy. 2019 , 230, 19-27		17
1141	Editors' Expert Forum 2018: Managing Big Data for Diabetes Research and Care. 2019 , 42, 1136-1146		7
1140	Euglycemic diabetic ketoacidosis in association with dapagliflozin use after gastric sleeve surgery in a patient with type II diabetes mellitus. 2019 , 7, 1087-1090		6
1139	Sodium-Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research. 2019 , 68, 1109-1120		25
1138	TRANSCULTURAL DIABETES CARE IN THE UNITED STATES - A POSITION STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS. 2019 , 25, 729-765		14
1137	Medical Therapy for Heart Failure Caused by Ischemic Heart Disease. 2019 , 124, 1520-1535		59
1136	Heart Failure With Preserved Ejection Fraction In Perspective. 2019 , 124, 1598-1617		229
1135	Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet. 2019 , 60, 728-735		11
1134	A Big Win for Diabetic Kidney Disease: CREDENCE. 2019 , 29, 1024-1027		15
1133	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2019 , 380, 1880-1881	59.2	45
1132	Promise, peril, and possible new treatment options incurred by sodium glucose co-transporter 2 (SGLT2) inhibitors: A precise review up to 2018. 2019 , 14, 100099		
1131	SGLT-2 Inhibitors and GLP-1 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease. 2019 , 24, 422-427		5
1130	Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis. 2019 , 3, 140-143		2
1129	Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. 2019 , 21, 1415-1422		28
1128	Quantitative Systems Pharmacology: An Exemplar Model-Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development. 2019 , 8, 380-395		15

1127	Diving into the unknown: sodium-glucose cotransporter-2 inhibitors in heart failure without diabetes. 2019 , 21, 874-876	2
1126	Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation. 2019 , 10, 362	21
1125	Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes. 2019 , 321, 1720-1721	10
1124	Loop diuretic use among patients with heart failure and type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors. 2019 , 33, 567-571	4
1123	A safety update on sodium glucose co-transporter 2 inhibitors. 2019 , 21 Suppl 2, 34-42	40
1122	What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition. 2019 , 21 Suppl 2, 43-52	33
1121	Effects of sodium-glucose cotransporter inhibitors on cardiorenal and metabolic systems: Latest perspectives from the outcome trials. 2019 , 21 Suppl 2, 5-8	5
1120	Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies. 2019 , 16, 415-423	18
1119	Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD. 2019 , 74, 328-337	18
1118	Effects of sodium glucose cotransporter type 2 inhibitors on heart failure. 2019 , 21 Suppl 2, 19-23	16
1117	Knockout of Na-glucose cotransporter SGLT1 mitigates diabetes-induced upregulation of nitric oxide synthase NOS1 in the macula densa and glomerular hyperfiltration. 2019 , 317, F207-F217	22
1116	Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey. 2019 , 10, 1523-1530	5
1115	Reduced hospitalization for heart failure using anti-diabetic drug dapagliflozin: implications of DECLARE-TIMI 58 for the basic science community. 2019 , 115, e54-e57	4
1114	An echocardiographic substrate for dyspnea identifies high risk patients with type 2 diabetes. 2019 , 289, 119-124	2
1113	A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors. 2019 , 21 Suppl 2, 9-18	43
1112	Beyond type 2 diabetes: sodium glucose co-transporter-inhibition in type 1 diabetes. 2019 , 21 Suppl 2, 53-61	6
1111	Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China. 2019 , 10, 480	8
1110	Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials. 2019 , 18, 59	11

1109	Assessment of the benefit-risk balance of SGLT2 inhibitors: Commentary on a new 'French paradox'. 2019 , 45, 319-321	6
1108	Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes. 2019 , 73, 2049-2058	12
1107	Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial. 2019 , 16, 171-177	3
1106	Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. 2019 , 62, 1154-1166	144
1105	Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. 2019 , 39, 631-641	15
1104	Are SGLT2 polymorphisms linked to diabetes mellitus and cardiovascular disease? Prospective study and meta-analysis. 2019 , 39,	5
1103	SGLT2 inhibition to address the unmet needs in diabetic nephropathy. 2019 , 35, e3171	12
1102	Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. 2019 , 7, 429-441	81
1101	SGLT2 inhibitor and incretin mimetic therapy for type 2 diabetes and chronic kidney disease. 2019 , 7, 414-415	
1100	SGLT2 Inhibition: Changing What Fuels the Heart. 2019 , 73, 1945-1947	7
1099	Residual cardiovascular risk among people with diabetes. 2019 , 21 Suppl 1, 28-38	25
1098	Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation. 2019 , 17, 127	53
1097	A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. 2019 , 10, 337-346	22
1096	Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials. 2019 , 12, 447-455	9
1095	Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome. 2019 , 16, 399-414	13
1094	Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: A meta-analysis of cardiovascular outcome trials. 2019 , 21, 1996-2000	37
1093	Statistical Appraisal of 6 Recent Clinical Trials in Cardiology: JACC State-of-the-Art Review. 2019 , 73, 2740-2755	14
1092	Will the new hypoglycaemic agents be effective on renal and cardiovascular protection in diabetes and renal diabetic disease?. 2019 , 39, 3-10	1

1091	Cardiologists' approach to managing cardiovascular risk in patients with type 2 diabetes. 2019 , 11, 605-609	1
1090	Heart failure prevention with sodium-glucose cotransporter 2 inhibitors. 2019 , 11, 601-604	1
1089	Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice. 2019 , 18, 100640	16
1088	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. 2019 , 95, 1304-1317	96
1087	How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study Protocol. 2019 , 10, 1163-1170	1
1086	Vascular Regenerative Cell Exhaustion in Diabetes: Translational Opportunities to Mitigate Cardiometabolic Risk. 2019 , 25, 640-655	8
1085	Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study. 2019 , 21, 1886-1894	12
1084	Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors. 2019 , 43, 158-173	10
1083	Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53. 2019 , 65, 781-790	7
1082	Management of patients with type 2 diabetes mellitus and acute coronary syndrome: Better be safe than sorry!. 2019 , 33, 465-467	6
1081	SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018). 2019 , 29, 369-384	10
1080	Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?. 2019 , 16, 303-309	17
1079	Should metformin still be the first-line of treatment in type 2 diabetes mellitus? A comprehensive review and suggested algorithm. 2019 , 13, 1935-1942	4
1078	Protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes. 2019 , 10, 1510-1517	7
1077	Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials. 2019 , 65, 15-24	17
1076	Diabetes und Herzinsuffizienz. 2019 , 15, 27-39	
1075	Poor risk factor control in outpatients with diabetes mellitus type 2 in Germany: The DIAbetes COhoRtE (DIACORE) study. 2019 , 14, e0213157	5
1074	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). 2019 , 21, 665-675	145

1073	Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes. 2019 , 8,	12
1072	Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial. 2019 , 19, 60	12
1071	Standards of medical care for type 2 diabetes in China 2019. 2019 , 35, e3158	180
1070	Analysis from the EMPA-REG OUTCOME trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. 2019 , 96, 489-504	47
1069	Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network. 2019 , 21, 1661-1667	14
1068	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 140, e596-e646	898
1067	Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus. 2019 , 139, 2591-2593	89
1066	The Serendipitous Story of SGLT2 Inhibitors in Heart Failure. 2019 , 139, 2537-2541	36
1065	Euglycemic diabetic ketoacidosis in type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitors. A report on two cases. 2019 , 13, 54-58	3
1064	Time-Matched Evaluation of Cardiovascular Risks Associated with Drugs for Type 2 Diabetes Mellitus. 2019 , 39, 469-476	2
1063	Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes. 2019 , 13, 1679-1683	5
1062	Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells. 2019 , 9, 4703	39
1061	Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists. 2019 , 286, 16-31	16
1060	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. 2019 , 139, 2516-2527	142
1059	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. 2019 , 139, 2528-2536	283
1058	Ambulatory Blood Pressure Reduction With SGLT-2 Inhibitors: Dose-Response Meta-analysis and Comparative Evaluation With Low-Dose Hydrochlorothiazide. 2019 , 42, 693-700	45
1057	News from the American Heart Association: more on sodium-glucose co-transporter 2 inhibitors, diabetes and heart failure. 2019 , 21, 261-263	2
1056	Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010-2017. 2019 , 21, 1576-1584	34

1055	Two Randomized Clinical Trials on the Treatment of Secondary Mitral Regurgitation-Contradictory or Complementary?. 2019 , 4, 311-313	8
1054	Sodium-Glucose Cotransporter 2 Inhibitors and Amputations. 2019 , 179, 451-452	
1053	Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?. 2019 , 21 Suppl 2, 24-33	9
1052	[Microbiome, diabetes and heart: a novel link?]. 2019 , 44, 223-230	3
1051	Heart failure and diabetes: management and open issues. 2019 , 44, 203-209	1
1050	Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction. 2019 , 4, 27-37	49
1049	Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatment. 2019 , 35, 1305-1306	1
1048	Understanding the cardiovascular risk with non-insulin antidiabetic drugs. 2019 , 18, 241-251	3
1047	Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. 2019 , 9, e022577	89
1046	Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. 2019 , 18, 20	57
1045	Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes. 2019 , 9, 3256	11
1044	Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. 2019 , 51, 655-669	6
1043	Metabolism of the failing heart and the impact of SGLT2 inhibitors. 2019 , 15, 275-285	32
1042	SGLT-2-Inhibitoren für die Primär- und Sekundärprävention. 2019 , 15, 47-49	
1041	What Clinicians Need to Know About the Cardiovascular Effects of the Most Recent Classes of Drugs Used for Type 2 Diabetes. 2019 , 132, 1027-1031	
1040	Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus. 2019 , 5, 25-36	3
1039	Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study. 2019 , 151, 20-32	31
1038	Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. 2019 , 104, 1520-1574	146

1037	Retrospective Analysis of the Efficacy of Dapagliflozin in Patients with Type 2 Diabetes in a Primary Clinic in Korea. 2019 , 34, 70-79	
1036	Diabetic Pharmacotherapies in Kidney Disease. 2019 , 49-74	
1035	Nine contemporary therapeutic directions in heart failure. 2019 , 11, e011150	1
1034	The Growing Case for Use of SGLT2i in Heart Failure: Additional Benefits of Empagliflozin in a HFpEF Rodent Model. 2019 , 4, 38-40	4
1033	Sodium-glucose cotransporter inhibitors: beyond glycaemic control. 2019 , 12, 322-325	12
1032	Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. 2019 , 139, e840-e878	301
1031	Non-immunological complications following kidney transplantation. 2019 , 8,	11
1030	Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. 2019 , 18, 30	24
1029	Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus. 2019 , 42, 1067-1074	58
1028	Effects of sarpogrelate on microvascular complications with type 2 diabetes. 2019 , 41, 563-573	4
1027	Improving Outcomes in Patients With Diabetes Mellitus. 2019 , 8, e011971	3
1026	Molecular Mechanisms Responsible for Diastolic Dysfunction in Diabetes Mellitus Patients. 2019 , 20,	22
1025	Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. 2019 , 62, 926-938	65
1024	Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis. 2019 , 10, 891-899	10
1023	Update on heart failure management and future directions. 2019 , 34, 11-43	48
1022	Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies. 2019 , 12, 299-308	12
1021	The Role of Platelets in Diabetes Mellitus. 2019 , 469-503	6
1020	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 74, 1376-1414	463

1019	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 74, e177-e232	516
1018	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 140, e563-e595	192
1017	Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. 2019 , 7, 356-367	102
1016	Utility of Invasive and Non-invasive Cardiovascular Research Methodologies in Drug Development for Diabetes, Obesity and NAFLD/NASH. 2019 , 275-308	
1015	Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis. 2019 , 42, 1165-1169	12
1014	Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits. 2019 , 21, 1780-1789	17
1013	Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care. 2019 , 139, 2822-2830	116
1012	Advancing pharmacotherapy for diabetic foot ulcers. 2019 , 20, 1153-1160	5
1011	Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: A meta-analysis of randomized controlled trials. 2019 , 21, 1871-1877	23
1010	Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence. 2019 , 96, 92-100	32
1009	Endocrine Health and Healthy Aging. 2019 , 201-212	
1008	SGLT receptors and myocardial ischaemia-reperfusion injury: inhibition of SGLT-1, SGLT-2, or both?. 2019 , 115, 1572-1573	2
1007	Eligibility of patients with type 2 diabetes for sodium-glucose co-transporter-2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry. 2019 , 21, 1985-1989	11
1006	Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials. 2019 , 21, 1790-1800	23
1005	A practical approach for a comprehensive evaluation and management of diabetes mellitus. 2019 , 13, 68-72	
1004	Molecular regulation of the renin-angiotensin system by sodium-glucose cotransporter 2 inhibition in type 1 diabetes mellitus. 2019 , 62, 1090-1093	13
1003	[Diabetic kidney disease (Update 2019) : Position paper of the Austrian Diabetes Association and the Austrian Society for Nephrology]. 2019 , 131, 151-163	1
1002	Clinical Credence - SGLT2 Inhibitors, Diabetes, and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2019 , 380, 2371-2373	59.2 16

1001	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2019 , 380, 2295-2306	59.2	2060
1000	[Individualising antihypertensive therapy in patients with diabetes. A guideline by the Austrian Diabetes Association (Update 2019)]. 2019 , 131, 124-135		
999	Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?. 2019 , 20, 1087-1090		3
998	Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus. 2019 , 49, 331-342		59
997	Inhibition of Sodium Glucose Cotransporter 2 Attenuates the Dysregulation of Kelch-Like 3 and NaCl Cotransporter in Obese Diabetic Mice. 2019 , 30, 782-794		11
996	Patient Assessment in Clinical Pharmacy. 2019 ,		2
995	Heart Failure and Metabolic Factors. 2019 , 123-133		
994	Of mice and men: Why progress in the pharmacological management of obesity is slower than anticipated and what could be done about it?. 2019 , 96, vi-xi		4
993	Prise de position de la Société Francophone du Diabète (SFD) : Évaluation du rapport bénéfices-risques des inhibiteurs de SGLT2. 2019 , 13, 195-209		4
992	SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence. 2019 , 131, 251-260		39
991	An update on the safety of SGLT2 inhibitors. 2019 , 18, 295-311		69
990	The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial. 2019 , 9, e026590		6
989	Heart Failure with Preserved Ejection Fraction: Time to Revisit the Stiff Heart. 2019 , 3, 409-420		1
988	Dethroning the king?: The future of metformin as first line therapy in type 2 diabetes. 2019 , 33, 462-464		3
987	The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury. 2019 , 44, 149-157		21
986	The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. 2019 , 18, 45		63
985	The direct effect of lobeglitazone, a new thiazolidinedione, on pancreatic beta cells: A comparison with other thiazolidinediones. 2019 , 151, 209-223		12
984	Bypass Surgery or Stenting for Left Main Coronary Artery Disease in Patients With Diabetes. 2019 , 73, 1616-1628		37

983	Diabetic cardiomyopathy: prevalence, determinants and potential treatments. 2019 , 10, 2042018819834869	39
982	Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitus. 2019 , 20, 129-138	5
981	Impact des nouvelles classes d'antidiabétiques sur le risque cardiovasculaire dans le diabète de type 2. 2019 , 13, 42-49	1
980	Le point sur un médicament : le dulaglutide (Trulicity®). 2019 , 13, 55-62	
979	Are gliflozins the new statins for diabetes?. 2019 , 153, 191-193	2
978	Renal effects of a sodium-glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status. 2019 , 21, 1715-1724	3
977	Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy. 2019 , 18, 46	86
976	Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. 2019 , 150, 8-16	59
975	Beyond glycemic control: New guidance on cardio-renal protection. 2019 , 99, 113-115	4
974	Evidence-Based Cardiovascular Risk Management in Diabetes. 2019 , 19, 439-448	5
973	Quantitative contrast-enhanced ultrasound of renal perfusion: a technology for the assessment of early diabetic nephropathy in cynomolgus macaques with type 2 diabetes mellitus. 2019 , 44, 1850-1857	2
972	Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?. 2019 , 4, 212-221	11
971	Sodium-Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes. 2019 , 37, 211-220	
970	Primary Prevention of Heart Failure in Women. 2019 , 7, 181-191	19
969	Clinical implications of cardiovascular outcome trials in type 2 diabetes. 2019 , 44, 192-202	3
968	Thérapie des Typ-2-Diabetes. 2019 , 15, 146-167	3
967	Full Issue PDF. 2019 , 4, I-CXLII	
966	SGLT2 inhibitors and protection against pancreatic beta cell failure. 2019 , 10, 1-2	6

965	Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications. 2019 , 21, 1277-1290	43
964	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. 2019 , 42, 1147-1154	138
963	Management of hypoglycemia in older adults with type 2 diabetes. 2019 , 131, 241-250	34
962	SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. 2019 , 34, 208-230	88
961	Treatment of diabetes and heart failure: a paradigm shift for cardiologists?. 2019 , 34, 207-212	2
960	PDM-ProValue meets cardiovascular outcome trials in diabetes. 2019 , 18, 10	2
959	SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob mice. 2019 , 18, 16	60
958	Effect of canagliflozin use on body weight and blood pressure at one-year follow-up: A systematic review and meta-analysis. 2019 , 26, 1680-1682	6
957	Diabetic cardiomyopathy: factual or factoid?. 2019 , 65, 61-69	5
956	Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy. 2019 , 10, 45	33
955	Cardiovascular Protection with Anti-hyperglycemic Agents. 2019 , 19, 249-257	13
954	The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes. 2019 , 35, 1283-1295	7
953	Sodium-glucose cotransporter-2 inhibitors: an overview and perioperative implications. 2019 , 32, 80-85	12
952	Personalizing Second-Line Type 2 Diabetes Treatment Selection: Combining Network Meta-analysis, Individualized Risk, and Patient Preferences for Unified Decision Support. 2019 , 39, 239-252	4
951	Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study. 2019 , 85, 1337-1347	15
950	Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome. 2019 , 10, 2042018818805674	2
949	The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus. 2019 , 79, 231-242	8
948	Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes. 2019 , 14, 75-83	4

947	Non-insulin treatments for Type 1 diabetes: critical appraisal of the available evidence and insight into future directions. 2019 , 36, 665-678	10
946	Advances in the clinical management of type 2 diabetes: a brief history of the past 15 years and challenges for the future. 2019 , 17, 46	12
945	Nonglycemic Outcomes of Antidiabetic Medications. 2019 , 37, 131-141	1
944	Clinical Implications of Baroreflex Sensitivity in Type 2 Diabetes. 2019 , 60, 241-246	3
943	Sodium-glucose cotransporter 2 inhibitor plus pioglitazone vs pioglitazone alone in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. 2019 , 2, e00050	7
942	Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use. 2019 , 62, 939-947	27
941	Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging. 2019 , 140, 303-315	114
940	Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney. 2019 , 34, 2015-2017	5
939	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. 2019 , 139, 2022-2031	345
938	Diabetes Mellitus and Cardiovascular Disease. 2019 , 39, 558-568	51
937	Canagliflozin review - safety and efficacy profile in patients with T2DM. 2019 , 12, 209-215	21
936	Therapeutic Inertia and the Legacy of Dysglycemia on the Microvascular and Macrovascular Complications of Diabetes. 2019 , 42, 349-351	12
935	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY. 2019 , 25, 69-100	191
934	Diuretic treatment of the patient with diabetes and heart failure. Role of SGLT2 inhibitors and similarities with carbonic anhydrase inhibitors. 2019 , 219, 208-217	1
933	SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. 2019 , 131, 82-88	44
932	The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm. 2019 , 10, 1-13	12
931	Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials. 2019 , 45, 436-445	22
930	Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. 2019 , 35, 1335-1343	21

929	Uric acid and the cardio-renal effects of SGLT2 inhibitors. 2019 , 21, 1291-1298	68
928	In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, dulaglutide reduced CV outcomes. 2019 , 171, JC27	
927	Disappearance of the National Guideline Clearinghouse. 2019 , 171, 71	
926	Excess Burden of Mental Illness and Hospitalization in Young-Onset Type 2 Diabetes. 2019 , 171, 78	
925	Excess Burden of Mental Illness and Hospitalization in Young-Onset Type 2 Diabetes. 2019 , 171, 78-79	1
924	Private Equity Acquisition of Physician Practices. 2019 , 171, 77-78	2
923	Private Equity Acquisition of Physician Practices. 2019 , 171, 78	10
922	Statins for Primary Prevention of Cardiovascular Disease. 2019 , 171, 74	
921	Statins for Primary Prevention of Cardiovascular Disease. 2019 , 171, 73	
920	Statins for Primary Prevention of Cardiovascular Disease. 2019 , 171, 73-74	
919	Statins for Primary Prevention of Cardiovascular Disease. 2019 , 171, 74-76	2
918	Fracture Risk After Initiation of Use of Canagliflozin. 2019 , 171, 79-80	
917	Fracture Risk After Initiation of Use of Canagliflozin. 2019 , 171, 80	5
916	Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study. 2019 , 171, 248-256	57
915	In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, oral semaglutide did not increase CV events. 2019 , 171, JC28	
914	In poorly controlled type 2 diabetes, oral semaglutide was noninferior to liraglutide for reducing HbA1c. 2019 , 171, JC29	0
913	Statins for Primary Prevention of Cardiovascular Disease. 2019 , 171, 72-73	
912	Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure. 2019 , 171, 76-77	2

911	To What Target Hemoglobin A1c Level Would You Treat This Patient With Type 2 Diabetes?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. 2019 , 171, 505-513	0
910	10. Cardiovascular Disease and Risk Management:. 2019 , 42, S103-S123	335
909	11. Microvascular Complications and Foot Care:. 2019 , 42, S124-S138	243
908	9. Pharmacologic Approaches to Glycemic Treatment:. 2019 , 42, S90-S102	550
907	Document on a comprehensive approach to type 2 diabetes mellitus. 2019 , 66, 443-458	13
906	The role of the heart failure nurse and use of sodium glucose cotransporter-2 inhibitors. 2019 , 1, 602-609	
905	Novel research into glucose-lowering drugs for heart failure shows promise. 2019 , 1, 530-531	
904	Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes (SCORE-IT): a patient and healthcare professional consensus on a core outcome set for type 2 diabetes. 2019 , 7, e000700	18
903	Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes. 2019 , 42, e150-e152	14
902	Newer Oral Antihyperglycemics: From Seinfeld to Breaking Bad. 2019 , 72,	
901	Ambulatory blood pressure monitoring-based analysis of long-term outcomes for kidney disease progression. 2019 , 9, 19296	5
900	Highlights in heart failure. 2019 , 6, 1105-1127	48
899	Treatment of Patients with Heart failure and Type 2 Diabetes: a review of the literature. 2019 , 13, 205-224	
898	Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. 2019 , 30, 2229-2242	57
897	Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?. 2019 , 7,	16
896	The historical evolution of knowledge of the involvement of neurohormonal systems in the pathophysiology and treatment of heart failure. 2019 , 38, 883-895	
895	Benefits and harms of intensive glycemic control in patients with type 2 diabetes. 2019 , 367, l5887	42
894	Pharmacotherapy of Children and Adolescents with Type 2 Diabetes Mellitus. 2020 , 261, 119-129	

893	Self-Care of Diabetic Nephropathy. 2019 , 20, 176	0
892	The historical evolution of knowledge of the involvement of neurohormonal systems in the pathophysiology and treatment of heart failure. 2019 , 38, 883-895	2
891	Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease. 2019 , 38, 721-735	1
890	Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus. 2019 , 13, 322-327	0
889	The role of the heart failure nurse and use of sodium glucose cotransporter-2 inhibitors. 2019 , 14, 1-12	
888	Sounding the alarm on rising diabetes-related amputations. 2019 , 191, E953-E954	1
887	Population-based secular trends in lower-extremity amputation for diabetes and peripheral artery disease. 2019 , 191, E955-E961	18
886	Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA. 2019 , 7, e000704	5
885	The Potential Cardioprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors. 2019 , 20, 81	
884	Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases. 2019 , 51, 3275-3280	17
883	Searching for optimal blood pressure targets in type 2 diabetic patients with coronary artery disease. 2019 , 18, 160	7
882	Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. 2019 , 124 Suppl 1, S45-S52	30
881	Lessons from the Trials for the Desirable Effects of Sodium Glucose Co-Transporter 2 Inhibitors on Diabetic Cardiovascular Events and Renal Dysfunction. 2019 , 20,	8
880	Renal Effects of Sodium-Glucose Co-Transporter Inhibitors. 2019 , 124 Suppl 1, S28-S35	22
879	Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. 2019 , 42, 2298-2306	70
878	Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review. 2019 , 17, 26	12
877	Heart Failure and Diabetes Mellitus: Defining the Problem and Exploring the Interrelationship. 2019 , 124 Suppl 1, S3-S11	14
876	Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials. 2019 , 158, 107927	10

875 Bringing the novel to the everyday. **2019**, 14, 1-2

874 Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus. **2019**, 10, 2150132719895188

873 Therapy of Type 2 Diabetes. **2019**, 127, S73-S92

12

872 Role of Hypoxia in Renal Failure Caused by Nephrotoxins and Hypertonic Solutions. **2019**, 39, 530-542

5

871 Importance of sodium-glucose cotransporter 2 inhibitor use in diabetic patients with acute heart failure. **2019**, 13, 1753944719894509

8

870 Clinical outcome comparison of percutaneous coronary intervention and bypass surgery in diabetic patients with coronary artery disease: a meta-analysis of randomized controlled trials and observational studies. **2019**, 11, 110

9

869 Scottish Society of Physicians 60th Annual Meeting, Thursday 1 & Friday 2 November 2018: abstract book. **2019**, 64, NP59-NP68

868 Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?. **2019**, 37, 316-337

5

867 Risk factor reduction in type 2 diabetes demands a multifactorial approach. **2019**, 26, 81-91

6

866 Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. **2019**, 26, 73-80

39

865 Targets for blood glucose: What have the trials told us. **2019**, 26, 64-72

6

864 Actionable Real-World Evidence to Improve Health Outcomes and Reduce Medical Spending Among Risk-Stratified Patients with Diabetes. **2019**, 25, 1442-1452

6

863 The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes. **2019**, 20,

7

862 Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus. **2019**, 2019, 3971060

22

861 Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease. **2019**, 2019, 9415313

3

860 Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages. **2019**, 10, 820

8

859 The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. **2019**, 1, e220-e228

20

858 Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats. **2019**, 18, 165

82

857	Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes. 2019 , 19, 132	3
856	Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient!. 2019 , 15, 1357-1364	16
855	Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date. 2019 , 12, 2515-2529	11
854	Lower extremity artery disease in patients with type 2 diabetes. 2019 , 26, 114-124	5
853	Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes. 2019 , 20,	25
852	Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial. 2019 , 12, e008018	15
851	Subtype-Dependent Reporting of Stroke With SGLT2 Inhibitors: Implications From a Japanese Pharmacovigilance Study. 2019 , 60, 629	7
850	Use of GLP-1 receptor agonists in patients with T2DM and chronic kidney disease. 2019 , 44, 20-28	
849	Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. 2019 , 34, 687-692	15
848	Improving the Standards of Reporting of Clinical Trial Data. 2019 , 2168479019879099	
847	Research into glucose-lowering drugs for heart failure treatment. 2019 , 24, 560-561	
846	Diabetes und Herzinsuffizienz. 2019 , 14, 180-192	
845	Efficacy of sodium-glucose co-transporter 2 inhibitors in patients with type II diabetes: A protocol for systematic review of randomised controlled clinical trials utilising a generalised pairwise modelling methodology. 2019 , 98, e18198	
844	[Austrian Consensus on High Blood Pressure 2019]. 2019 , 131, 489-590	3
843	Leçons des grandes Études cardiovasculaires et rénales portant sur les nouveaux antidiabétiques. 2019 , 11, S8-S17	
842	Les inhibiteurs des SGLT2 : traitement anti diabétiques et/ou de la prévention cardiovasculaire et/ou protection rénale ? Place au débat. 2019 , 11, S23-S29	
841	Cardioprotective diabetes drugs: what cardiologists need to know. 2019 , 8, 96-105	8
840	The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. 2019 , 37, 1334-1343	21

839	How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area. 2019 , 2019, 2018374	9
838	Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes. 2019 , 12, 30	4
837	JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure - Digest Version. 2019 , 83, 2084-2184	228
836	Updated management for patients with cardiovascular disease and diabetes. 2019 , 32, 51-53	1
835	Effects of glucose-lowering on outcome incidence in diabetes mellitus and the modulating role of blood pressure and other clinical variables: overview, meta-analysis of randomized trials. 2019 , 37, 1939-1949	4
834	Diabetes and Cardiovascular Disease: an Update. 2019 , 19, 161	20
833	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. 2019 , 140, 2108-2118	13
832	Dapagliflozin and DAPA-HF: from glycaemic control to heart failure therapy. 2019 , 36, 192-193	2
831	Update in recent clinical trials in heart failure. 2019 , 34, 307-314	2
830	Recent advances in diabetes treatments and their perioperative implications. 2019 , 32, 398-404	11
829	Predictors of heart failure development in type 2 diabetes: a practical approach. 2019 , 34, 578-583	9
828	Updates in the management of heart failure for the chronic kidney disease patient. 2019 , 28, 262-266	4
827	New drugs for the treatment of chronic heart failure with a reduced ejection fraction: What the future may hold. 2019 , 20, 650-659	5
826	Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis. 2019 , 98, e18245	38
825	Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. 2019 , 12, 2549-2557	4
824	Mécanismes possibles des effets bénéfiques cardiovasculaires des inhibiteurs SGLT2. 2019 , 11, S18-S22	
823	Anemia in patients of diabetic kidney disease. 2019 , 82, 752-755	8
822	A review of sotagliflozin for use in type 1 diabetes. 2019 , 10, 2042018819890527	6

821	Pharmacologic Randomized Clinical Trials in Prevention of Type 2 Diabetes. 2019 , 19, 154	3
820	Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease. 2019 , 38, 721-735	0
819	Nephropathie bei Diabetes. 2019 , 14, S235-S239	1
818	Reducing Cardiovascular Risk in Diabetes: Insights from Diabetes Trials. 2019 , 119-130	
817	Should sodium-glucose co-transporter-2 inhibitors be considered as first-line oral therapy for people with type 2 diabetes?. 2019 , 21, 207-209	4
816	Efficacy of intermittent empagliflozin supplementation on dietary self-management and glycaemic control in patients with poorly controlled type 2 diabetes: A 24-week randomized controlled trial. 2019 , 21, 303-311	3
815	Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?. 2019 , 17, 421-424	2
814	Novel and Emerging Therapeutics for Primary Prevention of Cardiovascular Disease. 2019 , 132, 16-24	4
813	Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes. 2019 , 10, 429-438	4
812	Diabetic patients with essential hypertension treated with amlodipine: blood pressure and arterial stiffness effects of canagliflozin or perindopril. 2019 , 37, 636-642	26
811	Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. 2019 , 21, 434-438	41
810	Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis. 2019 , 21, 340-348	42
809	Combination Therapy With Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients With Type 2 Diabetes: A Real-World Evidence Study. 2019 , 43, 186-192	13
808	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. 2019 , 40, 2907-2919	22
807	Prevention is back in the spotlight - Highlights from American Heart Association Scientific Sessions 2018. 2019 , 26, 502-506	
806	Health 2.0 2018. 2019 , 11, 102-106	
805	Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials. 2019 , 22, 280-287	4
804	Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus. 2019 , 49, 531-539	55

803	Obesity and type 2 diabetes: Also linked in therapeutic options. 2019 , 66, 140-149	1
802	Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. 2019 , 19, 907-919	44
801	The changing landscape of data monitoring committees-Perspectives from regulators, members, and sponsors. 2019 , 61, 1232-1241	3
800	Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. 2019 , 70, 711-724	112
799	Diabetes: Key Markers of Injury and Prognosis. 2019 , 41-51	5
798	Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis. 2019 , 14, 66-73	42
797	The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. 2019 , 21, 137-155	270
796	Cardiovascular outcome trials of glucose-lowering medications: an update. 2019 , 62, 357-369	56
795	Obesity and type 2 diabetes: Also linked in therapeutic options. 2019 , 66, 140-149	6
794	Diuretic treatment of the patient with diabetes and heart failure. Role of SGLT2 inhibitors and similarities with carbonic anhydrase inhibitors. 2019 , 219, 208-217	2
793	Heart Failure in Type 2 Diabetes Mellitus. 2019 , 124, 121-141	210
792	Canagliflozin and Stroke in Type 2 Diabetes Mellitus. 2019 , 50, 396-404	32
791	Good Guys, Bad Guys, Guesses, and Near Misses in Nephrology. 2019 , 14, 7-9	1
790	Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study. 2019 , 170, 155-163	59
789	Pharmacovigilance in the Real World. 2019 , 170, 201-202	2
788	Liraglutide in a real-world setting: Joint modeling of metabolic response, prediction of efficacy, and cardiovascular risk. 2019 , 66, 376-384	0
787	Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study. 2019 , 21, 1136-1145	42
786	Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis. 2019 , 8,	23

785	Cardiovascular effects of SGLT-2 inhibitors: What we have learned from cardiovascular outcome trials and what we still need to understand. 2019 , 35, e3124	9
784	New pharmacological strategies for protecting kidney function in type 2 diabetes. 2019 , 7, 397-412	44
783	The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis. 2019 , 21, 1018-1026	16
782	CANadian CANagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice. 2019 , 21, 691-699	6
781	Diabetes: the place of new therapies. 2019 , 10, 2042018818807599	6
780	Obesity and cardiovascular disease: revisiting an old relationship. 2019 , 92, 98-107	183
779	Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). 2019 , 123, 382-391	7
778	On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies. 2019 , 18, 166-183	27
777	Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies. 2019 , 115, 266-276	27
776	Protection of the kidney with sodium-glucose cotransporter 2 inhibitors: potential mechanisms raised by the large-scaled randomized control trials. 2019 , 23, 304-312	11
775	Sodium-glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter-organ crosstalk. 2019 , 21, 801-811	20
774	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2019 , 380, 347-357	59.2 2455
773	Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes. 2019 , 20, 151-161	15
772	Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME trial. 2019 , 10, 760-770	36
771	Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers. 2019 , 21, 720-725	10
770	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. 2019 , 393, 31-39	1300
769	Pump, pipes, and filter: do SGLT2 inhibitors cover it all?. 2019 , 393, 3-5	38
768	Sodium-glucose cotransporter inhibitors and oxidative stress: An update. 2019 , 234, 3231-3237	51

767	Treatment Goals in Diabetic Nephropathy. 2019 , 435-450	0
766	Prevalence of heart failure and the diagnostic value of MR-proANP in outpatients with type 2 diabetes. 2019 , 21, 736-740	9
765	Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. 2019 , 21, 812-821	65
764	Diabetes pharmacotherapy and effects on the musculoskeletal system. 2019 , 35, e3100	26
763	Diabetes Care for Patients Experiencing Homelessness: Beyond Metformin and Sulfonylureas. 2019 , 132, 408-412	6
762	Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. 2019 , 131, 31-42	42
761	A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses. 2019 , 105, 1213-1223	39
760	Future and Novel Compounds in the Treatment of Diabetic Nephropathy. 2019 , 515-539	2
759	Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure. 2019 , 139, 362-365	6
758	Preventing and treating kidney disease in patients with type 2 diabetes. 2019 , 20, 277-294	23
757	Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus. 2019 , 21, 829-836	5
756	Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease. 2019 , 10, 1004-1011	50
755	Future perspectives of the pharmacological management of diabetic dyslipidemia. 2019 , 12, 129-143	12
754	Diabetic Kidney Disease. 2019 , 42-61.e5	
753	The Role of the Chronic Kidney Disease Clinic and Multidisciplinary Team Care. 2019 , 121-135.e6	0
752	Improving Drug Use and Dosing in Chronic Kidney Disease. 2019 , 250-272.e5	
751	Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope. 2019 , 21, 1081-1087	33
750	Post-transplant diabetes mellitus in patients with solid organ transplants. 2019 , 15, 172-188	77

749	Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options. 2019 , 20, 585-593	9
748	Increasing ESKD in Diabetes in the Land Down Under: What Can Be Done, We Must Wonder. 2019 , 73, 293-296	1
747	Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis. 2019 , 36, 444-452	20
746	The effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes. 2019 , 42, 406-412	6
745	Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making. 2019 , 105, 867-877	68
744	The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. 2019 , 62, 621-632	21
743	Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients-a description of the DAPACARD study. 2019 , 124, 59-64	7
742	Evaluation and management of ketosis-prone diabetes. 2019 , 14, 43-48	3
741	Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts. 2019 , 115, 1533-1545	48
740	Response by Figtree et al to Letter Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)". 2019 , 139, 418-419	3
739	Diabetic cardiomyopathy. 2019 , 105, 337-345	37
738	Changing the Concept of Type 2 Diabetes: Beta Cell Workload Hypothesis Revisited. 2019 , 19, 121-127	6
737	Common Questions and Misconceptions in the Management of Renal Transplant Patients: A Guide for Health Care Providers in the Posttransplant Setting. 2019 , 53, 419-429	1
736	Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes. 2019 , 4, 94-102	16
735	Narrative review of the effects of antidiabetic drugs on albuminuria. 2019 , 234, 5786-5797	11
734	Why not adding a glucose-lowering agent with proven cardioprotection in high-risk patients with type 2 diabetes at HbA1c target on metformin?. 2019 , 147, 169-171	7
733	Adherence to treatment and its predictive factors among adults with type 2 diabetes in northern Iran. 2019 , 12, 45-59	
732	Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes. 2019 , 45, 110-121	31

731	Will the new molecules be effective in renal and cardiovascular protection in diabetes mellitus and diabetic kidney disease?. 2019 , 39, 3-10	2
730	Renal effects of sodium glucose co-transporter 2 inhibitors in Japanese type 2 diabetes mellitus patients with home blood pressure monitoring. 2019 , 41, 637-644	3
729	Change in Proteinuria or Albuminuria as a Surrogate for Cardiovascular and Other Major Clinical Outcomes: A Systematic Review and Meta-analysis. 2019 , 35, 77-91	8
728	Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial. 2019 , 21, 710-714	11
727	Effect of Canagliflozin on Heart Function Involving Ketone Bodies in Patients with Type 2 Diabetes. 2019 , 69, 297-300	8
726	The relationships between markers of tubular injury and intrarenal haemodynamic function in adults with and without type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. 2019 , 21, 575-583	9
725	Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk. 2019 , 73, 28-32	11
724	Diabetes Mellitus. 2022 , 7017-7043	
723	Metformin Protects against Diabetic Cardiomyopathy: An Association between Desmin/Barcomere Injury and the iNOS/mTOR/TIMP-1 Fibrosis Axis. 2022 , 10, 984	3
722	Pharmacology. 2022 ,	
721	Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials.. 2022 ,	1
720	Comparison of Serum Ketone Levels and Cardiometabolic Efficacy of Dapagliflozin versus Sitagliptin among Insulin-Treated Chinese Patients with Type 2 Diabetes Mellitus.. 2022 ,	0
719	Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor.. 2022 , 13, 799915	0
718	Trends in Use of High-Cost Antihyperglycemic Drugs Among US Adults with Type 2 Diabetes.. 2022 , 1	
717	The position of SGLT2 inhibitors in current medical practice - update 2022. 2022 , 68, 96-103	0
716	What connects SGLT2 inhibitors, diabetes mellitus, heart failure and empagliflozin?. 2022 , 68, 195-196	
715	Heterogeneous treatment effects of intensive glycemic control on major adverse cardiovascular events in the ACCORD and VADT trials: a machine-learning analysis.. 2022 , 21, 58	0
714	Polymer-Based Delivery of Peptide Drugs to Treat Diabetes: Normalizing Hyperglycemia and Preventing Diabetic Complications. 1	3

713	Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics.. 2022,	1
712	Novel Drugs for Diabetes Also Have Dramatic Benefits on Hard Outcomes of Heart and Kidney Disease.. 2022,	1
711	Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: Five Japanese cases.. 2022, 23, 168	0
710	Individualized Glycemic Goals for Older Adults Are a Moving Target.. 2022, 45, 1029-1031	0
709	Recent advances in the pharmacotherapeutic management of diabetic kidney disease.. 2022, 23, 791-803	0
708	Secondary Prevention of Atherosclerotic Cardiovascular Disease. 2022, 475-482	
707	Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Pancreatic β Cell Mass and Function.. 2022, 23,	
706	The rationale for the need to study sodium-glucose co-transport 2 inhibitor usage in peritoneal dialysis patients.. 2022, 8968608221096556	0
705	Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations.. 2022,	1
704	Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a population-based cohort study.. 2022,	0
703	Sodium-glucose cotransport-2 inhibitor induced ketoacidosis following coronary artery bypass surgery: implications for management.. 2022, 52, 876-879	
702	Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Current Evidence and Future Perspectives.. 2022,	0
701	Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin.. 2022, 79, 273	2
700	The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus.. 2022, 11,	0
699	New therapies for the treatment of heart failure with preserved ejection fraction.. 2022,	1
698	Concomitant treatment with insulin and sodium-glucose cotransporter 2 inhibitors was associated with the renal composite outcome in Japanese patients with type 2 diabetes and chronic kidney disease: A propensity score-matched analysis.. 2022,	0
697	Microvascular disease increases the risk of lower limb amputation - a Western Danish cohort study.. 2022, e13812	0
696	Prescribing SGLT2 Inhibitors in Patients with Chronic Kidney Disease: Expanding Indications and Practical Considerations. 2022,	3

695	Different SGLT 2 inhibitors: Can they prevent death?. 2022,	0
694	Editorial Commentary for "Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF" by McDowell, K, et al.. 2022,	
693	Association of Eligibility for a Sodium-Glucose Co-transporter 2 Inhibitor and Cardiovascular Events in Patients with Atrial Fibrillation.. 2022,	
692	Rationale, Design and Baseline Characteristics of the Effect of Canagliflozin in Type 2 Diabetic Patients with Microalbuminuria in Japanese Population (CANPIONE) study.. 2022,	
691	Picturing Vascular Health in Patients with Type 2 Diabetes Mellitus: Review based on the Special Lecture 2021. 2021, 5, 1-6	
690	Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.. 2022, 21, 64	0
689	Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes.. 2022, 109927	3
688	Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management.. 2022, 21, 74	1
687	Dapagliflozin Attenuates Myocardial Fibrosis by Inhibiting the TGF- β /Smad Signaling Pathway in a Normoglycemic Rabbit Model of Chronic Heart Failure. 2022, 13,	0
686	Research Progress on the Protective Effect of SGLT2 Inhibitor on Kidney. 2022, 12, 3926-3930	
685	Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study.. 2022,	1
684	Effects of the SGLT2 Inhibition on Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats, a Model of Type 1 Diabetes Mellitus. 2022, 11, 982	0
683	Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction: JACC Review Topic of the Week.. 2022, 79, 2058-2068	4
682	The use of glucagon-like-peptide-1 receptor agonist in the cardiology practice.. 2022, 1-13	
681	Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial.. 2022,	1
680	Empagliflozin in Patients Post Myocardial Infarction Rationale and Design of the EMPACT-MI Trial. 2022,	5
679	Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study.. 2022,	0
678	Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?. 2022, 117, 27	1

- 677 Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?. **2022**, 0
- 676 Canagliflozin and Atrial Fibrillation in Type 2 Diabetes Mellitus: A secondary analysis from the CANVAS Program and CREDENCE trials and meta-analysis.. **2022**, 0
- 675 Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study.. **2022**, 377, e069400 0
- 674 Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus.. **2022**, 21, 67 1
- 673 Precision Medicine for Diabetes and Cardiovascular Disease. **2022**, 53-64
- 672 Precision Medicine Approaches for Management of Type 2 Diabetes. **2022**, 1-52
- 671 Empagliflozin as a part of optimal medical therapy for chronic heart failure. **2022**, 17, 16
- 670 A Post Hoc Analysis of KidneyIntelXTM and Cardiorenal Outcomes in Diabetic Kidney Disease. 10.34067/KID.00021720 0
- 669 Phenome-Wide Association Study of UMOD gene variants and differential associations with clinical outcomes across populations in the Million Veteran Program a multiethnic biobank. **2022**,
- 668 The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. **2022**, 21, 1
- 667 Association of Dietary Fish and n-3 Unsaturated Fatty Acid Consumption with Diabetic Nephropathy from a District Hospital in Northern Taiwan. **2022**, 14, 2148 0
- 666 SGLT2 inhibitors in acute decompensated heart failure, what do we know?. **2022**, 94, 565-571 0
- 665 Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology. **2022**, 9, 1
- 664 SGLT2 Inhibitors and Peripheral Vascular Events. **2022**, 0
- 663 Empagliflozin restores cardiac metabolic flexibility in diet-induced obese C57BL6/J mice. **2022**, 5, 232-239 0
- 662 Management of Diabetic Nephropathy. **2022**, 671-690
- 661 Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes: A Narrative Review on Existing Evidence from Randomized Controlled Trials and Clinical Perspective. **2022**, 14, 1180
- 660 Impact of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging: What Do We Know So Far? (A Narrative Review). **2022**, 12, 803 3

- 659 Dipeptidyl peptidase-4 inhibitors attenuate osteoporosis in patients with diabetes: A nationwide, retrospective, matched-cohort study in Taiwan. **16**, Publish Ahead of Print, ○
- 658 Fibroblast Growth Factor 23 and Cardiovascular Risk in Diabetes Patients. *Cardiologists Be Aware.* **2022**, 12, 498
- 657 Effect of Sodium-Glucose Co-transporter Protein 2 Inhibitors on Arrhythmia in Heart Failure Patients With or Without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. **2022**, 9, ○
- 656 Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes. 1
- 655 Conocimiento del cardiólogo clínico sobre diabetes mellitus tipo 2 de alto riesgo. ¿Qué sabemos y cómo podemos mejorar?. **2022**, ○
- 654 SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis. ○
- 653 An update on the approaches of avoidance of propagation of chronic kidney disease resulting in reversal or possible need or avoidance of kidney transplantation - a systematic review. **2022**, 6, 040-057
- 652 Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin. 1
- 651 Gaps of Medication Treatment Management Between Guidelines and Real-World for Inpatients With Type 2 Diabetes in China From Pharmacist's Perspective. **2022**, 13,
- 650 ANMCO statement on the use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a practical guide for a streamlined implementation. **2022**, 24, C272-C277 ○
- 649 Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis. **2022**, 13, ○
- 648 Gliflozins in the Management of Cardiovascular Disease. *New England Journal of Medicine*, **2022**, 386, 2024-2034 59.2 6
- 647 OSTEOCALCIN ROLE IN THE REGULATION OF INSULIN SECRETION AND OSTEOTROPIC EFFECTS OF DIFFERENT CLASSES OF ANTI-DIABETIC DRUGS (LITERATURE REVIEW AND OWN RESEARCH). **2022**,
- 646 Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial. **2022**, 2022, 1-12
- 645 Precision Nephrology in Patients with Diabetes and Chronic Kidney Disease. **2022**, 23, 5719 ○
- 644 Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients. **2022**, 11, 2935 ○
- 643 Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes. **2022**, 2022, 1-10
- 642 Mechanisms of action of the SGLT2 inhibitor canagliflozin on tubular inflammation and damage: a post-hoc mediation analysis of the CANVAS trial. ○

641	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus. 2022 , 18, 402-411	
640	SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?.	0
639	The Risk of Cardiovascular Events in Individuals With Primary Glomerular Diseases. 2022 ,	2
638	Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents. 2022 ,	4
637	Mapping Knowledge Landscapes and Emerging Trends of the Links Between Bone Metabolism and Diabetes Mellitus: A Bibliometric Analysis From 2000 to 2021. 2022 , 10,	0
636	Discordance in the reduction rate between glycated albumin and glycated hemoglobin levels in type 2 diabetes patients receiving SGLT2 inhibitors. 2022 , 108225	
635	Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association.	8
634	Brain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure. 2022 , 11, 3192	0
633	Promise of sodium-glucose co-transporter-2 inhibitors in heart failure with mildly reduced ejection fraction.	0
632	Sodium-Glucose Cotransporter-2 (SGLT2) Expression in Diabetic and Non-Diabetic Failing Human Cardiomyocytes.	
631	Use of Guideline-Based Therapy for Diabetes, Coronary Artery Disease, and Chronic Kidney Disease After Acute Kidney Injury: A Retrospective Observational Study. 2022 , 9, 205435812211036	
630	Sex and Gender Related Differences in Diabetic Kidney Disease. 2022 , 42, 170-184	0
629	Sex, Gender, and Cardiovascular Disease in Chronic Kidney Disease. 2022 , 42, 197-207	1
628	Contrast-Induced Acute Kidney Injury in Patients on SGLT2 Inhibitors Undergoing Percutaneous Coronary Interventions: A Propensity-Matched Analysis. 9,	1
627	Sodium-glucose Cotransporter Type 2 Inhibitors: A New Insight into the Molecular Mechanisms of Diabetic Nephropathy. 2022 , 28,	
626	Diabetes and Progression of Heart Failure. 2022 , 79, 2285-2293	0
625	Renoprotective mechanisms of SGLT2 inhibitor in diabetic kidney disease. 2022 ,	
624	Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review.	0

623	Anthropomorphic Character Animations Versus Digital Chalk Talks in a Resident Diabetes Pharmacotherapy Curriculum: a Randomized Controlled Trial.	0
622	Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D.	0
621	Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS).	1
620	SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF-2 β signaling pathway in arrhythmogenic cardiomyopathy. 2022 , 36,	1
619	Clinical Benefits of Sodium-Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects. 2022 , 2, 287-293	
618	Exploring heterogeneities of cardiovascular efficacy and effectiveness of SGLT2 inhibitors in patients with type 2 diabetes: an umbrella review of evidence from randomized clinical trials versus real-world observational studies.	0
617	New Hypoglycemic Drugs: Combination Drugs and Targets Discovery. 13,	1
616	Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease.	0
615	The sodium-glucose co-transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE-deficient mice with streptozotocin-induced diabetes. 2022 , 10,	0
614	Chinese expert consensus on the diagnosis and treatment of chronic heart failure in elderly patients (2021).	0
613	Sodium Glucose Cotransporter-2 Inhibitor Protects Against Diabetic Neuropathy and Nephropathy in Modestly Controlled Type 2 Diabetes: Follow-Up Study. 13,	
612	Hypertension and Type 2 Diabetes—The Novel Treatment Possibilities. 2022 , 23, 6500	0
611	Inpatient perioperative euglycemic DKA due to SGLT2 inhibitors —Lessons from a case series and strategies to decrease incidence. 2022 ,	0
610	Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice. 13,	1
609	Significant reduction in chronic kidney disease progression with sodium glucose co-transporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.	1
608	Pharmacological Anti-Remodelling Effects of Disease-Modifying Drugs in Heart Failure with Reduced Ejection Fraction.	1
607	Rethinking the role of pioglitazone in modern diabetology as a cardiorenoprotective agent. 2022 , 10-21	0
606	Safety and effects of SGLT-2 inhibitor use among LVAD patients with type 2 diabetes mellitus. 2022 , 100154	

605	In Vivo Functional Assessment of Sodium-Glucose Cotransporters (SGLTs) Using [18F]Me4FDG PET in Rats. 2022 , 2022, 1-7	
604	Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors. 2022 , 101367	1
603	Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan.	0
602	The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD. 13,	0
601	Hypoglycaemic therapy in frail older people with type 2 diabetes mellitus—choice determined by metabolic phenotype.	3
600	Col4a3-/- Mice on Balb/C Background Have Less Severe Cardiorespiratory Phenotype and SGLT2 Over-Expression Compared to 129x1/SvJ and C57Bl/6 Backgrounds. 2022 , 23, 6674	1
599	Updated NICE guidelines on type 2 diabetes [what's new?]. 2022 , 2022, 12-16	
598	Therapie des Typ-2-Diabetes.	0
597	Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus. 2022 ,	0
596	The Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1. 2022 , 2, 349-368	0
595	Acute SGLT-2i treatment improves cardiac efficiency during myocardial ischemia independent of Na ⁺ /H ⁺ exchanger-1. 2022 ,	0
594	Prevention of Cardiorenal Complications with Sodium-Glucose Cotransporter Type 2 Inhibitors: A Narrative Review.	0
593	Novel perspectives of sodium handling in type 2 diabetes mellitus. 1-9	0
592	Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease.	0
591	Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis. 2022 , 50, 101510	0
590	Is There Room for New Drugs in the Treatment of Advanced Heart Failure: SGLT2i?. 2022 , 2, 195-197	
589	Treating Cardiometabolic Continuum by SGLT2 Inhibitors: From Diabetes Mellitus to Heart Failure. 2,	
588	SGLT2-Inhibitors are Effective and Safe in the Elderly: The SOLD Study.	

- 587 SEA 2022 standards for the comprehensive control of cardiovascular risk. **2022**, 34, 130-179
- 586 Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonist Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United States. **2022**, 100510 ○
- 585 An Early Assessment of the Real-World Treatment Patterns of Type 2 Diabetes: A Comparison to the 2018 ADA/EASD Consensus Report Recommendations.
- 584 Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States. 1-11 ○
- 583 Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data. **2022**, 23, 7261 ○
- 582 Cardiometabolism: Newer Pharmacologic Strategies for Reducing Cardiovascular Disease Risks.
- 581 New strategies and therapies for the prevention of heart failure in high-risk patients. **2022**, 45,
- 580 The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications. **2022**, 11, 3649 1
- 579 New Therapeutic Options for Type 2 Diabetes Mellitus and Their Impact Against Ischemic Heart Disease. 13,
- 578 The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study. **2022**, 21, 2
- 577 Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis. **2022**, 24, 1448-1457 ○
- 576 Assessing non-white ethnic participation in type 2 diabetes mellitus randomized clinical trials: A Meta-Analysis.
- 575 Epidemiology and Outcomes for the Chronic Kidney Disease. **2022**, 21, 121-134
- 574 Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?. **2022**, 37, 415-429 ○
- 573 The Efficacy and Safety of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients. Publish Ahead of Print, 1
- 572 Renal water transport in health and disease. ○
- 571 Safety outcomes of SGLT2i in the heart failure trials: A systematic review and Meta-analysis. **2022**, 1
- 570 The role of Recent Pharmacotherapeutic Options on the Management of Treatment Resistant Type 2 Diabetes. 1-13 1

- 569 The Role of the NLRP3 Inflammasome in Mediating Glomerular and Tubular Injury in Diabetic Nephropathy. 13, 0
- 568 Diabetes mellitus und Herz.
- 567 SGLT2 Inhibitors. **2022**, 95-129
- 566 Putative protective effects of sodium-glucose cotransporter 2 inhibitors on atrial fibrillation through risk factor modulation and off-target actions: potential mechanisms and future directions. **2022**, 21, 0
- 565 Sodium-glucose co-transporter 2 inhibitors: An additional management option for patients with atrial fibrillation?.
- 564 Diagnosis and Management of Heart Disease. **2022**, 139-172
- 563 Dapagliflozin for the treatment of chronic kidney disease. 1-17 1
- 562 New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Treated With Novel Glucose-Lowering Therapies. 2
- 561 Percutaneous coronary intervention with peripheral artery disease in the contemporary era: Still life or limb?. **2022**,
- 560 Low-dose sodium-glucose cotransporter 2 inhibitor ameliorates ischemic brain injury in mice through pericyte protection without glucose-lowering effects. **2022**, 5, 0
- 559 The Extraglycemic Effect of SGLT-2is on Mineral and Bone Metabolism and Bone Fracture. 13, 1
- 558 Therapy of Type 2 Diabetes. 0
- 557 Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor. 0
- 556 Diabetes Mellitus. **2022**, 395-406
- 555 Effects of 26-week treatment with empagliflozin versus glimepiride on myocardial glucose metabolic rate in patients with type 2 diabetes: the randomized, open-label, active-controlled crossover FIORE trial. 1
- 554 Sodium Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy. 8, 0
- 553 The efficacy of canagliflozin in diabetes subgroups stratified by data-driven clustering or a supervised machine learning method: a post hoc analysis of canagliflozin clinical trial data. 1
- 552 Multimodal Strategies for the Diagnosis and Management of Refractory Congestion. An Integrated Cardiorenal Approach. 13, 0

551	Diabetes in Elderly Cardiovascular Disease Patients: Mechanisms and Regulators. 2022 , 23, 7886	
550	Glucose-Lowering Agents and the Risk of Hypoglycemia: a Real-world Study.	
549	Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure. 2022 , 9, 225	1
548	Effect of Sodium-Glucose Cotransporter Inhibitors on Major Adverse Cardiovascular Events and Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus and Atrial Fibrillation. 2022 ,	1
547	Use of sodium-glucose co-transporter 2 inhibitors, changes in body mass index and risk of fracture: a population-based cohort study 2022 , 109993	
546	The Diabetic Cardiorenal Nexus. 2022 , 23, 7351	1
545	Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program. 2022 , 21,	2
544	Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial. 2022 , 10, 1656	
543	Re-examining the widespread policy of stopping SGLT2 inhibitors during acute illness: A perspective based on the updated evidence.	1
542	Head-to-head comparison of two SGLT-2 inhibitors on AKI outcomes in a rat ischemia-reperfusion model. 2022 , 153, 113357	0
541	New guidance on sodium glucose co-transporter 2 inhibitors in adults with kidney disease. 2021 , 6, 300-304	
540	Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes.	
539	Sodium-glucose cotransporter-2 inhibitors as first-line pharmacological therapy for type 2 diabetes?. 2022 , 102580	
538	Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties.	0
537	Effect of SGLT2 inhibitor medication on new prescriptions of antihypertensives, antigout/antihyperuricemics, and antidyslipidemics in Japan: Analysis using the JMDC Claims Database.	
536	Development and Validation of Prediction Models of Adverse Kidney Outcomes in the Population With and Without Diabetes Mellitus.	0
535	Contrast-Induced Acute Kidney Injury in Diabetic Patients and SGLT-2 Inhibitors: A Preventive Opportunity or Promoting Element?. 2022 , Publish Ahead of Print,	1
534	An investigation of physicians' prescribing behaviors related to antidiabetic agents for Type 2 diabetes mellitus patients and associated factors in Taiwan. 1-19	

- 533 Progress in the management of patients with diabetes and chronic kidney disease. **2022**, 31, 456-463
- 532 Clinical Characteristics of Inpatients With New-Onset Diabetes Mellitus in Eastern China: Based on Novel Clustering Analysis. 13, ○
- 531 Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 study in Japan. ○
- 530 SGLT2 inhibitors: suggestions from the amphibian world. 34, 63-69
- 529 A New Hope: Sodium-Glucose Cotransporter-2 Inhibition to Prevent Atrial Fibrillation. **2022**, 9, 236 1
- 528 Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P-TIMI 50 trial. ○
- 527 Twenty-Year Temporal Trends in Risk of Ischemic Stroke in Incident Type 2 Diabetes: A Danish Population-Based Cohort Study. ○
- 526 Quality of Care Among Patients with Diabetes and Cerebrovascular Disease. Insights from The Diabetes Collaborative Registry. **2022**,
- 525 Sodium-glucose cotransporter 2 (SGLT2) inhibitors for the prevention and treatment of diabetic kidney disease: A network meta-analysis of randomized controlled trials. **2021**, 1, 114-124
- 524 Practical aspects of initiation and use of SGLT2 inhibitors: inpatient and outpatient perspectives. **2022**, 25, 275-287
- 523 Comparison of Cardiovascular Outcomes Between Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis. **2022**,
- 522 Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort.
- 521 Glycemic status and the association of change in blood pressure with incident cardiovascular disease. **2022**,
- 520 Physical performance and glycemic control under SGLT-2-inhibitors in patients with type 2 diabetes and established atherosclerotic cardiovascular diseases or high cardiovascular risk (PUSH): Design of a 4-week prospective observational study. 9,
- 519 Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism. **2022**, 23, 7966 ○
- 518 Information and consensus document for the detection and management of chronic kidney disease. **2022**, ○
- 517 Do Glucagonlike Peptide-1 Receptor Agonist and Sodium-glucose Co-transporter 2 Inhibitor Prescriptions in Germany Reflect Recommendations for Type 2 Diabetes with Cardiovascular Disease of the ADA/EASD Consensus Report?.
- 516 Dual sodium-glucose cotransporter (SGLT) 1/2 versus pure SGLT2 inhibitors: two distinct drug categories or one class with multiple faces?. 1-6

515	Prolonged dual antiplatelet therapy after drug-eluting stent implantation in patients with diabetes mellitus: A nationwide retrospective cohort study. 9,	
514	Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria. 1-16	0
513	2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults. 2022 , 38, 1153-1167	1
512	Managing thrombotic risk in patients with diabetes. 2022 , 21,	0
511	Outcomes of myocardial revascularization in diabetic patients with left main coronary artery disease: A multicenter observational study from three gulf countries. 2022 ,	0
510	Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial. 2022 , 11,	
509	The Effect of SGLT-2 inhibitors and GLP-1RA on Major Cardiovascular Conditions: A Meta-Analysis.	
508	Potential molecular mechanism of action of sodium-glucose co-transporter 2 inhibitors in the prevention and management of diabetic retinopathy. 1-12	
507	The impact of sodium glucose cotransporter inhibitors on blood pressure: a meta-analysis and metaregression of 111 randomized-controlled trials. Publish Ahead of Print,	1
506	SGLT-2 inhibition by empagliflozin has no effect on experimental arterial thrombosis in a murine model of low-grade inflammation.	
505	SGLT2 Inhibitor Empagliflozin Modulates Ion Channels in Adult Zebrafish Heart. 2022 , 23, 9559	0
504	WITHDRAWN: American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan 2022 Update. 2022 ,	8
503	Is there any robust evidence showing that SGLT2 inhibitor use predisposes to acute kidney injury?.	
502	Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. 2022 , 21,	0
501	The complex interplay between diabetes mellitus and atrial fibrillation. 1-11	0
500	Correlation between albuminuria and interstitial injury marker reductions associated with SGLT2 inhibitor treatment in diabetic patients with renal dysfunction. 2022 , 27,	
499	Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?. 2022 , 23, 8631	0
498	Up-Date on Diabetic Nephropathy. 2022 , 12, 1202	2

- 497 SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. 3
- 496 Reconsidering the role of glycemic control on cardiovascular disease risk in type 2 diabetes: A 21 st century assessment. 0
- 495 **DipIn eGFR: Stay the Course With SGLT-2 Inhibition. 2022, 146, 463-465**
- 494 Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors. 2022, 0
- 493 Signal Detection of Acute Renal Failure Following the Use of SGLT-2 Inhibitors: Stratified Analysis and Time Trend Analysis in Japan and the United States. 2022, 45, 1077-1083
- 492 Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors. 0
- 491 Patterns and patient characteristics associated with use of SGLT2 inhibitors among adults with type 2 diabetes: A population-based cohort study. 2022, 2
- 490 Association of the cumulative triglyceride-glucose index with major adverse cardiovascular events in patients with type 2 diabetes. 2022, 21, 1
- 489 Potential diabetic cardiomyopathy therapies targeting pyroptosis: A mini review. 9, 0
- 488 Emerging roles of Sodium-glucose cotransporter 2 inhibitors in Diabetic kidney disease.
- 487 The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis. 2022, 38, 1201-1210 0
- 486 SGLT2 Inhibitors: New Hope for the Treatment of Acute Myocardial Infarction?.
- 485 Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review. 9,
- 484 Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program.
- 483 Canagliflozin Inhibits Human Endothelial Cell Inflammation through the Induction of Heme Oxygenase-1. 2022, 23, 8777 2
- 482 Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study. 2022, 183, 106374 0
- 481 Cardiorenal protection of SGLT2 inhibitors: Perspectives from metabolic reprogramming. 2022, 83, 104215 1
- 480 Empagliflozin improves cardiac mitochondrial function and survival through energy regulation in a murine model of heart failure.. 2022, 931, 175194 0

- 479 SGLT2-inhibitors are effective and safe in the elderly: The SOLD study. **2022**, 183, 106396 ○
- 478 Effects of a selective PPAR δ modulator, sodium-glucose cotransporter 2 inhibitor, and statin on the myocardial morphology of medaka nonalcoholic fatty liver disease model. **2022**, 625, 116-121
- 477 A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present. **2022**, 6, 100074
- 476 Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report. **2022**, 21, ○
- 475 Proximal tubular epithelia-specific transcriptomics of diabetic mice treated with dapagliflozin. **2022**, 8, e10615 ○
- 474 Beyond HbA1c cardiovascular protection in type 2 diabetes mellitus. 1-7 ○
- 473 Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study. ○
- 472 Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes. **2022**, 184, 106448 ○
- 471 Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice. **2022**, 63, 825 ○
- 470 Sodium-Glucose Cotransporter-2 (SGLT2) Expression in Diabetic and Non-Diabetic Failing Human Cardiomyocytes. ○
- 469 SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review. **2022**, 18, 62-72 ○
- 468 Herz und Diabetes. **2022**, 1-14 ○
- 467 Therapeutic peptidomimetics in metabolic diseases. **2022**, 521-550 ○
- 466 Kidney Disease Section □The Emerging Importance of Cellular Insulin Resistance in Diabetic Kidney Disease. **2022**, ○
- 465 Flozins in heart failure □ a new reimbursement indication. **2022**, 20, 19-25 ○
- 464 Evaluating Impact of Empagliflozin on Lipid Profile of Patients of Type 2 Diabetes Mellitus. **2022**, 9, 20-24 ○
- 463 Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS. 1
- 462 Antifibrotic effect and long-term outcome of SGLT 2 inhibitors in patients with NAFLD complicated by diabetes mellitus. ○

461	Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction.	1
460	Diabetic Cardiomyopathy: Pathophysiology and Novel Therapies. 2022 , 1,	0
459	Diabetes Mellitus Type 2, Prediabetes, and Chronic Heart Failure.	0
458	Effects of Sodium-Glucose Co-Transporter-2 Inhibition on Pulmonary Arterial Stiffness and Right Ventricular Function in Heart Failure with Reduced Ejection Fraction. 2022 , 58, 1128	0
457	Protective or inhibitory effect of pharmacological therapy on cardiac ischemic preconditioning: a literature review. 2022 , 20,	0
456	Meta-analysis of the association between new hypoglycemic agents and digestive diseases. 2022 , 101, e30072	0
455	Tratamiento farmacológico del paciente que vive con diabetes mellitus tipo 2. 2022 , 36, 81-105	0
454	How many and who are patients with heart failure eligible to SGLT2 inhibitors? Responses from the combination of administrative healthcare and primary care databases. 2022 ,	0
453	Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure. 2022 , 21,	0
452	Factors influencing diabetes-related foot ulcer healing in Australian adults: A prospective cohort study.	2
451	SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study.	1
450	Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).	12
449	Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease.	0
448	Glycemia Reduction in Type 2 Diabetes [Microvascular and Cardiovascular Outcomes. 2022 , 387, 1075-1088	4
447	Heterogeneity in cardiovascular deaths or hospitalizations for heart failure from cardiovascular outcome trials is linked to weight: A meta-regression analysis.	0
446	Impact of breakthrough trials on prescription trends of sodium-glucose cotransporter-2 inhibitors in Japan: An interrupted time-series analysis.	1
445	Effects of Antidiabetic Medications on the Risk of Bone Fracture in Patients With Type 2 Diabetes Mellitus. 2633559X2211227	0
444	Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study. 9,	0

- 443 Diabetic Proteinuria Revisited: Updated Physiologic Perspectives. **2022**, 11, 2917 ○
- 442 Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study. ○
- 441 Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 16
- 440 Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases. **2022**, 23, 10882 ○
- 439 Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. **2022**, 12, ○
- 438 Sodium-glucose Cotransporter 2 Inhibitors and Urinary Tract Infection: Is there room for real concern?. 10.34067/KID.0005722022 1
- 437 Intravital imaging of hemodynamic glomerular effects of enalapril or/and empagliflozin in STZ-diabetic mice. 13, ○
- 436 Benefits of Taking Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: A Systematic Review. **2022**, ○
- 435 Is there a paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors. **2022**, 47, ○
- 434 Renoprotective effects of dapagliflozin in an iron overload non-diabetic rat model. **2022**, 67, 311-315 ○
- 433 Comparative effectiveness of empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care. **2022**, ○
- 432 Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with glucagon-like peptide-1 receptor agonists (GLP -1 RAs) : A pooled analysis of type 2 diabetes trials. ○
- 431 Potential Benefits of Sodium-Glucose Transporter-2 Inhibitors in the Symptomatic and Functional Status of Patients With Heart Failure: A Systematic Review and Meta-Analysis. **2022**, ○
- 430 New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure. 9, ○
- 429 The Next Frontier: Biomarkers and Artificial Intelligence Predicting Cardiorenal Outcomes in Diabetic Kidney Disease. **2022**, 3, 1480-1483 ○
- 428 Sodium-glucose Co-transporter-2 inhibitors (SGLT2i): A class of drugs with promising cardiorenal protective effects beyond glycemetic control. **2022**, 81, 104536 ○
- 427 Emerging Treatment Approaches to Improve Outcomes in Patients with Heart Failure. Publish Ahead of Print, ○
- 426 Treatment of Diabetes and Osteoporosis: A Reciprocal Risk?. **2022**, 10, 2191 ○

425	Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials. 9,	3
424	The Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors Reduce Platelet Activation and Thrombus Formation by Lowering NOX2-Related Oxidative Stress: A Pilot Study. 2022 , 11, 1878	1
423	Cost-Effectiveness of Dapagliflozin for Chronic Kidney Disease in Japan. 2022 ,	0
422	Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options. 2022 , 10, 2274	2
421	Ethnic and socioeconomic disparities in initiation of second-line antidiabetic treatment in people with type 2 diabetes in England: a cross-sectional study.	0
420	Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom. 2022 , 22,	0
419	ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents.	2
418	Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study. 13,	0
417	Real-world risk of lower-limb amputation associated with sodium glucose cotransporter 2 inhibitors versus metformin: A propensity score-matched model analysis in Japan.	0
416	Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End-Stage Kidney Disease. 2022 , 11,	1
415	A Network Pharmacology to Explore the Potential Targets of Canagliflozin and Dapagliflozin in Treating Atherosclerosis. 2022 , 1, 53-70	0
414	Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure. 2022 , 12,	0
413	Sodium-glucose cotransporter-2 inhibitors: A treatment option for recurrent vasovagal syndrome?. 2022 , 155309	0
412	Clinical and Pathological Features of Chinese Patients with Type 2 Diabetes, Biopsy-Proven Diabetic Kidney Disease, and Rapid eGFR Decline. Volume 15, 2847-2856	0
411	Patient preferences for newer oral therapies in type 2 diabetes. 2022 ,	0
410	A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country.	0
409	Use of Glucose-Lowering Agents in Diabetes and Chronic Kidney Disease. 2022 ,	0
408	Prevention is still the key to success. 2022 , 8, 537-538	0

407	Diabetic kidney disease treatment: new perspectives. 2022 , 41, S63-S73	1
406	Diabetes and cardiovascular risk according to gender: an overview of epidemiological data from the early Framingham reports to the cardiovascular outcomes trials. 2022 ,	0
405	A 96-Week, Double-Blind, Randomized, Controlled Trial Comparing Bexagliflozin to Glimepiride as an Adjunct to Metformin for the Treatment of Type 2 Diabetes in Adults.	0
404	Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes. 2022 , 192, 110094	0
403	Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy. 9,	0
402	Sodium-glucose cotransporter 2 inhibitors and the risk of pneumonia and septic shock: A systematic review and meta-analysis.	1
401	Prise en charge de l'arthropathie des membres inférieurs chez les patients diabétiques présentant une plaie du pied. 2022 ,	0
400	Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events. 2022 , 18, 597-607	0
399	SGLT2 Inhibitors in Type 2 Diabetes Mellitus. 2022 , 18, 551-559	0
398	Diabetic Kidney Disease Back in Focus: Management Field Guide for Health Care Professionals in the 21st Century. 2022 , 97, 1904-1919	0
397	First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.	4
396	Canagliflozin reduces proteinuria by targeting hyperinsulinemia in diabetic patients with heart failure: a post-hoc analysis of the CANDLE trial.	0
395	The effect of allopurinol on cardiovascular outcomes in patients with type 2 diabetes: a systematic review.	0
394	Renoprotective Effects of SGLT2 Inhibitors. 2022 , 18, 539-549	0
393	SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction. 2022 , 18, 561-577	0
392	The presence of sodium glucose co-transporter 2 in mesangial cells and pericytes and its roles in mesangial lesions and in capillaries under diabetic and ischemic conditions. 2022 , 192, 110096	0
391	The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus. 2022 , 51,	0
390	SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction. 2022 , 18, 579-586	0

- 389 Long-Term Outcomes Among Young Adults With Type 2 Diabetes, Based on Durability of Glycemic Control: Results From the TODAY Cohort Study. ○
- 388 SGLT2 Inhibitors Are Lifesavers in Heart Failure. **2022**, 18, xi-xiv ○
- 387 SGLT2 Inhibitors and Safety in Older Patients. **2022**, 18, 635-643 ○
- 386 Reporting and Definition of Kidney Death in Heart Failure Clinical Trials. **2022**, 47, 101382 ○
- 385 **Missed Therapeutic Opportunity? SGLT-2 Inhibitor Use in General Medicine Patients With Heart Failure: A Retrospective Audit of Admissions to a Tertiary Health Service** **2022**, 16, 117954682211336 ○
- 384 **Putting It All Together: An Algorithmic Approach to Treat Patients with Peripheral Arterial Disease.** **2022**, 319-327 ○
- 383 Pharmacologic Interventions in Patients with Peripheral Arterial Disease. **2022**, 67-79 ○
- 382 **The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney.** **2022**, 23, 11987 ○
- 381 Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY study. **2022**, 21, ○
- 380 Toward Revision of the Best Practice for Diabetic Patients on Hemodialysis 2012 **2022**, 2, 495-511 ○
- 379 Diabetes Mellitus and Heart Failure. **2022**, 12, 1698 ○
- 378 Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease. **2022**, 17, e0269414 ○
- 377 Preoperative evaluation and perioperative management of patients undergoing major vascular surgery. **2022**, 27, 496-512 ○
- 376 **Physicians' Considerations and Practice Recommendations Regarding the Use of Sodium-Glucose Cotransporter-2 Inhibitors.** **2022**, 11, 6051 1
- 375 Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors Cover title: SGLT2i versus DPP4i in T2D patients after PAD revascularization. ○
- 374 **Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus [Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft für Angiologie (DGA), der Deutschen Gesellschaft für Interventionelle Radiologie und minimal-invasive Therapie (DeGIR) sowie der Deutschen** ○
- 373 New principles for the treatment of chronic heart failure: the phenomenon of sodium-glucose cotransporter type 2 inhibitors. **2022**, 44-51 ○
- 372 Effect of SGLT2 inhibitors on the course of chronic heart failure in patients with type 2 diabetes mellitus. **2022**, 16, 10-16 ○

371	SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice. 2022 , 10, 2458	0
370	Diabetes mellitus und Herz. 2022 , 17, S323-S326	0
369	Ketones: the double-edged sword of SGLT2 inhibitors?.	1
368	Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease.	0
367	New strategies to improve clinical outcomes for diabetic kidney disease. 2022 , 20,	0
366	Effect of dapagliflozin on cardiac function and metabolic and hormonal responses to exercise..	0
365	Benefits of SGLT2 inhibitors in arrhythmias. 9,	0
364	Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: A meta-analysis of randomized controlled clinical trials. 9,	0
363	Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease. 2022 , 14,	1
362	Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare Insured Adults With CKD in the United States. 2022 , 100564	0
361	The quest for the mechanism responsible for the cardiovascular benefits of novel antidiabetic agents. 2022 ,	0
360	Safety of sodium-glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations.	0
359	Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. 13,	1
358	Unmet needs in clinical trials in CKD: Questions we have not answered, and answers we have not questioned.	0
357	The Cardiovascular Benefits and Infections Risk of SGLT2i versus Metformin in Type 2 Diabetes: A Systemic Review and Meta-Analysis. 2022 , 12, 979	0
356	Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease. 2022 , 10, 2509	0
355	Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?.	0
354	SGLT2 inhibitors for the composite of cardiorenal outcome in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. 2022 , 175354	2

353	Gaps in our knowledge of managing inpatient dysglycaemia and diabetes in non-critically ill adults: A call for further research.	1
352	Emerging roles of sodium-glucose co-transporter inhibitors. 2022 , 33, 11-17	0
351	Remission of Proteinuria in a Patient Affected by Crescentic IgA Nephropathy with Rapidly Progressive Glomerulonephritis Treated by Sodium-Glucose Cotransporter-2 Inhibitors: Casual or Causal Relationship?. 2022 , 2, 545-552	0
350	Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults with Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials.	0
349	Cardioprotective Effect of Empagliflozin in Rats with Isoproterenol-Induced Myocardial Infarction: Evaluation of Lipid Profile, Oxidative Stress, Inflammation, DNA Damage, and Apoptosis.	0
348	Expert opinion on the cooperation of diabetologists and internists with nephrologists in the care of patients with chronic kidney diseases. 2022 , 68, 426-431	0
347	Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice. 2022 , 23, 12823	2
346	SGLT2i reduces renal injury by improving mitochondrial metabolism and biogenesis. 2022 , 101613	0
345	Cardiac Autonomic Neuropathy in Type 1 and 2 Diabetes: Epidemiology, Pathophysiology, and Management. 2022 ,	0
344	Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes After Catheter Ablation for Atrial Fibrillation. 2022 ,	1
343	The role of blood pressure management in stroke prevention: current status and future prospects. 2022 , 20, 829-838	0
342	COOrdinating CaRDIology CliNics RANdomized Trial of Interventions to Improve OutcomEs (COORDINATE) IDiabetes: Rationale and Design. 2022 ,	1
341	Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes. 2022 , 5, e2235995	0
340	Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies.	0
339	Metabolomic analysis of the effect of canagliflozin on HFpEF rats and its underlying mechanism.	0
338	KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. 2022 , 102, S1-S127	8
337	Metabolomic profiling in kidney cells treated with a sodium glucose-cotransporter 2 inhibitor.	0
336	Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes.	0

- 335 Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria. **2022**, 80, 1721-1731 ○
- 334 Prevalence of cardiovascular events among patients with type 2 diabetes in the west region of Saudi Arabia. **2022**, ○
- 333 Dual inhibition of SGLT2 and DPP-4 promotes natriuresis and improves glomerular hemodynamic abnormalities in KK/Ta-Ins2 mice with progressive diabetic kidney disease. **2022**, 635, 84-91 ○
- 332 Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5/6-nephrectomy. **2022**, 156, 113947 1
- 331 Use of real-world evidence data to evaluate the comparative effectiveness of second-line type 2 diabetes medications on chronic kidney disease. **2022**, 30, 100309 ○
- 330 Pharmacotherapy of type 2 diabetes: An update and future directions. **2022**, 137, 155332 3
- 329 Distinctive effects of SGLT2 inhibitors on angiogenesis in zebrafish embryos. **2022**, 156, 113882 ○
- 328 Lumbrokinase regulates endoplasmic reticulum stress to improve neurological deficits in ischemic stroke. **2022**, 221, 109277 ○
- 327 Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis. **2022**, 54, 101697 ○
- 326 The treatment of diabetes in advanced liver disease: Change of a paradigm. **2023**, 28, 100772 ○
- 325 Session Two: Changing the Type 2 Diabetes Mellitus Management Paradigm with Fixed-Ratio Combinations. 46-55 ○
- 324 Editor's Pick: How Can We Develop More Effective Strategies for Type 2 Diabetes Mellitus Prevention? A Paradigm Shift from a Glucose-Centric to a Beta Cell-Centric Concept of Diabetes. 46-52 ○
- 323 Rewriting Medical Textbooks: The Kidney as a Window to the Heart [The Role of Sodium-Glucose Transport Protein 2 Inhibitors in Cardiovascular and Renal Disease in Type 2 Diabetes Mellitus. 36-45 ○
- 322 Sodium-glucose co-transporter 2 inhibitors in 2022: mechanisms of cardiorenal benefit. **2022**, 7, 216-224 ○
- 321 The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials. 13, 1 ○
- 320 Inadequate Use of Newer Treatments and Glycemic Control by Cardiovascular Risk and Sociodemographic Groups in US Adults with Diabetes in the NIH Precision Medicine Initiative All of Us Research Program. ○
- 319 Assessment of Glucose Lowering Medications' Effectiveness for Cardiovascular Clinical Risk Management of Real-World Patients with Type 2 Diabetes: Targeted Maximum Likelihood Estimation under Model Misspecification and Missing Outcomes. **2022**, 19, 14825 ○
- 318 A New Chapter in the Treatment of Patients with Heart Failure. The Role of Sodium-Glucose Co-transporter Type 2 Inhibitors. **2022**, 18, 606-613 ○

- 317 Variations in Use of Diabetes Drugs With Cardiovascular Benefits Among Medicaid Patients. **2022**, 5, e2240117 ○
- 316 Depot-specific adipose tissue modulation by SGLT2 inhibitors and GLP1 agonists mediates their cardioprotective effects in metabolic disease. **2022**, 136, 1631-1651 ○
- 315 Estimated Glomerular Filtration Rate (eGFR) Slope Assessment as a Surrogate End-point in Cardiovascular trials: Implications, Impediments, and Future Directions. **2022**, 101508 ○
- 314 Prospective associations of circulating thrombospondin-2 level with heart failure hospitalization, left ventricular remodeling and diastolic function in type 2 diabetes. **2022**, 21, ○
- 313 Hypertension management in patients with cardiovascular comorbidities. ○
- 312 Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. **2022**, 10 ○
- 311 Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: A systematic review. **2022**, 100729 ○
- 310 Alogliptin and Heart Failure Outcomes in Patients With Type 2 Diabetes. 089719002211356 ○
- 309 Care Gaps in Sodium-Glucose Cotransporter-2 Inhibitor and Renin Angiotensin System Inhibitor Prescriptions for Patients with Diabetic Kidney Disease. ○
- 308 Prescribing Trends of the Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitors Among Different Physician Specialties in Canada (2015-2021).. **2022**, ○
- 307 Empagliflozin protects against renal ischemia/reperfusion injury in mice. **2022**, 12, ○
- 306 Meta-analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes. ○
- 305 Role of Ertugliflozin in the Management of Diabetes Mellitus. **2022**, ○
- 304 Renal function during hospitalization and outcome in Chinese patients with acute decompensated heart failure: A retrospective study and literature review. ○
- 303 Diabetic cardiomyopathy: a brief summary on lipid toxicity. 1
- 302 Impact of early initiation of sodium-glucose cotransporter 2 inhibitor on cardiovascular outcomes in people with diabetes and known or at risk of atherosclerotic cardiovascular disease: Propensity score matched analysis. **2022**, 17, e0277321 ○
- 301 Safe use of sodium glucose co-transporter 2 inhibitors in the management of type 2 diabetes. ○
- 300 Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial. ○

299	Instituting a Successful Discharge Plan for Patients With Type 2 Diabetes: Challenges and Solutions. 2022 , 35, 440-451	0
298	Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure.	0
297	Rationale and Design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in Patients with High-Risk Diabetic Cardiomyopathy. 2022 ,	1
296	Risk of hypovolemia associated with sodium glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials. 9,	1
295	Empagliflozin in heart failure with preserved ejection fraction: first success in mission impossible. 2022 , 24, 1153-1159	0
294	Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China. 9,	0
293	Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. 2022 , 21,	1
292	Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.	0
291	Preliminary observations on the use of ertugliflozin in the management of hyperinsulinaemia and laminitis in 51 horses: A case series.	0
290	Sodium-glucose co-transporter 2 inhibitors: A comprehensive review from cells to bedside.	0
289	Short term effects of sodium-glucose cotransporter 2 inhibitors on lipid regulation in coronary artery disease patients undergoing Percutaneous Coronary Intervention: A Propensity-Matched Analysis.	0
288	Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58.	0
287	Secondary Diseases of the Kidney. 2022 , 366-399	0
286	PHARMACOKINETIC INVESTIGATION OF REMOGLIFLOZIN IN RAT PLASMA SAMPLES BY HIGH-THROUGHPUT HPLC-MS-MS. 178-185	0
285	Meta-Analysis on the Safety and Efficacy of Sodium Glucose Cotransporters 2 Inhibitors in Patients With Heart Failure With and Without Diabetes. 2023 , 187, 93-99	0
284	Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. 2022 , 18, 40-53	0
283	Effect of sodium-glucose cotransporter-2 inhibitors on patients with essential hypertension and pre-hypertension: a meta-analysis. 2022 , 13, 204201882211424	0
282	Effect of new glucose-lowering drugs on stroke in patients with type 2 diabetes: A systematic review and Meta-analysis. 2023 , 37, 108362	0

- 281 Effect of empagliflozin in patients with type 2 diabetes during Ramadan on volume status, ketonaemia, and hypoglycaemia. **2023**, 17, 102680 ○
- 280 Corrigendum to Mechanisms and pharmacotherapy of hypertension associated with type 2 diabetes [Biochem. Pharmacol. 206 (2022) 115304]. **2023**, 207, 115349 ○
- 279 SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: A population-based propensity score-matched cohort study. **2023**, 195, 110200 ○
- 278 Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry. **2023**, 187, 106597 3
- 277 Contributors to impaired bone health in type 2 diabetes. **2023**, 34, 34-48 ○
- 276 Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study. **2022**, 9, 205435812211450 ○
- 275 Intestinal Cholesterol Absorption in Diabetes Mellitus. **2022**, ○
- 274 The NO-cGMP-PKG Axis in HFpEF: From Pathological Mechanisms to Potential Therapies. **2022**, 0 ○
- 273 Metabolic effects of empagliflozine. **2022**, 38-56 ○
- 272 Combining metabolic surgery with medications for type 2 diabetes: Is there a benefit?. **2022**, 0 ○
- 271 Non-albuminuric Diabetic Kidney Disease Phenotype: Beyond Albuminuria. **2022**, 18, 102 ○
- 270 Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium-Glucose Co-transporter-2 Inhibitors. **2022**, 18, 106 ○
- 269 Sodium-glucose cotransporter 2 inhibitors as the first universal treatment of chronic kidney disease. **2022**, 42, 390-403 ○
- 268 SGLT-2 Inhibitors in Cancer Treatment Mechanisms of Action and Emerging New Perspectives. **2022**, 14, 5811 1
- 267 Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Patients With Diabetes and Chronic Kidney Disease (CKD): A Meta-analysis of Randomized Control Trials. **2022**, ○
- 266 Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease. **2022**, 94, 1188-1196 ○
- 265 The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction. **2022**, 10, 166 ○
- 264 The Role of Bone Cell Energetics in Altering Bone Quality and Strength in Health and Disease. ○

- 263 Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial. **2022**, 21, 0
- 262 Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Prescribing in Patients With Diabetes Mellitus With and Without Cardiovascular Disease. **2022**, 0
- 261 Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice. 0
- 260 Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis. 14, 599-616 0
- 259 Mechanisms of GLP-1 Receptor Agonists on the Cardio-Renal Protective Effects. **2022**, 53, 249-262 0
- 258 Influence of type 2 sodium-glucose co-transporter inhibitors (dapagliflozin) on the indicators of total mortality in patients with type 2 diabetes (CARDIA-MOS study, Moscow). **2022**, 25, 439-448 0
- 257 Efficacy of SGLT2 inhibitors in patients with heart failure: An overview of systematic reviews. **2022**, 0
- 256 Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and Genital Infections in Patients With Diabetic Mellitus and Concomitant Coronary Artery Disease: A Single-Center Experience. **2022**, 0
- 255 Albuminuria testing and nephrology care among insured US adults with chronic kidney disease: a missed opportunity. **2022**, 23, 0
- 254 Secular trends in the utility of SGLT -2 inhibitors in heart failure patients with type 2 diabetes mellitus across Metro South Health hospitals in South-East Queensland. 0
- 253 Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: A sub analysis of the CANDLE trial. **2022**, 0
- 252 Recommendations for Early and Comprehensive Management of Type 2 Diabetes and Its Related Cardio-Renal Complications. 0
- 251 Trends in the incidence of renal replacement therapy by type of primary kidney disease in Japan, 2006-2020. 1
- 250 Cardiovascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors, a network meta-analysis of randomized trials. 9, 0
- 249 Diabetic cardiomyopathy: Clinical phenotype and practice. 13, 1
- 248 Clinical Pharmacy Specialist Collaborative Management and Prescription of Diabetes Medications with Cardiovascular Benefit. 089719002211443 0
- 247 Clinical and economic impact of ferric carboxymaltose treatment for iron deficiency in patients stabilized following acute heart failure: a multinational study. **2023**, 26, 51-60 1
- 246 Mechanisms of current therapeutic strategies for heart failure: more questions than answers?. 0

245	The International Society for Heart and Lung Transplantation (ISHLT) Guidelines for the Care of Heart Transplant Recipients. 2022 ,	0
244	Managing Diabetes. 2022 ,	0
243	Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials.	0
242	Heart failure with reduced ejection fraction and the intersection of cardio-renal-metabolic medicine #CaReMe. 2022 , 24, L29-L37	0
241	Sodium-Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study.	0
240	13. Older Adults: Standards of Care in Diabetes 2023. 2023 , 46, S216-S229	2
239	Liver autophagy-induced valine and leucine in plasma reflect the metabolic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin. 2022 , 86, 104342	0
238	Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting.	0
237	The membrane-associated protein 17 (MAP17) is upregulated in response to empagliflozin on top of RAS blockade in experimental diabetic nephropathy.	0
236	SGLT2 inhibitor empagliflozin promotes revascularization in diabetic mouse hindlimb ischemia by inhibiting ferroptosis.	0
235	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes 2023. 2023 , 46, S158-S190	7
234	SGLT2 Inhibition Benefits in Cardiorenal Risk in Men and Women.	0
233	What Is the Best Medicine for Chronic Kidney Disease in Diabetes?. 2022 , 45, 2814-2816	0
232	Therapeutics in Metabolic Diseases. 2023 , 255-273	0
231	Diabetic Kidney Care Redefined with a New Way into Remission. 2022 ,	0
230	Coronary Atherosclerosis Burden and Progression to Guide Clinical Decision Making: A Report from the American College of Cardiology Innovations in Prevention Working Group. 2022 ,	0
229	A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes.	0
228	Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes Mellitus Fasting During Ramadan: A Real-World Study from Bangladesh. Volume 15, 4011-4021	0

- 227 Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease. ○
- 226 Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis. 13, ○
- 225 Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease. **2022**, 108330 ○
- 224 Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure. 9, ○
- 223 Comparison of gliclazide vs linagliptin on hypoglycemia and cardiovascular events in type 2 diabetes mellitus: A systematic review. 13, 1168-1183 ○
- 222 Diabetic foot ulcer: Challenges and future. 13, 1014-1034 ○
- 221 Factors affecting prescription of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus with established cardiovascular disease/ chronic kidney disease in Hong Kong: a qualitative study. **2022**, 23, ○
- 220 Novel glucose-lowering drugs and the risk of acute kidney injury in routine care; the Stockholm CREATinine Measurements (SCREAM) project. ○
- 219 Are arrhythmias the drivers of sudden cardiac death in heart failure with preserved ejection fraction? A review. ○
- 218 Renal outcomes with sodium-glucose cotransporters 2 inhibitors. 13, ○
- 217 Effects of Dapagliflozin on Echocardiographic Measures of Cardiac Structure and Function in Patients with CKD. 10.34067/KID.0006982022 ○
- 216 New Insights into the Use of Empagliflozin: A Comprehensive Review. **2022**, 10, 3294 ○
- 215 Renal Disease in Patients with Type 2 Diabetes: Magnitude of the Problem, Risk Factors and Preventive Strategies. **2022**, 104159 ○
- 214 Benefits of Intensified Reductions in Blood Glucose and in Blood Pressure for Patients with Type 2 Diabetes. **2022**, 104160 ○
- 213 Statistical power for MACE and individual secondary endpoints in cardiovascular outcomes trials for type 2 diabetes: a systematic review. **2022**, 12, ○
- 212 Nationwide cardiovascular risk categorization: applying the European Society of Cardiology (ESC) guidelines to the Swedish National Diabetes Register. ○
- 211 Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. ○
- 210 The International Society for Heart and Lung Transplantation (ISHLT) Guidelines for the Care of Heart Transplant Recipients. **2022**, ○

- 209 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes. **2023**, 46, S191-S202 ○
- 208 Dapagliflozin improves pancreatic islet function by attenuating microvascular endothelial dysfunction in type 2 diabetes. ○
- 207 A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes. ○
- 206 Bibliometric and visualized analysis of sodium-glucose cotransporter 2 inhibitors. 13, ○
- 205 Chronic Kidney Disease – Another Step Forward. **2023**, 388, 179-180 ○
- 204 Blood Pressure Control in Patients with Diabetic Kidney Disease. **2022**, 20, 39 ○
- 203 New Antidiabetic Agents: Relevance to Cardiovascular Outcomes. **2023**, 337-349 ○
- 202 Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms.. **2023**, 106667 ○
- 201 Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure With Preserved Ejection Fraction and Diabetes. **2023**, ○
- 200 Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral artery disease: A review. 1358863X2211438 ○
- 199 Recent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease. **2023**, 24, 1646 ○
- 198 Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. ○
- 197 Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value. **2023**, 81, 4-14 ○
- 196 Canagliflozin Pretreatment Attenuates Myocardial Dysfunction and Improves Postcardiac Arrest Outcomes After Cardiac Arrest and Cardiopulmonary Resuscitation in Mice. ○
- 195 Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy. 29, 61-74 ○
- 194 Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 2. **2023**, 67-138 ○
- 193 Advances on Long-Term Antihypertensive Treatment and Diabetes. **2023**, 351-363 ○
- 192 Diabetes and Sympathetic Nervous System. **2023**, 153-165 ○

- 191 Sex-dependent effects of canagliflozin and dapagliflozin on hemostasis in normoglycemic and hyperglycemic mice. **2023**, 13, ○
- 190 Diabetic Chronic Kidney Disease in Type 2 Diabetes Mellitus (Albuminuric/Non-albuminuric). **2023**, 243-269 ○
- 189 Hypertension and Type 2 Diabetes. **2023**, 39-56 ○
- 188 Potential Medicinal Value of Rhein for Diabetic Kidney Disease. ○
- 187 Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. **2023**, 15, ○
- 186 Baseline eGFR, albuminuria and renal outcomes in patients with SGLT2 inhibitor treatment: an updated meta-analysis. ○
- 185 Efficacy and Safety of Janagliflozin Monotherapy in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Diet and Exercise: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial. ○
- 184 Evaluation of sodium-glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics. ○
- 183 Gliflozins: From Antidiabetic Drugs to Cornerstone in Heart Failure Therapy A Boost to Their Utilization and Multidisciplinary Approach in the Management of Heart Failure. **2023**, 12, 379 1
- 182 Novel Therapeutics for Type 2 Diabetes, Obesity, and Heart Failure. **2023**, 43, 1-7 ○
- 181 Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome. **2023**, 188, 106659 1
- 180 Albuminuric diabetic kidney disease predicts foot ulcers in type 2 diabetes. **2023**, 37, 108403 ○
- 179 Effect of sodium-glucose co-transporter 2 inhibitors on plasma potassium: A meta-analysis. **2023**, 196, 110239 ○
- 178 Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?. **2023**, 49, 101419 ○
- 177 Canagliflozin inhibits inflammasome activation in diabetic endothelial cells 1 Revealing a novel calcium-dependent anti-inflammatory effect of canagliflozin on human diabetic endothelial cells. **2023**, 159, 114228 ○
- 176 Trends in add-on medications following metformin monotherapy for type 2 diabetes. **2022**, 28, 1253-1259 ○
- 175 From Kidney Protection to Stroke Prevention: The Potential Role of Sodium Glucose Cotransporter-2 Inhibitors. **2023**, 24, 351 ○
- 174 Multinational Patterns of Second-line Anti-hyperglycemic Drug Initiation Across Cardiovascular Risk Groups: A Federated Pharmacoepidemiologic Evaluation in LEGEND-T2DM. ○

- 173 Role of Sodium Glucose Cotransporter 2 Inhibitor in Hypertension. 8 ○
- 172 Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes. ○
- 171 Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials. **2022**, 101, e32489 ○
- 170 The effect of sodium-glucose co-transporter 2 inhibitors on stroke and atrial fibrillation: A systematic review and meta-analysis. **2022**, 101582 ○
- 169 Qui un nephrologue doit-il prescrire un iSGLT2 ? Indications of SGLT2 inhibitors in kidney disease: who, why and when?. **2022**, 18, 6S17-6S24 ○
- 168 Comparative evaluation of clinical outcomes of dapagliflozin and empagliflozin in type-2 diabetes mellitus. ○
- 167 Preparing for Colonoscopy in People with Diabetes: A Review with Suggestions for Clinical Practice. ○
- 166 Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease. **2023**, 30, ○
- 165 Diabetes mellitus. **2022**, 267-285 ○
- 164 Empagliflozin reduces arrhythmogenic effects in rat neonatal and human iPSC-derived cardiomyocytes and improves cytosolic calcium handling at least partially independent of NHE1. ○
- 163 Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight. ○
- 162 SGLT2 Inhibitors: The Sweet Success for Kidneys. **2023**, 74, 369-384 ○
- 161 Research Progress in Treatment of Diabetic Proteinuria. **2023**, 13, 1252-1260 ○
- 160 Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods. ○
- 159 Glifozinas en el tratamiento de la diabetes tipo 2: más allá de los beneficios en el control metabólico. **2023**, 6, 49-64 ○
- 158 Efficacy and safety of empagliflozin: a Real-world Experience from Saudi Arabia. **2023**, 43, 50-56 ○
- 157 Multimodal Care for Diabetes Combining Pharmacotherapy and Metabolic Surgery. **2023**, 1013-1027 ○
- 156 Obesity in relation to cardiorenal function. **2023**, 243-264 ○

155	SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease. 2023 , 11, 279	0
154	The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥75 years): a retrospective, pharmacovigilance study. 2023 , 22,	0
153	Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome. 14,	0
152	Sodium glucose cotransporter 2 inhibition does not improve the acute pressure natriuresis response in rats with type 1 diabetes.	0
151	Impact of baseline kidney function on the effects of SGLT2 inhibitors on kidney and heart failure outcomes: a systematic review and meta-analysis of randomized controlled trials.	0
150	Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. 2023 , 47, 10-26	0
149	Medical therapy. 2023 , 353-361	0
148	Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care. 2023 , 10, 205435812211505	1
147	The Kidney Failure Risk Equation: Evaluation of Novel Input Variables including eGFR Estimated Using the CKD-EPI 2021 Equation in 59 Cohorts. 2023 , Publish Ahead of Print,	1
146	Clinical and Pharmacotherapeutic Profile of Patients with Type 2 Diabetes Mellitus Admitted to a Hospital Emergency Department. 2023 , 11, 256	0
145	Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. 2023 , 5, 1	2
144	Cell-Cycle Dysregulation in the Pathogenesis of Diabetic Kidney Disease: An Update. 2023 , 24, 2133	0
143	Metabolomic profiling in kidney cells treated with a sodium glucose-cotransporter 2 inhibitor. 2023 , 13,	0
142	II. Details: Therapeutic Agents for Chronic Heart Failure; 2. SGLT2 Inhibitor. 2022 , 111, 228-234	0
141	Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts. 2022 , 42, 519-530	0
140	Beyond Blood Glucose and Blood Pressure Control in Type 2 Diabetes: Alternative Management Strategies to Prevent the Development and Progression of CKD. 2023 , 14, 215013192311535	0
139	The Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Improving Morbidity and Mortality of Heart Failure: A Systematic Review. 2023 ,	0
138	Effects of Sodium-Glucose Cotransporter Inhibitor Use in Type 2 Diabetes Mellitus Patients With Heart Failure. 2023 ,	0

- 137 The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review. **2023**, 12, 2253 ○
- 136 Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. **2023**, 11, 233-241 ○
- 135 Research progress on the effects of novel hypoglycemic drugs in diabetes combined with myocardial ischemia/reperfusion injury. **2023**, 86, 101884 ○
- 134 Narrative Review of Glycemic Management in People With Diabetes on Peritoneal Dialysis. **2023**, 8, 700-714 ○
- 133 Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study. ○
- 132 Comparison of the effects of sitagliptin and dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index: A sub-analysis of the DIVERSITY-CVR study. ○
- 131 Cerebrovascular, Cognitive and Cardiac Benefits of SGLT2 Inhibitors Therapy in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus: Results from a Global Federated Health Network Analysis. **2023**, 12, 2814 ○
- 130 Integrated analysis for treatment scheme of sodium-glucose cotransporter 2 inhibitors in patients with diabetic kidney disease: a real-world study. **2023**, 13, ○
- 129 Heart failure and diabetes: Clinical significance and epidemiology of this two-way association. ○
- 128 Usage des gliflozines dans la maladie rénale chronique. **2023**, ○
- 127 Management of diabetes: Current concepts. 14, 396-411 ○
- 126 Combined treatment with teneligliptin and canagliflozin additively suppresses high-fat diet-induced body weight gain in mice with modulation of lipid metabolism-related gene expression. **2023**, 947, 175682 ○
- 125 Diabetes care among individuals with and without schizophrenia in three Canadian provinces: A retrospective cohort study. **2023**, 82, 19-25 ○
- 124 Peripheral arterial disease (PAD) [A challenging manifestation of atherosclerosis. **2023**, 171, 107489 ○
- 123 Type 2 Diabetes: SGLT2i-Associated Genitourinary Infections and Lower Urinary Tract Dysfunction. **2023**, 19, 104615 ○
- 122 Newer Glucose-Lowering Therapies in Older Adults with Type 2 Diabetes. **2023**, 52, 355-375 ○
- 121 Advances in Chronic Kidney Disease in Africa. **2023**, 13, 4924 ○
- 120 Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients [DACAMI (a randomized controlled clinical trial). **2023**, 379, 9-14 ○

- 119 Recent developments in adjunct therapies for type 1 diabetes. **2022**, 31, 1311-1320 ○
- 118 Predictors, Disparities, and Facility-Level Variation: SGLT2 Inhibitor Prescription Among US Veterans With CKD. **2023**, ○
- 117 Clinical pharmacology of SGLT-2 inhibitors in heart failure. **2023**, 16, 149-160 ○
- 116 The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. 14, ○
- 115 SGLT2 Inhibitors for Nephrologists. 114-119 ○
- 114 Amelioration of diabetic kidney injury with dapagliflozin is associated with suppressing renal HMGB1 expression and restoring autophagy in obese mice. **2023**, 37, 108409 ○
- 113 Clinical effectiveness of second-line antihyperglycemic drugs on major adverse cardiovascular events: An emulation of a target trial. 14, ○
- 112 Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?. **2023**, 5, 100608 ○
- 111 Luseogliflozin and caloric intake restriction increase superoxide dismutase 2 expression, promote antioxidative effects, and attenuate aortic endothelial dysfunction in diet-induced obese mice. **2023**, 14, 548-559 ○
- 110 Cardiovascular Manifestations in Rheumatoid Arthritis. Publish Ahead of Print, ○
- 109 Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy. Volume 19, 133-142 ○
- 108 Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels. **2023**, 183, 242 ○
- 107 Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis. ○
- 106 Fracture risks associated with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients across eGFR and albuminuria categories: A population-based study in Hong Kong. **2023**, 197, 110576 ○
- 105 Interest and place of new therapeutic classes in the treatment of elderly diabetic patients. **2023**, 49, 101431 ○
- 104 Renoprotective effects of empagliflozin are linked to activation of the tubuloglomerular feedback mechanism and blunting of the complement system. **2023**, 324, C951-C962 ○
- 103 The importance of targeting multiple risk markers in patients with type 2 diabetes: A post-hoc study from the CANVAS programme. ○
- 102 Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors. 14, ○

- 101 Risk of New-onset Stroke in Patients with Type 2 Diabetes with Chronic Kidney Disease on Sodium-glucose Co-transporter-2 Inhibitor Users. ○
- 100 A Web-based Application for Risk Stratification and Optimization in Patients with Cardiovascular Disease (STOP-CVD): Pilot Study (Preprint). ○
- 99 Urate Transporter 1 Can Be a Therapeutic Target Molecule for Chronic Kidney Disease and Diabetic Kidney Disease: A Retrospective Longitudinal Study. **2023**, 11, 567 ○
- 98 Canagliflozin ameliorates epithelial-mesenchymal transition in high-salt diet-induced hypertensive renal injury through restoration of sirtuin 3 expression and the reduction of oxidative stress. **2023**, 653, 53-61 ○
- 97 SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?. **2023**, 59, 388 1
- 96 Mechanisms of SGLT2 Inhibitors in the Treatment of Myocardial Ischemia-Reperfusion Injury in Animal Models. **2023**, 13, 2232-2240 ○
- 95 Sodium-Glucose Cotransporter 2 Inhibitors Among Heart Failure With Mildly Reduced and Preserved Ejection Fraction. 106002802311540 ○
- 94 The risk of all-cause death with dapagliflozin versus placebo: a systematic review and meta-analysis of phase III randomized controlled trials. **2023**, 22, 133-140 ○
- 93 Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset hip fracture risks in patients with type-2 diabetes: A propensity score-matched study with competing risk analysis. ○
- 92 Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors. **2023**, 24, 4144 ○
- 91 Effects of luseogliflozin treatment on hyperglycemia-induced muscle atrophy in rats. **2023**, ○
- 90 Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments. **2023**, 12, ○
- 89 Emerging Role of Sodium-Glucose Co-Transporter 2 Inhibitors for the Treatment of Chronic Kidney Disease. Volume 16, 43-57 ○
- 88 RE: The Efficacy and Safety of SGLT2 Inhibitor in Kidney Transplant Recipients With Diabetes. **2023**, 107, e80-e81 ○
- 87 Meta-Analysis of Cardiovascular Risk Factors in Offspring of Preeclampsia Pregnancies. **2023**, 13, 812 ○
- 86 Analysis of the Value of SGLT2i Combined with GLP-1RAs in Cardiovascular Benefit of Elderly T2DM Patients. **2023**, 13, 2736-2743 ○
- 85 Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD and Type 2 Diabetes: Population-Based US Cohort Study. **2023**, Publish Ahead of Print, ○
- 84 Effect of Intensive Glycemic Control on Myocardial Infarction Outcome in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. **2023**, 2023, 1-11 ○

83	Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study.	1
82	SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes.	0
81	Estimating the value of sodium-glucose cotransporter-2 inhibitors within the context of contemporary guidelines and the totality of evidence.	0
80	SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat. 2023 , 293, 550-558	0
79	Safety and cardiometabolic efficacy of novel antidiabetic drugs. 2023 , 22, 119-124	0
78	Effect of sodium-glucose transporter 2 inhibitor empagliflozin on proteinuria and kidney function progression in patients with non-diabetic glomerulonephritis: a pilot superiority randomized controlled trial.	0
77	Hypoxia-Inducible Factor-Prolyl-Hydroxylase and Sodium-Glucose Cotransporter 2 Inhibitors for Low-Risk Myelodysplastic Syndrome-Related Anemia in Patients with Chronic Kidney Disease: A Report of Three Cases. 2023 , 15, 180-187	0
76	Significant publications in diabetes pharmacotherapy and technology in 2020.	0
75	Significant publications in diabetes pharmacotherapy and technology in 2020. 2023 , 18, 131-142	0
74	New Insight in Cardiorenal Syndrome: From Biomarkers to Therapy. 2023 , 24, 5089	0
73	Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. 2023 ,	0
72	Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With PreHeart Failure With Preserved Ejection Fraction. 2023 , 8, 366	0
71	Paradigm shift of the medical care in diabetes. 2023 , 19, 32-41	0
70	Feasibility Study to Assess Canagliflozin Distribution and Sodium-Glucose Co-Transporter 2 Occupancy Using [¹⁸ F]Canagliflozin in Patients with Type 2 Diabetes.	0
69	Comparative Efficacy of Novel Antidiabetic Drugs on Albuminuria Outcomes in Type 2 Diabetes: A Systematic Review.	0
68	Surgery or Endovascular Therapy for Chronic Limb Ischemia. 2023 , 388, e37	0
67	CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes. 2023 , 22,	0
66	Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.	0

- 65 Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials. **2023**, 22, ○
- 64 Copeptin adaptive response to SGLT2 inhibitors in patients with type 2 diabetes mellitus: The GLIRACo study. 17, ○
- 63 Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents. **2023**, 117-167 ○
- 62 Understanding the Mechanisms and Treatment of Heart Failure: Quantitative Systems Pharmacology Models with a Focus on SGLT2 Inhibitors and Sex-Specific Differences. **2023**, 15, 1002 ○
- 61 Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE. ○
- 60 A Role of Sodium-Glucose Co-Transporter 2 in Cardiorenal Anemia Iron Deficiency Syndrome. **2023**, 24, 5983 ○
- 59 Update on Medical Management of Diabetes. **2023**, ○
- 58 Adherence to cardiovascular prevention guidelines in an academic center. **2023**, ○
- 57 Empagliflozin increases kidney weight due to increased cell size in the proximal tubule S3 segment and the collecting duct. 14, ○
- 56 SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence. 5, ○
- 55 The Potential of SGLT-2 Inhibitors in the Treatment of Polycystic Ovary Syndrome: The Current Status and Future Perspectives. **2023**, 11, 998 ○
- 54 Prescription appropriateness of anti-diabetes drugs in elderly patients hospitalized in a clinical setting: evidence from the REPOSI Register. ○
- 53 Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction. **2023**, 22, ○
- 52 Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events. ○
- 51 Lower-limb peripheral arterial disease and amputations in people with diabetes: Risk factors, prognostic value and management. **2023**, 52, 104164 ○
- 50 EFFECTIVENESS OF DAPAGLIFLOZIN IN PATIENTS WITH CHRONIC HEART FAILURE. **2023**, ○
- 49 The health and budget impact of sodium-glucose co-transporter-2 inhibitors (SGLT2is) in The Netherlands. **2023**, 26, 547-553 ○
- 48 Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. **2023**, 4, e143-e154 ○

- 47 Management of Heart Failure with Reduced Ejection Fraction Globally and in Lebanon: Where Do SGLT-2is Stand?. **2023**, 13, 138-169 ○
- 46 The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials. **2023**, 15, 1092 ○
- 45 Safety of SGLT2 Inhibitors in Three Chronic Diseases. **2023**, 64, 246-251 ○
- 44 Peripheral arterial disease and the cardiometabolic syndrome: assessment and management. **2023**, 469-489 ○
- 43 Cardiac energy metabolism in heart failure. **2023**, 175-198 ○
- 42 Sodium-glucose Co-transporter-2 inhibitors: a new era of cardioprotection and renoprotection. **2023**, 337-363 ○
- 41 Meta-analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus. ○
- 40 Embedding guidelines into clinical practice. **2023**, 40, 28 ○
- 39 Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023). **2023**, 153, 40060 ○
- 38 Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). **2023**, 22, ○
- 37 Consumer-Based Brand Equity Among Beverage Manufacturing Firms in Sub-Saharan Africa. **2022**, 2422-2438 ○
- 36 Avoiding and managing the side effects of type 2 diabetes treatments. **2023**, 5, 158-165 ○
- 35 Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study. Publish Ahead of Print, ○
- 34 Prevention of Cardiovascular Events in Patients With Chronic Kidney Disease. 106002802311657 ○
- 33 Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of the Positive Implications on Cardiovascular and Renal Health and Dynamics for Clinical Practice. **2023**, ○
- 32 Diabetic vascular diseases: molecular mechanisms and therapeutic strategies. **2023**, 8, ○
- 31 Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?. **2023**, 59, 742 ○
- 30 IGFBP7 and left ventricular mass regression: a sub-analysis of the EMPA-HEART CardioLink-6 randomized clinical trial. ○

- 29 Impact of diabetes duration on left ventricular mass regression with empagliflozin. ○
- 28 Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease. **2023**, 12, 2824 ○
- 27 Use of Animal Models for Investigating Cardioprotective Roles of SGLT2 Inhibitors. ○
- 26 Use of Computation Ecosystems to Analyze the Kidney-Heart Crosstalk. **2023**, 132, 1084-1100 ○
- 25 Speckle tracking echocardiography in early disease stages: a therapy modifier?. **2023**, 24, e55-e66 ○
- 24 Cardiovascular Calcification Heterogeneity in Chronic Kidney Disease. **2023**, 132, 993-1012 ○
- 23 Hypertension as Cardiovascular Risk Factor in Chronic Kidney Disease. **2023**, 132, 1050-1063 ○
- 22 Metabolic Syndrome and Cardiac Remodeling Due to Mitochondrial Oxidative Stress Involving Gliflozins and Sirtuins. ○
- 21 Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms. **2023**, 22, ○
- 20 Prevention of Coronary Atherosclerosis. **2023**, 39-57 ○
- 19 Perspectives In Weight Control In Diabetes Sglt2 Inhibitors And Glp-1Raglutan Dual Agonism. **2023**, 110669 ○
- 18 Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Preserved Trial. ○
- 17 Anti-Diabetic Therapy and Heart Failure: Recent Advances in Clinical Evidence and Molecular Mechanism. **2023**, 13, 1024 ○
- 16 Management of Heart Failure in Patients With Diabetes Mellitus in the UAE: A Call to Action. **2023**, 28, 107424842311622 ○
- 15 Treatment of type 2 diabetes patients with heart conditions. 1-11 ○
- 14 Emerging sodium-glucose cotransporter-2 inhibitor therapies for managing heart failure in patients with chronic kidney disease. 1-11 ○
- 13 The Role of SGLT2 Inhibitors in Cardiovascular Management. Publish Ahead of Print, ○
- 12 Pharmacological management of youth with type 2 diabetes and diabetic kidney disease: a comprehensive review of current treatments and future directions. 1-12 ○

- 11 Dapagliflozin induced hypernatremia via osmotic diuresis: a case report.
- 10 The interplay between bone and heart health as reflected in medication effects: A narrative review. **2023**, 19, 174550572311655
- 9 Canagliflozin alleviates pulmonary hypertension partially by inhibition of PPAR δ phosphorylation and PPAR δ -mediated suppression of oxidative stress.
- 8 Adoption of sodium-glucose cotransporter-2 inhibitors among prescribers caring for nursing home residents.
- 7 Glutamine Deficiency Promotes Immune and Endothelial Cell Dysfunction in COVID-19. **2023**, 24, 7593
- 6 Impact of Baseline Clinical Variables on SGLT2i Antiproteinuric Effect in Diabetic Kidney Disease. **2023**, 13, 1061
- 5 Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors.
- 4 Diagnose und Management der Osteoporose bei Diabetes mellitus (Update 2023). **2023**, 135, 207-224
- 3 Treatment of type 2 diabetes.
- 2 Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS.
- 1 COMBINSI (COMBat to INSufficient Insulin therapy) A Portuguese project in type 2 diabetes. **2023**, 17, 102776